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ABSTRACT 
 
Adeno-associated virus vector encoding codon optimised human factor IX (AAV-LP1-hFIXco) 
has demonstrated great promise for the treatment of patients with severe haemophilia B. 
However, in some patients treated with a high vector dose, hepatocellular toxicity was 
observed. To improve AAV vector potency, various scaffold/matrix attachment regions 
(S/MARs) were cloned at the 3’ end of a modified single-stranded (ss) AAV-LP1-hFIXco 
expression cassette.  In a head to head comparison, a vector containing a S/MAR element 
from the human hypoxanthine-guanine phosphoribosyl-transferase gene in the forward 
orientation (ssAAV-LP1-hFIXco-HPRT-F) was found to mediate the highest levels of hFIX 
expression in mice. In comparison to animals transduced with a control vector containing 
no S/MAR, the ssAAV-LP1-hFIXco-HPRT-F transduced cohort expressed hFIX at 28-fold 
higher levels. This trend was reproducible in rhesus macaques where 10-fold higher FIX 
levels were observed following transduction with ssAAV-LP1-hFIXco-HPRT-F as compared to 
delivery of ssAAV-LP1-hFIXco-control vector. Through a deletion analysis, short regions 
from the IFNβ and HPRT S/MARs with potent enhancer activity were identified. This 
allowed for the in-silico elicitation of motifs with a potential role in S/MAR function and 
also minimised the space occupied by S/MARs within our AAV expression cassette. When 
cloned into a self-complementary (sc) AAV-LP1-hFIXco expression cassette, the 130bp 
region from the HPRT S/MAR (fragment 2b) was sufficient to enhance FIX levels in mice by 
35-fold over that observed with a control self-complementary vector. Mechanistic studies 
showed that S/MAR elements enhanced AAV transgene expression by reducing 
heterochromatin marks (H3K9me2 and HP1α) in the promoter region, resulting in an 
increase in FIX mRNA levels by up to 20-fold. S/MARs therefore provide a novel inbuilt 
process for enhancing AAV mediated transgene expression by preventing epigenetic 
silencing of the provirus. As such, S/MARs offer the possibility to improve gene transfer to 
humans through using lower and potentially safer doses of AAV.         
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CHAPTER 1 INTRODUCTION 
 
1.1 Haemophilia B 
 
Haemophilia B is a genetic bleeding disorder characterised by the absence of a functional 
plasma protein known as coagulation Factor IX (FIX). The disease is transmitted as an X-
linked recessive disorder, due to mutation at Xq27.1, with an incidence of 1 in 25000 male 
births (Ljung et al, 1990). Due to non-random X chromosome inactivation, females can 
occasionally demonstrate markedly low FIX levels but are typically carriers of the disorder 
only (Kasper & Buzin, 2009).  
Factor IX plays a central role in the coagulation cascade and is required for the activation of 
Factor X in partnership with activated Factor VIII. In the absence of active Factor X, 
thrombin formation is significantly impaired.  As thrombin is required for platelet activation 
and the generation of fibrin, deficiency of FIX results in aberrant blood clot formation which 
subsequently allows for haemorrhage after only minimal trauma (Cancio et al, 2013). In 
Haemophilia patients, excessive deep bleeding into the joints and muscle is characteristic 
and can eventually lead to debilitating arthropathy.  
Based on the quantity of active FIX present in patient plasma, the bleeding phenotype can 
be classified as mild, moderate or severe. Those with a severe phenotype demonstrate 
active FIX levels of ≤1% of normal physiological levels whilst moderate and mild phenotypes 
corresponds to FIX levels of 1-5% and 5-40% of normal values respectively. A severe 
phenotype is apparent at infancy with haemorrhage often occurring spontaneously 
irrespective of prophylactic use of FIX protein concentrates. In contrast, for excessive 
bleeding to occur, those with a mild or moderate phenotype must usually be challenged by 
severe or mild trauma respectively (Cancio et al, 2013).   
In the early 1980s the first cloning of the human FIX gene led to the generation of 
recombinant FIX concentrates that later received  US Food and Drug Administration (FDA) 
approval (Kurachi & Davie, 1982). This development has crucially enabled prophylactic 
administration of FIX protein to patients. As a result, the health and life expectancy of 
those with haemophilia B has significantly improved. However, as patients with a severe 
phenotype typically require multiple infusions per week and bleeding is still known to occur 
in spite of prophylactic therapy, current treatment is not without limitation.  
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To improve upon this matter, several gene therapy strategies have been designed with the 
aim of providing correct FIX gene copies to patients for long term correction of the disorder 
(Herzog et al, 1997; High et al, 2004b; High, 2011; Palmer et al, 1989). Most recently, 
patients with a severe phenotype have been successfully treated following transduction of 
the liver with a self-complementary adeno-associated virus (AAV) expressing human factor 
IX (Nathwani et al, 2011). However, in this trial, whilst patients treated with a high vector 
dose (2×1011 vector genomes (vg)/Kg) demonstrated the greatest improvement in FIX 
levels; they also showed a transient elevation in levels of serum aminotransferase which is 
indicative of liver toxicity. This transaminitis was believed to occur through immune 
mediated clearance of hepatocytes presenting AAV capsid antigens. As such, it has been 
recognised that vector potency must be increased to minimise the dose required for 
therapeutic effect and subsequently improve safety. This thesis herein describes a study 
designed to improve AAV vector potency in the context of the human FIX expression 
cassette previously used in the clinic. 
1.2 Gene therapy using adeno-associated virus 
 
Genetic disease represents a significant problem in human health and a substantial burden 
on the health care system. However, for many of the more common inherited disorders 
including sickle cell anaemia and cystic fibrosis, treatment options remain limited. The most 
obvious solution for the long term treatment of genetic diseases is gene therapy. This 
refers to the transfer of normal gene copies to an individual with a mutation in the gene 
being provided (High, 2011). Approximately 23 years ago, clinical gene therapy commenced 
in a trial for the treatment of children diagnosed with adenosine deaminase deficient 
severe combined immunodeficiency (ADA-SCID) (Blaese et al, 1995). Due to the safety 
demonstrated in these early trials, in recent years many gene therapy products have 
entered late phase testing and true gene therapeutics are beginning to materialise (Yla-
Herttuala, 2012).  
The main goal of gene therapy is to achieve sustained transgene expression at levels  that 
are considered to be therapuetic. To accomplish this goal, current gene therapy appears to 
be focusing on two major approaches. In the first strategy, viral vectors that integrate their 
genomes into host DNA, such as lentiviruses and retroviruses, are used for the ex-vivo 
delivery of therapeutic genes to host cells (Bank, 1996).  As vector genomes are maintained 
in the cells via integration, long term transgene expression can be achieved upon re-
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infusion of transduced cells into patients. This strategy has been used for the successful 
treatment of ADA-SCID and X-linked adrenoleukodystrophy by transducing patient 
haematopoietic stem cells (HSCs) with retroviral or lentiviral vectors carrying the gene of 
interest (ADA and ABCD1 respectively) (Aiuti et al, 2009; Cartier et al, 2009). More recently, 
by transducing patient HSCs with a lentiviral vector expressing the arylsulfatase gene 
(ARSA), Luigi Naldini’s group demonstrated the ability to safely and effectively treat 
patients with late infantile metachromatic leukodystrophy (MLD):  a lysosomal storage 
disorder characterised by mass demyelination and neurodegeneration due to accumulation 
of the arylsulfatse substrate (sulfatide) in cells of the nervous system (Biffi et al, 2013). 
After re-infusion of treated cells, therapeutically relevant myeloid cells (enzyme-proficient 
CD14+ and CD15+ cells that are able to migrate to the CNS and scavenge stored sulfatide) 
taken from patient peripheral blood demonstrated greater than normal generation of ARSA 
as compared to cells taken from healthy donors.  In contrast to older un-treated siblings, at 
18 to 24 months follow up, the neurodegenerative disorder was not found to progress in 
any of the three patients who all demonstrated continuous motor and cognitive 
development and normal brain MRI. Using this strategy, the same group also demonstrated 
the ability to effectively treat patients with Wiskott-Aldrich syndrome (WAS) (Aiuti et al, 
2013). Following re-infusion of patient HSCs transduced with a lentiviral vector expressing 
WAS protein (WASP), all three patients enrolled in this phaseI/II trial demonstrated 
improved platelet counts and protection from the severe infection, bleeding and eczema 
that characterises this primary X-linked  immunodeficiency.  
 In the second strategy, post mitotic tissues such as skeletal muscle, central nervous system 
(CNS) and liver are transduced with non integrating vectors such as adenovirus and adeno-
associated virus (AAV) (Ehrhardt et al, 2008). As these tissues do not divide rapidly 
episomal/non-integrated vector genomes are stabilised and transgene expression can be 
maintained long term. One of the greatest success stories for this strategy includes the use 
of AAV vectors expressing the RPE65 gene to transduce the retina of patients diagnosed 
with Leber’s congenital amaurosis (Bainbridge et al, 2008; Maguire et al, 2008). For 
example, in a 2009 trial, subretinal injection of an AAV-RPE65 vector at a dose range of 
1.5×1010 to 1.5×1011 vector genomes (vg) was well tolerated in all patients with the greatest 
improvements observed in children who all gained ambulatory vision (Maguire et al, 2009). 
More recently, rAAV has been used to successfully treat patients with advanced heart 
failure (HF) through delivery of the SERCA2a gene involved in myocyte contraction (Jessup 
et al, 2011). In the Calcium Up-regulation by Percutaneous Administration of Gene Therapy 
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in Cardiac Disease (CUPID) trial, HF patients received a serotype one rAAV vector 
expressing the SERCA2a gene at either a high (1×1013vg) intermediate (3×1012vg) or low 
(6×1011vg) dose via intracoronary infusion. At 12 months follow up, patients in the high 
dose group met the criteria for clinical efficacy in terms of maximal rate of oxygen 
consumption (VO2-max), reduced  N-terminal prohormone brain natriuretic peptide levels (a 
HF biomarker),  left ventricular end-systolic volume and decreased frequency of 
cardiovascular events. As a result of this success, a further 200 patients will be recruited to 
a CUPID 2 phase 2b trial. All patients will be treated at the high vector dose that was 
previously shown to be efficacious (Sikkel et al, 2014).     
Although substantial progress has been made in the field of gene therapy, vectors 
commonly used for gene transfer are not without their drawbacks. For instance, 
integration of vector genomes is associated with the risk of insertional mutagenesis.  This 
was clearly demonstrated when X-linked SCID patients receiving HSCs transduced with 
retroviral vectors developed leukaemia (Cole, 2008; Hacein-Bey-Abina et al, 2003a; Hacein-
Bey-Abina et al, 2003b). Non-integrating vectors also have their disadvantages, such as 
adenoviral vectors, which are highly immunogenic. The issues associated with such 
immunogenicity were clearly evident in pre-clinical studies for the treatment of 
Haemophilia B whereby rhesus macaques transduced with adenoviral vectors expressing 
coagulagtion factor IX (FIX) showed signs of hepatotoxicity due to destruction of 
transduced hepatocytes that was mediated by the cellular immunity (Lozier et al, 1999).  In 
contrast, the adeno-associated virus demonstrates an improved safety profile.  
Wild type AAV is a small, non-pathogenic, human parvovirus that depends on co-infection 
of a helper virus (e.g. adenovirus, papillomavirus or herpesvirus) for the completion of 
replication (Conway et al, 1997; Hoggan et al, 1966; Mueller & Flotte, 2008). The single 
stranded DNA genome of AAV is approximately 4.7kb in size and consists of two large open 
reading frames (rep and cap) flanked by 145bp t-shaped hairpin structures known as 
inverted terminal repeats (ITRs). The ITRs provide  free 3’ hydroxyl groups that prime 
second strand DNA synthesis and contain terminal resolution sites (trs) involved in the 
regulation of viral gene expression and genome encapsidation (Goncalves, 2005; Koczot et 
al, 1973). The 5’ open reading frame (ORF) rep encodes four regulatory  proteins (Rep78, 
Rep68, Rep52 and Rep40) that control replication and site specific integration of wild type 
viral genomes whilst the 3’ ORF cap encodes the three structural  proteins VP1 (90kDa), 
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VP2 (72kDa) and VP3 (60kDa)  that form the multiple subunits of icosahedral AAV capsids in 
a 1:1:20 ratio (Berns & Linden, 1995; Rose et al, 1971). 
Amongst vectors of viral origin, recombinant AAV (rAAV) vectors have several attributes 
that make them attractive for gene therapy: 
 As ITR sequences are typically the only viral DNA elements retained in rAAV 
genomes, the absence of regulatory genes renders recombinant vectors replication 
defective and minimises the risk of host genome integration, with viral genomes 
persisting predominantly as concatemeric episomes (Smith, 2008).   
 AAV vectors are regarded as non-pathogenic and are not associated with any 
known human diseases (Daya & Berns, 2008). 
 AAV vectors can transduce both dividing and quiescent cells (Alexander et al, 
1996).  
 Multiple serotypes of AAV have been discovered and characterised in terms of 
capsid antigenicity (with the most well characterised designated AAV1-12) 
(Atchison et al, 1965; Bantel-Schaal & zur Hausen, 1984; Gao et al, 2004; Gao et al, 
2002; Hoggan et al, 1966; Mori et al, 2004; Rutledge et al, 1998). As each serotype 
has a distinct tissue tropism and immunologic profile, changes in serotype can be 
exploited to avoid neutralising immune responses arising due to previous AAV 
exposure whilst also enabling some control over vector biodistribution (Table 1). 
For instance AAV8 and AAV1 efficiently transduce hepatocytes and muscle cells 
respectively  (Nathwani et al, 2011; Stroes et al, 2008) while AAV2 has been used 
to transduce retinal cells for the successful treatment of Lebers congenital 
amaurosis (LCA)(Bainbridge et al, 2008; Maguire et al, 2009).   
 In several animal models, the ability to achieve long term transgene expression in 
post mitotic tissues (including muscle, liver, brain and retina) has been established 
following a single infusion of rAAV. A broad range of disorders have now been 
targeted with rAAV including Duchene muscular dystrophy, Parkinson’s disease, α-
1-antitrypsin deficiency, LCA and Haemophilia B (Bainbridge et al, 2008; Flotte et 
al, 2004; Flotte et al, 2011; Kaplitt et al, 2007; Manno et al, 2006; Stedman et al, 
2000).   
 The successful use of rAAV in pre-clinical models has allowed for the transition of 
rAAV to many phase I/II clinical studies (Bainbridge et al, 2008; Flotte et al, 2004; 
Flotte et al, 2011; High et al, 2004a; Maguire et al, 2008; Nathwani et al, 2011; 
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Stroes et al, 2008). This includes trials for the treatment of patients with severe 
haemophilia B, which will be discussed in the following paragraphs. 
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Table 1: Summary of tissue tropism for AAV serotypes 1-9. 
 
 
 
  
AAV Serotype Tissue tropism 
1 Skeletal muscle (Stroes et al, 2008), CNS (Wang et 
al, 2003), pancreas (Loiler et al, 2005) 
2 Skeletal muscle(Manno et al, 2003), CNS (Bartlett et 
al, 1998), liver (Koeberl et al, 1997), kidney (Takeda 
et al, 2004) 
3 Skeletal muscle (Chao et al, 2000) 
4 CNS (Davidson et al, 2000), retina (Weber et al, 
2003) 
5 Skeletal muscle(Chao et al, 2000), CNS (Davidson et 
al, 2000), retina (Maguire et al, 2009), liver 
(Nathwani et al, 2007) 
6 Skeletal muscle (Blankinship et al, 2004), heart 
(Zincarelli et al, 2010), lung (Halbert et al, 2001) 
7 Skeletal muscle (Gao et al, 2002), CNS (Taymans et 
al, 2007), retina (Allocca et al, 2007) 
8 Liver (Nakai et al, 2005), skeletal muscle (Wang et 
al, 2005), retina (Allocca et al, 2007), pancreas 
(Nakai et al, 2005), heart (Wang et al, 2005), CNS 
(Taymans et al, 2007) 
9 Skeletal muscle (Yue et al, 2011), liver 
(Vandendriessche et al, 2007), heart (Inagaki et al, 
2006), CNS (Foust et al, 2009), lung (Bostick et al, 
2007), kidney (Bostick et al, 2007) 
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Haemophilia B has long been one of the most extensively studied diseases in terms of gene 
therapy. This is because an increase in factor IX to only 1% of normal physiological levels is 
enough to convert a patient’s phenotype from severe to mild (Ljung, 1999). In addition to 
this modest target, well defined coagulation assays and small and large animal models of 
the disease exist for ease of preclinical testing (Murphy & High, 2008).  Using 
immunodeficient mice and a canine model of Haemophilia B, long term stable expression 
of coagulation factor IX (FIX) following intramuscular delivery of an AAV2-FIX vector was 
demonstrated. In this study stable FIX expression levels of 5-7% and 1-2% of normal were 
observed in mice and dogs respectively (Herzog et al, 1997; Herzog et al, 1999). However, 
as anti-hFIX neutralising antibodies were detected in dogs treated with higher vector doses, 
subsequent clinical investigation was limited to a dose of 1.5×1012vg/injection site (Herzog 
et al, 2002; Manno et al, 2003). In addition to this limitation, the expression of collagen IV 
in human muscle prevents the relase of FIX into the plasma (Schuettrumpf et al, 2005). This 
resulted in sub-therapeutic increments of human factor IX (hFIX) observed in each 
participant. Nonetheless, this study successfully demonstrated the saftey of AAV mediated 
gene transfer to haemophilia B patients (with vector administration well tolerated in all 
participants at doses of up to 1.8×1012vg/kg); thus a foundation for further clinical 
investigation was established.      
Given the issues associated with FIX release from skeletal muscle, subsequent haemophilia 
B gene transfer trials have focused on transduction of the liver (Mount et al, 2002; 
Nathwani et al, 2011). Indeed, the liver is known to secrete FIX more efficiently than the 
muscle. Moreover, by pre-clinical evaluation in the haemophilic dog model, this approach 
was shown to promote FIX immune tolerance (Mingozzi et al, 2003). This work led to the 
clinical trial utilising a single stranded AAV2 vector expressing hFIX delivered via the hepatic 
artery (High et al, 2004a; Manno et al, 2006). Vector infusion of doses up to 2×1012vg/kg 
was well tolerated in all patients and therapeutic hFIX levels of 3% to 11% were observed in 
patients receiving the high vector dose. However, hFIX expression was transient (lasting 
approximately 8 weeks) and began to declined in conjunction with a period of 
transaminitis. As greater than 70% of humans are AAV2 positive, liver injury was found to 
be mediated by memory T cell responses against hepatocytes presenting AAV2 capsid 
antigens (High et al, 2004a; High et al, 2004b). Thus the need to use alternative serotypes 
of vector or to implement an immunomodulatory regimen was recognised (Manno et al, 
2006).  
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As previously described, improved tropism to the liver has been well documented with 
capsid serotype 8 (Nakai et al, 2005; Nathwani et al, 2011). Furthermore, there is a lower 
seroprevalence of antibodies to this capsid in the human population as compared to AAV2 
(Boutin et al, 2010). Preclinical studies in nonhuman primates using serotype 8 vectors 
demonstrated great promise with stable FIX levels of  22% to 26% of normal achieved 
following liver transduction at a dose of 1×1012 vg/kg (Nathwani et al, 2007). Crucially this 
success was achieved in the clinical setting, with four out of six participants able to 
discontinue FIX prophylaxis while the other two received prophylactic injections at greater 
intervals (Nathwani et al, 2011). Such clinical success has been attributed to three 
important advances in vector design. Firstly, a codon-optimised Factor IX (FIXco) expression 
casette was generated for improved transgene expression. Secondly, the self 
complementary format of the AAV genome allowed complementary positive and negative 
DNA strands to be packaged within the same virion, circumventing the inefficient process 
of second strand synthesis (McCarty et al, 2003; McCarty et al, 2001). Finally, vectors were 
pseudotyped with serotype 8 capsids in order to evade an immune response against capsid 
proteins previously reported with AAV2 (Mingozzi et al, 2007; Pien et al, 2009; 
Vandenberghe et al, 2006). As AAV8 is liver-tropic, non-invasive infusion of the vector via 
the peripheral vein was also made possible by the switch in capsid serotype. However, as 
observed in other previous trials, to achieve therapeutically relevant transgene expression 
high vector doses were required (High et al, 2004a; Nathwani et al, 2011).  
In addition to putting pressure on vector production, the need for high MOIs (multiplicity of 
infection) of rAAV is associated with an increased risk of toxicity (Manno et al, 2006; 
Mingozzi et al, 2009). Indeed, whilst both participants that received the highest vector dose 
(2×1012 vg/kg) showed the greatest FIX expression (7-12% of normal), they also 
demonstrated elevated aminotransferase levels which is indicative of liver toxicity 
(Nathwani et al, 2011). In participant 5, aspartate aminotrasferase and alanine 
aminotransferase reached levels of 143 and 202 IU per litre respectively by day 58 
(maximum of normal range 37 and 41 IU per litre respectively) whilst in Participant 6, 
although liver  enzyme levels remained within the normal range, aminotransferase levels 
approximately doubled by day 62 when compared to baseline. In both cases liver injury was 
suspected to be due to T-cell dependent immune-mediated clearance of hepatocytes in 
response to AAV8 capsid antigens.   
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In summary, rAAV vectors have demonstrated great promise in the field of clinical gene 
therapy. However, in some cases, high doses of vector are required to achieve therapeutic 
levels of gene expression. This is clearly demonstrated in clinical studies of factor IX gene 
transfer. The greater risk of toxicity associated with increased MOIs means that vector 
potency must be improved to render lower doses efficacious. Such improvements are 
achievable by first understanding the limitations of the AAV transduction pathway.    
  
1.3 Improving vector potency 
 
This next section will discuss the limitations imposed on AAV throughout the transduction 
pathway and will focus on capsid and expression cassette modifications that have been 
shown to overcome these limitations (summarised in table 2). As such modifications 
improve vector potency; they represent major steps towards AAV dose minimisation which 
is a focal point of this study. 
1.3.1 The AAV transduction pathway 
 
Major steps of the AAV cellular transduction pathway include: 1) binding to cell surface 
receptors (listed in Table 3), 2) virion internalisation by endocytosis, 3) intracellular 
trafficking, 4) uncoating and release of viral genome 5) single stranded to double stranded 
conversion of viral DNA and 6) concatemerisation of double stranded genomes (Choi et al, 
2005; Nonnenmacher & Weber, 2012). Known rate limiting steps of AAV infection include 
the low abundance/absence of required cell surface receptors, inefficient escape of virions 
from the endosome (resulting in lysosomal/proteasomal degradation) and the slow 
conversion of genomes to transcriptionally active double stranded forms (Figure 1.1) (Choi 
et al, 2005). As previously mentioned, neutralising immune responses against capsid 
proteins also represent a formidable challenge to successful AAV gene transfer. With these 
barriers in mind a number of rationally modified rAAV capsids and genomes have been 
engineered with the overall aim of enhancing vector potency. 
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Table 2: Summary of AAV transduction limitations and solutions. 
  
Transduction Limitation Potential Solution 
Pre-existing immunity to capsid antigens Change serotype 
Immune escape capsid mutations/epitope 
tagging 
Low abundance/ absence of required cell 
surface receptors in target tissues 
Change serotype 
Hybrid capsids 
Capsid epitope tagging 
Inefficient endosome escape Hybrid capsids 
Capsid tyrosine mutations 
Slow single strand to double strand genome 
conversion 
Self-complementary vectors 
Limited expression levels Change promoter 
Include additional cis-regulatory elements 
Codon optimisation 
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Table 3: Summary of cell surface receptors for AAV serotypes 1-9. - = undefined, HSPG= 
heparin sulphate proteoglycan, FGFR= Fibroblast growth factor receptor, HGFR= 
Hepatocyte growth factor receptor, LamR= Laminin receptor, PDGFR= Platelet derived 
growth factor receptor, EGFR= Epidermal growth factor receptor.       
  
AAV Serotype Primary Receptor Co-receptors 
1 N-linked sialic acid (Wu et al, 
2006) 
- 
2 HSPG (Summerford & 
Samulski, 1998) 
FGFR (Qing et al, 1999), 
HGFR (Kashiwakura et al, 
2005), LamR (Akache et al, 
2006), αvβ5 (Summerford et 
al, 1999), α5β1 (Akache et al, 
2006) 
3 HSPG (Rabinowitz et al, 
2002) 
FGFR (Blackburn et al, 2006), 
HGFR (Ling et al, 2010), 
LamR (Akache et al, 2006)  
4 O-linked sialic acid (Kaludov 
et al, 2001) 
- 
5 N-linked sialic acid (Kaludov 
et al, 2001) 
PDGFR (Di Pasquale et al, 
2003) 
6 HSPG (Ng et al, 2010), N-
linked sialic acid (Wu et al, 
2006) 
EGFR (Weller et al, 2010) 
7 - - 
8 - LamR (Akache et al, 2006) 
9 N-linked galactose (Shen et 
al, 2011) 
LamR (Akache et al, 2006) 
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Figure 1.1: Schematic of the AAV transduction pathway. The major stages of AAV 
transduction are represented schematically including cell surface binding, endocytosis, 
endosome trafficking, nuclear transport, uncoating and double stranded conversion of 
vector genomes. Limiting stages of AAV gene transfer are highlighted with text. 
Adapted from: (Ding et al, 2005). 
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1.3.2 Capsid modifications 
 
Multiple capsid modifications can be used to improve the potency of AAV vectors. This 
includes capsids that evade immune responses, improve the targeting of specific cell types 
or protect vectors from endosomal degradation. The use of such capsids and the ways in 
which they improve vector potency will be discussed in this section.   
1.3.2.1 Changing serotype/transcapsidation 
 
AAV2 was the first naturally occurring AAV isolate to be fully characterised (Hoggan et al, 
1966). As a result, early AAV clinical trials focused heavily on the use of serotype 2 vectors. 
However, as previously described, in 2004 a phase I/II haemophilia B gene therapy study 
evaluating liver transduction with rAAV2 was closed due to unexpected toxicity (High et al, 
2004a). These adverse events were believed to be due to pre-existing immunity against 
AAV2 capsid antigens (High et al, 2004b). Transcapsidation/pseudotyping refers to the 
packaging of AAV genomes containing ITRs from one serotype into the capsid of another 
serotype (Choi et al, 2005). As AAV2 ITRs are the most extensively studied they are 
frequently used for such cross-packaging whilst capsids alternative to serotype 2 are 
utilised to minimise the chances of invoking an immune response. Indeed in a study 
regarding the prevalence of total anti-AAV IgG for each serotype in a healthy human 
population, AAV2 and AAV1 antibodies were found to be most common (72 and 67% of the 
population respectively) with AAV9, 6, 5 and 8 antibodies demonstrating comparably lower 
seroprevalence (47, 46, 40 and 38% respectively) (Boutin et al, 2010). As such, the use of 
transcapsidation can improve AAV transduction efficiency by minimising the chances of 
neutralisation by pre-existing humoral immunity. 
Additionally, changes in serotype can be exploited to selectively target tissues more 
effectively. For instance, vectors pseudotyped with AAV8 and rh.10 capsids have been 
found to transduce hepatocytes more effectively than AAV7 and 9 capsids at equivalent 
doses (Nathwani et al, 2009). This was determined by levels of hFIX transgene expression 
achieved following tail vein injection of each vector into 6-8 week old C57BL/6 mice. In 
these studies, at a dose of 4×1010vg/kg, hFIX levels of 13±4µg/mL and 12±2µg/mL 
(approximately 250% of physiological levels) were observed 57 days after injection of 
AAV2/8 and 2/rh.10 cohorts respectively. These levels were substantially greater than that 
achieved with AAV2/9 and 2/7 vectors which gave hFIX levels of 7±3µg/mL and 3±1µg/mL 
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respectively when administered at the same dose. Therefore, changes in serotype also 
allow for enhanced transduction efficiency by improving cell targeting.  
1.3.2.2 Hybrid capsids 
 
Further studies have demonstrated that AAV transduction can be improved by combining 
the attributes of two parental serotypes. Hybrid capsids can be produced by mixing 
plasmids encoding capsid proteins of different serotypes during vector production (Hauck 
et al, 2003). An example of the successful use of hybrid vectors was demonstrated by Jude 
Samulski’s group through mixing of AAV1 and AAV2 capsid proteins (Rabinowitz et al, 
2004).  The resulting vector designated AAV1/2 was found to be capable of transducing the 
C2C12 mouse myoblast cell line which is known to be refractory to transduction with 
individual AAV1 or AAV2 vectors alone. The increased efficacy of transduction was believed 
to be due to the combined ability of AAV2 epitopes to bind heparin sulphate whilst AAV1 
properties allowed for alternative trafficking of virions that prevented endosomal 
degradation. As such, hybrid capsids can improve the potency of AAV vectors by enhancing 
transduction of a target cell type whilst also preventing endosomal degradation.     
1.3.2.3 Epitope tagging 
 
By tagging rAAV capsids with specific epitopes, capsids can be engineered to target certain 
cell types more effectively. For example, by inserting a ligand derived from apolipoprotein E 
(ApoE) at the N-terminus of the VP2 protein, the resulting vector demonstrated 220-fold 
greater ex vivo  transduction of low density lipoprotein receptor (LDL-R) expressing human 
islet cells as compared to unaltered rAAV2 (Loiler et al, 2003). Furthermore, as heparin 
sulphate proteoglycans (HSPGs) are present on all animal cell types , by carefully selecting 
the site of epitope insertion within the AAV2 capsid, HSPG binding can be ablated to 
improve tissue specificity: with prevention of HSPG binding known to be optimal by epitope 
insertion at positions 1 to 587 of the VP3 protein (Girod et al, 1999; Loiler et al, 2003; 
Nicklin et al, 2001; Opie et al, 2003).  
1.3.2.4 Immune escape capsids 
 
Through inserting peptides at capsid sites corresponding to known immunogenic epitopes, 
AAV vectors can be engineered to evade neutralising immune responses (Bartel et al, 
2011). By screening AAV2 capsid mutants with a panel of polyclonal human sera, Hildegard 
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Büning’s group observed that mutations at capsid position 534 or 573 significantly reduced 
antibody binding affinity (approximate 31% binding reduction in 42% of sera tested) 
(Huttner et al, 2003). Furthermore, by inserting a peptide that targets Mec1 cells at 
position 587, the same group demonstrated the ability of this mutant vector to effectively 
transduce target cells even in the presence of neutralising antisera. This observation 
suggests the possibility of simultaneously modulating cell tropism and immune 
neutralisation through a single peptide insertion (Huttner et al, 2003). Thus, epitope 
tagging can improve the potency of AAV vectors by enhancing specific cell targeting and by 
preventing immune responses.   
1.3.2.5 Empty capsid decoys 
 
It has recently been shown that the co-administration of empty AAV capsids, along with 
gene therapy vectors containing the transgene of interest, allows for neutralising anti-AAV 
antibodies (NAbs) to be titrated out in human serum in-vitro and in mice and nonhuman 
primate serum following intravascular delivery (Mingozzi et al, 2013). In this study, mouse 
models of anti-AAV response were immunised with human intravenous immunoglobulin 
(IVIg) 24 hours prior to administration of gene therapy vectors. AAV8 vectors expressing 
human FIX were injected intravenously at doses of 1×109 or 5×109vg per animal with or 
without a 10X excess of empty AAV8 capsid. In naïve animals, FIX expression levels 
between groups receiving vector formulated in 10X empty capsids or PBS only were 
equivalent. However, in immunised animals, liver transduction was blocked when using 
gene therapy vector alone; whereas FIX expression was partially rescued in animals 
receiving vector combined with empty capsid (25% and 83% residual FIX expression at the 
low and high dose respectively). This approach was also successful in animals with higher 
AAV8 antibody titres of 1:10 and 1:100 when using a 50X and 100X excess of empty capsids 
respectively. Using an ELISA based assay to detect IgG-capsid immune complexes, this 
effect was shown to be implemented through absorption of NAbs by excess AAV capsid. As 
such, it was suggested that empty capsids act as decoys to protect AAV from neutralisation. 
This observation was recapitulated in rhesus macaques that are natural hosts of AAV8 and 
thus demonstrate neutralising activity. Following injection of 2×1012vg/kg, monkeys 
receiving gene therapy vector only demonstrated undetectable or reduced levels of FIX 
(120-250ng/ml) when compared to animals receiving vector prepared in a 9X excess of 
empty capsid (300-450ng/ml).  
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By mutating the AAV2 capsid so that cell surface binding was disrupted, it was also 
demonstrated that empty; non-infective AAV capsids; which do not compete for cell entry 
and subsequently cannot cause antigen presentation; can be generated.  However, the fact 
that professional antigen presenting cells are able to take up antigens without cell surface 
binding means that mutant empty capsids may indeed be immunogenic and, as a result, 
may enable immune mediated clearance of transduced cells. As such, this strategy may not 
overcome the limitation of T-cell responses to transduced hepatocytes that has been 
observed in humans. Furthermore, this approach was not found to be effective in mice 
with NAb titres exceeding 1:3000 even in the presence of 1000X excess empty capsids. As a 
result, this approach may not be beneficial in patients with higher antibody titres.  
 
1.3.2.6 Capsids that bypass cellular blocks 
 
As previously described, after entering the cell, AAV vector particles are processed through 
the endosomal compartment. By performing tyrosine-to-phenylalinine mutations of capsid 
residues, endosomal degradation of viral particles can be avoided by preventing capsid 
ubiqutination (Petrs-Silva et al, 2009). Tyrosine mutants have indeed been accepted as 
viable tools for retinal gene therapy and have been shown to restore retinal function and 
visual behaviour in a mouse model of retinitis pigmentosa for at least 6 months after 
subretinal injection of AAV8 Y733F mutants expressing the PDEβ gene (Pang et al, 2011). 
Similar capsid mutations have also been utilised for liver transduction. In these studies, 
long term therapeutic gene expression of human coagulation factor IX (hFIX) was observed 
in a mouse model of Haemophilia B following administration of AAV2 Y730F and triple 
mutant AAV2 (Y444+500+730F) at doses previously reported to be subtherapeutic using 
non-mutant AAV2 vectors (Markusic et al, 2010). The use of capsid mutants in the liver 
crucially infers the feasibility of using these vectors  in tissues that are less immune 
privaleged  than the eye. However, due to a lower seroprevelance in humans, AAV8 
pseudotyped vectors still remain a stronger candidate for effective human liver 
transduction as compared to mutant AAV2. Indeed it is stated in the 2010 Markusic paper 
that tyrosine mutations are not thought to overcome the previously reported neutralizing 
immune responses to AAV2. Nonetheless tyrosine capsid mutations are a possible avenue 
of for improving vector potency by preventing degradation of viral particles. 
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1.3.2.7 Critique of capsid modifications 
 
As demonstrated in previous literature, several modifications can be made to serotype 2 
capsid proteins in order to enhance the potency of AAV2 vectors. This includes the 
insertion of epitopes to enhance binding to target cells or to avoid immune responses 
against capsid antigens. Although these modifications show great promise in AAV2, these 
results have not been reproduced in vectors of alternative serotypes, likely due to such 
modifications disrupting cell surface binding. For instance, in our unpublished data, we 
observed a decrease in liver transduction in mice when using an AAV8-FIX vector with 
mutated capsid tyrosine residues as compared to transduction using vectors with a wt 
AAV8 capsid. From these results one can speculate that these mutations resulted in the 
ablation of AAV8’s natural liver tropism. Furthermore, due to a lower seroprevelance in 
humans, AAV8 pseudotyped vectors still remain a stronger candidate for effective human 
gene transfer as compared to mutant AAV2. In this study we aimed to test the potency of 
our AAV constructs by assessing expression of human factor IX following transduction of 
the liver. Serotype 8 was selected due to the strong liver tropism previously described. 
However, it should be noted that, contrary to previously mentioned  literature reports, 
AAV9 has also been demonstrated as highly liver tropic (Vandendriessche et al, 2007). As 
capsid modifications have not been successfully used in serotype 8 vectors, mutant capsids 
were not used in this work. As such, we aimed to focus on expression cassette alterations.    
1.3.3 Cassette optimisation 
 
In addition to capsid modifications, vector potency can also be improved through alteration 
of the AAV expression cassette. This matter will be discussed in the following section with 
reference to the use of self-complementary vectors, cis-regulatory elements and codon-
optimisation. 
1.3.3.1 Self complementary vectors 
 
As previously mentioned, single to double stranded conversion of AAV genomes is an 
essential step for generating transcriptionally active DNA forms. This complex process is 
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known to be a major rate limiting step for efficient gene expression. To overcome this 
limitation it is possible to generate a vector that delivers a duplex genome (McCarty et al, 
2001). This is achievable by packaging complementary sense and antisense sequences 
within the same virion. The resulting so-called self-complemetary genomes are single 
stranded inverted repeat sequences with a mutated ITR in the middle of the molecule. 
Deletion of a terminal resolution site (trs) from the central ITR means that the ITR can no 
longer act as a replication origin but is still capable of forming a hairpin structure. Thus 
upon uncoating, sense and antisense strands anneal by folding together at the hairpin to 
form transcriptionally active dimers (McCarty et al, 2003). With self-complementary 
vectors, stable hepatocyte transduction has been achieved at almost a log higher level than 
that observed with single stranded vectors at equivalent doses (Nathwani et al, 2009).             
1.3.3.2 Promoter selection 
 
Careful selection of promoters is important for obtaining high levels of transgene 
expression and for mediating tissue specific expression/preventing off target effects. In one 
example, to assess the potency of different promoters in the context of rAAV, Nathwani et 
al produced four vectors containing either the CMV (cytomegalovirus), MSCV (murine stem 
cell virus), CAGG (CMV enhancer/β-actin promoter complex) or HBV (hepatitis B 
enhancer/core promoter complex) regulatory elements upstream of human factor IX 
(Nathwani et al, 2001). By portal vein injection, 1×1011 vg of each vector was administered 
to C57Bl/6 SCID mice. At 12 weeks post injection and thereafter FIX levels of approximately 
10% of normal (506 ± 61 ng/mL) were observed in plasma samples from CAGG vector 
transduced mice. Expression from all other vectors was significantly lower (20-54 ng/mL) 
and southern blot analysis on genomic liver DNA showed that this difference was not due 
to variation in vector copy number. This suggests that careful selection of regulatory 
elements can enhance transgene expression. However, to restrict FIX expression to the 
liver, the use of a strong tissue specific promoter such as LP1 or HCR-hAAT is necessary.     
A further example for the importance of cis-regulatory elements was provided by Mark 
Kay’s group in 2000. In this study 20µg of retroviral hFIX plasmid constructs containing 
various regulatory sequences were delivered to C57BL/6 mice by tail vein injection (Miao et 
al, 2000b). By this analysis the ApoE-HCR-hAAT-FIXmg-bpA construct containing the ApoE 
hepatic locus control region, the human α antitrypsin promoter and the hFIX minigene 
(containing a portion of the first intron; the 3’ untranslated region and the bovine growth 
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hormone polyA) demonstrated the highest serum hFIX levels of up to 18µg/ml one day 
after injection. This was a striking 68.9±27.5 fold increase in transgene expression as 
compared to basal levels obtained from animals receiving an equivalent dose of the hFIX 
cDNA construct without internal promoters. This construct has also demonstrated high 
levels of in-vivo transgene expression when cloned into a single stranded AAV expression 
cassette (vector designated AAV-hFIX16) (High et al, 2004a; Mingozzi et al, 2003). Thus, 
when designing AAV vectors with improved potency, it is worth considering the 
incorporation of intronic and UTR (untranslated region) sequences as well as exploring 
various promoter-enhancer combinations.             
When optimising a sequence for use in a mammalian expression vector, it is also worth 
considering the use of an optimal Kozak sequence for efficient initiation of translation. The 
sequence GCCRCCaug (where R is a purine and aug is the initiation codon) is known to be 
the optimal Kozak sequence for expression of proteins in mammalian organisms and cell 
lines and is frequently used in gene therapy vectors (Xia, 2007).          
1.3.3.3 Codon-optimisation 
 
Codon optimisation has previously been shown to significantly enhance protein production 
and therefore must be considered as an option during vector optimisation (Haas et al, 
1996; Nathwani et al, 2006).  Analysis of the human FIX (hFIX) cDNA sequence has revealed 
several genetic elements that may limit hFIX expression in mammals. This includes a low GC 
content, an RNA instability motif, a high frequency of rare codons and a cryptic splice donor 
site (Wu et al, 2008). Using GeneOptimizer software Paul Monahan’s group successfully 
engineered a codon- optimised hFIX (hFIXopt) sequence by removing negative cis-acting 
features, changing codon usage bias to Homo sapiens, and increasing GC content from 41 
to 61% (Wu et al, 2008).  
Using a self-complementary AAV2 format the optimised vector was delivered to C57BL/6 
mice via portal vein injection at doses ranging from 3×109 to 1×1011 vg/mouse. At all doses 
tested non-optimised self-complementary vectors mediated a moderate increase in hFIX 
levels (1.5-2.6 fold) as compared to a single stranded vector.  In contrast markedly higher 
levels of hFIX were observed with the hFIXopt vector (5.5-21.2 fold increase as compared 
with single stranded AAV). Notably at the lowest dose of 3×109 vg, hFIX levels remained in a 
therapeutic range when using scAAV2- hFIXopt. This suggests that codon-optimisation can 
be exploited to enhance the potency of AAV at lower doses.    
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In summary various modifications to AAV expression cassettes can be exploited to enhance 
viral transduction efficiency (summarised in Table 2). As such, vectors used in this study 
contained the improved codon-optimised hFIX expression cassette previously used in the 
clinic (Nathwani et al, 2011). To achieve liver specific expression, this cassette contained 
the LP1 promoter that consists of core domains from the human apolipoprotein hepatic 
control region and the human alpha-1-antitrypsin promoter (Nathwani et al, 2006). These 
cis-regulatory components prevented off target effects whilst also enhancing expression.   
However, studies of rAAV proviral DNA structure suggest that there may be yet another 
avenue of AAV biology that can be altered to enhance vector potency. In previous studies, 
AAV concatemers have been found to form chromatin like structures in-vitro and in-vivo 
(Marcus-Sekura & Carter, 1983; Penaud-Budloo et al, 2008). This would infer that AAV 
genomes have the potential to undergo epigenetic silencing. Furthermore, in mice, 
enhanced AAV mediated transgene expression has been observed following co-
administration of histone deacetylase (HDAC) inhibitors. This suggests that AAV genomes 
are subject to association with histone proteins that prevent transcription (Okada et al, 
2006). Nonetheless, the effects of epigenetic silencing on AAV concatemers still remain to 
be explored as a potential route of vector improvement. This matter will be approached in 
the following sections.   
 
1.4 Repeat induced gene silencing  
 
The epigenetic silencing of exogenous DNA sequences is a phenomenom known to occur 
following gene transfer. This concept, known as repeat induced gene silencing, may 
represent an additional limitation of rAAV mediated gene expression. Repeat induced gene 
silencing and the impact that it may have on the potency of rAAV will be discussed in this 
section.   
The theory of repeat induced gene silencing (RIGS) suggests that transgenes arranged in 
multicopy concatemeric arrays are subject to epigenetic silencing (Garrick et al, 1998; 
Selker, 1999). The first evidence for the silencing of multicopy transgenic loci was 
discovered in plants by Jorgensen and Mol through the introduction of extra pigment 
producing genes into petunias (Jorgensen et al, 1996; Napoli et al, 1990; van der Krol et al, 
1990). Following  gene transfer, mosaic pigmentation or even completely white flowers 
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were observed as opposed to the anticipated deep purple colouration. This suggests not 
only the silencing of transgene copies but also the silencing of homologous endogenous 
sequences.  
Gene silencing events of this nature often occur at the post transcriptional level and are 
believed to operate through an ‘abberant RNA’ based mechanism (Sharp, 2001). In 1999 
Hamilton and Baulcombe made the breakthrough discovery that short stretches of  RNA 
(approximately 25nt) of both sense and antisense polarity are detectable in plants in 
stringent association with the occurance of post transcriptional gene silencing (PTGS) 
(Hamilton & Baulcombe, 1999). The generation of such RNA species is now known to occur 
through the accumulation of double stranded RNA (dsRNA) which is later ‘cut’ by the 
ribonuclease Dicer in order to form the short sequences now designated small interfering 
RNAs (siRNAs) (Bernstein et al, 2001). As the dsRNA generated is derived from the 
transcription of exogenous sequences, siRNAs are able to bind to corresponding mRNAs 
and transgenes through base complementation. Thus, siRNAs demonstrate the ability to 
bring their associated protein complexes, RNA induced silencing complex (RISC) and RNA 
induced initiation of transcriptional gene silencing complex (RITS), into contact with 
complimentary sequences for the degradation of mRNA by ribonucleases and silencing of 
transgenic loci via histone modifications (transcriptional gene silencing (TGS))  respectively 
(Moazed, 2009). Although at present the RITS complex has only been identified  in fission 
yeast, fungi and fruit flies, it is believed that analogous silencing events exist in higher 
species including mammals. However, the exact mechanism of silencing and composition of 
protein complexes involved in mammals remains undefined (Ahlenstiel et al, 2012).  
So how does this theory relate to the silencing of rAAV genomes? Where transgenes are 
arranged in arrays that give rise to inverted repeat sequences, dsRNAs are more readily 
generated due to the direct provision of adjacent complementary sense and antisense 
transcripts (Figure 1.2). In this situation the silencing of transgene expression is known to 
be enhanced (Muskens et al, 2000; Wolffe & Matzke, 1999). Consequently, in the context 
of rAAV, one can envisage a state whereby viral genomes concatamerise in  orientations 
that generate palindromes. This would potentiate the production of dsRNAs for subsequent 
silencing of transgene sequences. Furthermore, as 3’ ITR and PolyA sequences are often 
deleted, the potential for read-through transcription of AAV inverted repeats and 
subsequent dsRNA generation is increased (McLaughlin et al, 1988; Rutledge & Russell, 
1997; Yang et al, 1997).      
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Figure 1.2: Silencing of inverted repeat arrays through RNA interference 
(RNAi). Through the direct provision of adjacent sense and antisense 
sequences, inverted repeats increase the potential for double stranded 
RNA formation. Double stranded RNAs are cut by the ribonuclease 
deisgnated Dicer into small interfering RNAs (siRNAs). siRNAs then join 
with associated proteins to form complexes involved in mRNA cleavage 
and DNA heterochromatinisation of sequences complimentary to the 
siRNA (RISC and RITS complexes respectively) with the overall effect of 
gene silencing. 
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Indeed this theory does serve to explain the nonlinear dose response and 
variagated/mosaic stable expression pattern observed in AAV transduced murine 
hepatocytes (Nakai et al, 2002). Furthermore, in non human primates, AAV vector genomes 
have been found to form chromatin like structures through assimilation with host DNA 
modifications (Leger et al, 2011). Concurrently in our group we have found that, following 
gene transfer, a proportion of exogenous sequences undergo heterochromatinisation 
(unpublished data).  
The use of cis-regulatory elements that prevent gene silencing events may, therefore, 
improve the potency of rAAV vectors. For this reason we have developed  single stranded 
AAV expression casettes containing  scaffold/matrix attachment regions (S/MARs).  
 
1.5 Scaffold/Matrix Attachment Regions  
 
The enhancer activity of S/MARs has been demonstrated in multiple gene transfer 
experiments using retroviruses, lentiviruses and plasmid DNA (Argyros et al, 2008; Dang et 
al, 2000; Kurre et al, 2003; Ramezani et al, 2003). As such, the incorporation of S/MAR 
elements into AAV expression cassettes may enhance vector potency and thus permit the 
use of lower doses. However, S/MARs have yet to be tested in the context of rAAV. The 
function of S/MARs in enhancing gene expression will be discussed in this section. 
The nuclear matrix (NM) is defined as a network of proteinaceous filaments that constitute 
the framework of the cell nucleus (Berezney & Coffey, 1974). Branching filaments of the 
NM accommodate the formation of organised DNA domains as they provide a supporting 
structure for the attachment of chromatin loops (Mirkovitch et al, 1984). Furthermore, the 
NM acts as a hub of nuclear activity by tethering DNA into close proximity with proteins 
required for transcription, replication, RNA processing, RNA transport and recombination 
(Berezney et al, 1995). 
Scaffold/matrix attachment regions play a fundamental role in genome organisation and 
co-ordination of expression from specific gene loci (summarised in table 4). They do so by 
serving as anchor points on DNA for the nuclear matrix and thereby place genes in close 
proximity to the aforementioned nuclear proteins required for gene expression (Ma et al, 
1999). S/MARs generally consist of AT-rich regions found in the 5’ or 3’ flanking regions of 
genes, in introns, or at gene breakpoint cluster regions and, although S/MAR elements are 
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highly conserved across eukaryotic species, they do not contain any obvious consensus 
sequences. Instead S/MARs are defined by structural consensus as opposed to primary 
sequence (Argyros et al, 2011; Benham et al, 1997; Gluch et al, 2008).  
For instance, a strong propensity to undergo DNA strand separation is a known property of 
S/MARs (Bode et al, 2006). Indeed S/MARs typically contain multiple base unpairing regions 
(BURs) that are readily detectable by chemical probing studies using reagents with a strong 
affinity for single stranded DNA (including potassium permanganate and 
chloroacetaldehyde) (Bode et al, 2000). The In Silico method known as Stress Induced 
Duplex Destabilisation (SIDD) also serves to map S/MARs through the prediction of the 
amount of energy (G) required to separate the DNA strand at any given base pair (X) under 
negative superhelical tension and in the context of the full sequence under analysis. Where 
less energy (G(X)) is required the probability of unpairing at that particular base position 
(P(X)) increases and so potent S/MAR sequences are identifiable as regions with low G(X) 
and high P(X) values (Benham et al, 1997; Bode et al, 2006).  
Through such helix destabilization S/MARs are able to form their characteristic non-B DNA 
structures. For example, as S/MARs commonly contain palindromic sequences, DNA strand 
separation enables the formation of cruciform DNA (Figure 1.3) (Bode et al, 2000). 
Furthermore, S/MARs frequently contain sequences that allow for the formation of triple 
helical structures (including TG, TA, GC repeats and polypyrimidine/polypurine stretches) 
and DNA bending (oligod(A) stretches) (Boulikas, 1993).  
It is these secondary structures that determine the association of S/MAR binding proteins. 
For instance, known S/MAR binding proteins include lamins (an NM component) and 
nucleolin (a histone chaperone protein), which recognise single-stranded DNA, and high 
mobility group proteins (HMG) that preferentially bind to cruciform structures (Kohwi-
Shigematsu et al, 1998). The binding of proteins involved in histone distribution such as 
nucleolin and HMG-I/Y enables the associated DNA to be maintained in an open 
euchromatin state (Angelov et al, 2006; Bianchi & Agresti, 2005). As such, S/MAR 
sequences are thought to facilitate the initiation of transcription and thus enhance gene 
expression.  
Additionally S/MARs can shield gene expression from position effects and/or block the 
action of distant enhancers thus serving as genetic insulators (Goetze et al, 2005). They also 
have origin of replication support functions which in the context of episomal vectors has 
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been shown to facilitate episome retention and replication in dividing mammalian cells 
(Baiker et al, 2000; Piechaczek et al, 1999; Schaarschmidt et al, 2004). For instance, the 
SV40 large T-antigen is a viral trans-acting factor required for replication of the SV40 
episome. After deleting the large T-antigen gene from the SV40 genome and replacing it 
with a S/MAR element from the 5’ region of the IFNβ gene, rescue of SV40 episome 
replication has been demonstrated in-vitro with episomes retained at low copy numbers 
following successive cell divisions (Piechaczek et al, 1999).      
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Table 4: Summary of the role of S/MAR elements. 
  
S/MAR Function Mechanism 
Prevention of silencing  Formation of partitioned looped 
domains  
 Insulation from positional effects 
Increasing expression  High propensity for DNA strand 
separation facilitates access of proteins 
involved in transcription potentiation 
and chromatin remodelling  
Stabilising expression  Anchoring chromatin to the nuclear 
matrix 
 Origin of replication complexes form at 
S/MAR regions 
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Figure 1.3: Cruciform formation. The ability for DNA strand separation to cause secondary 
structure formation is represented schematically. Strand separation at regions containing 
palindromic sequences enables binding of complementary sequences to form cruciform 
DNA. 
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1.6 Research aim 
 
The aim of this project was to improve the potency of AAV vectors. As such, we 
hypothesised that the incorporation of matrix attachment regions into AAV expression 
casettes would improve transgene expression by preventing epigenetic silencing. To 
address this matter we aimed to carry out a head to head comparison of multiple S/MARs 
in the single stranded AAV2/8 LP1-hFIXco format (Figure 1.4). 
1.7 Brief outline of strategy: 
 
S/MARs selected for head to head comparison in ssAAV8-LP1-hFIXco included regions from 
the human interferon-β (IFN-β), apolipoprotein B (apoB) and hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) genes. Additionally, a region of the Kaposi sarcoma 
herpes virus (KSHV) genome known to promote autonomous replication was utilised as a 
non-S/MAR control element (Stedman et al, 2008). The IFN-β S/MAR has been shown to 
enhance transgene expression in multiple gene transfer vectors whilst the apoB S/MAR is 
well documented to have an insulatory role against positional chromatin effects (Namciu et 
al, 1998). Further to this, in the context of our AAV construct, the in silico approximation of 
energy required for unwinding (GX) is particularly low at the theoretical apoB S/MAR site. 
In contrast, the HPRT S/MAR has primarily been documented to have a role in autonomous 
replication (Sykes et al, 1988).  In order to identify sequence regions required for enhancer 
activity and to minimise the space occupied by S/MARs within a given expression cassette, 
a deletion analysis was carried out on S/MAR sequences. The mechanism behind S/MAR 
activity was assessed by chromatin immunoprecipitation and RNA studies. 
Strategy: 
 S/MAR elements or fragments thereof were cloned into the pAV-LP1-hFIXco-
SV40pA vector plasmid which was used for production of rAAV. 
 The vectors were initially tested in-vitro prior to assessment in-vivo using the 
C57Bl/6 mouse model.   
 HFIX expression levels were normalised for genome copy number in order to 
correct for discrepancy in transduction efficiency. 
 This was followed by studies to establish the mechanisms responsible for 
augmentation of rAAV mediated transgene expression.  
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 To ascertain efficacy and safety across species promising vectors were tested in 
rhesus macaques. 
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Figure1.4: Schematic of the single stranded rAAV cassette. All epigenetic modifiers 
(S/MAR elements) were cloned  immediately 3’ of codon optimised human Factor IX; 
upsteam of a truncated  SV40 poly A sequence. Expression was driven from the LP1 liver 
specific promoter. 
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CHAPTER 2 MATERIALS AND METHODS 
 
Specific methods are discussed in the relevant results chapter 
2.1 Molecular biology 
2.1.1 Reagents 
 
 HotStar Taq Plus DNA Polymerase (Qiagen, Crawley, UK) 
 Phusion High-Fidelity DNA Polymerase (New England Biolabs UK Ltd, Hitchin, UK)        
 Custom primers (Integrated DNA Technologies, Leuven, Belgium) 
 Restriction enzymes (New England Biolabs UK Ltd, Hitchin, UK) 
 NEBuffers 1-4 (New England Biolabs UK Ltd, Hitchin, UK) 
 100X BSA (New England Biolabs UK Ltd, Hitchin, UK) 
 Molecular biology water (Sigma-Aldrich Company Ltd, Poole, UK) 
 Agarose (Bioline, London, UK) 
 Ethidium bromide (Sigma-Aldrich Company Ltd, Poole, UK) 
 Tris base (VWR International Ltd, Lutterworth, UK)               
 Boric acid (VWR International Ltd, Lutterworth, UK)               
 Ethylenediaminetetraacetic acid (EDTA) (VWR International Ltd, Lutterworth, UK)               
 Sucrose (Sigma-Aldrich Company Ltd, Poole, UK) 
 Bromophenol blue (Sigma-Aldrich Company Ltd, Poole, UK) 
 QIAquick Gel Extraction Kit (Qiagen, Crawley, UK) 
 DNA Polymerase I, Large (Klenow) Fragment (New England Biolabs UK Ltd, Hitchin, 
UK)        
 Calf Intestinal Phosphatase (New England Biolabs UK Ltd, Hitchin, UK)        
 T4 DNA Ligase (New England Biolabs UK Ltd, Hitchin, UK)   
 L-Broth capsules (MP Biomedicals, Cambridge, UK)  
 Ampicillin (Melford Laboratories Ltd, Ipswich, UK)  
 NEB 5-alpha Competent E.coli (High efficiency) (New England Biolabs UK Ltd, 
Hitchin, UK)        
 pUC19 Vector (New England Biolabs UK Ltd, Hitchin, UK)        
 SOC Outgrowth Medium (New England Biolabs UK Ltd, Hitchin, UK)      
 NucleoSpin® Plasmid kit (Fisher Scientific, Loughborough, UK)  
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 Qiagen Plasmid Mega Kit (Qiagen, Crawley, UK)           
2.1.2 Polymerase chain reaction (PCR) 
 
Through amplification of specific plasmid DNA regions, PCR was used to generate short 
IFNβ and HPRT S/MAR fragments. Using a Dyad® thermal cycler (BioRad Laboratories Ltd, 
Hemel Hempstead, UK) amplification was achieved by cycling between temperatures that 
enabled the denaturation of template DNA, annealing of sequence specific oligonucleotide 
primers, and extension of DNA polymerisation. All reactions were done in conjunction with 
a no template negative control to ensure no contaminating DNA was present. DNA 
polymerases used during this work included HotStar Taq DNA Polymerase (Qiagen, 
Crawley, UK) and Phusion High-Fidelity DNA Polymerase (New England Biolabs UK Ltd, 
Hitchin, UK).        
The standard reaction mix for a 100µl PCR using HotStar Taq DNA Polymerase contained 
10µl 10X PCR buffer (contains Tris.Cl, KCl, (NH4)2SO4, 15 mM MgCl2; pH 8.7), 0.5µM of each 
primer, 200µM of each dNTP, 2.5U HotStar Taq DNA Polymerase and 1µg DNA template. 
Standard cycling conditions used included an initial activation step of 95ᵒC for 15 minutes 
followed by 35 cycles of denaturation at 94ᵒC for 1 minute, annealing of primers for 1 
minute and extension at 72ᵒC for 1 minute. After the 35 cycles a final extension step was 
carried out at 72ᵒC for 10 minutes. 
The standard reaction mix for a 50µl PCR using Phusion High-Fidelity DNA Polymerase 
contained 10µl 5X Phusion HF buffer (containing 7.5 mM MgCl2), 0.5µM of each primer, 
200µM of each dNTP, 1U Phusion High-Fidelity DNA Polymerase and 250ng DNA template. 
Standard cycling conditions used included an initial denaturation step of 98ᵒC for 30 
seconds followed by 35 cycles of denaturation at 98ᵒC for 5 seconds, annealing primers for 
30 seconds and extension at 72ᵒC for 15 seconds. After the 35 cycles a final extension step 
was carried out at 72ᵒC for 10 minutes. 
 
2.1.3 Restriction enzyme digests 
 
Restriction enzyme digests were used to cut plasmid DNA at specific sites for subsequent 
molecular cloning experiments or to screen DNA extracted from transformed E.coli colonies 
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for the presence of desired plasmid constructs.  All restriction enzymes and buffers used in 
this work were supplied by New England Biolabs UK Ltd (Hitchin, UK).  
In addition to DNA the standard reaction mix for all restriction digests contained 10% 10X 
NEBuffer (buffer selection depended on the enzyme chosen)1% 100X BSA (included only 
when required by the selected enzyme) and between 1% to 10% of the chosen restriction 
enzyme (depending on enzyme units and the amount of DNA to be digested). Final reaction 
volumes were made up with molecular biology water. Digests were carried out by heating 
the reaction mixes for 1 to 3 hours (dependent on the amount of DNA used) at 37ᵒC using a 
Dyad® thermal cycler (BioRad Laboratories Ltd, Hemel Hempstead, UK). 
Where subsequent purification of DNA fragments was required, samples were run on 1% to 
2% weight/volume agarose gels. DNA bands were then visualised using a transilluminator 
and excised with a sharp scalpel. DNA was purified using the QIAquick Gel Extraction Kit 
(Qiagen, Crawley, UK) as per the manufacturer’s instructions. 
2.1.4 Agarose gel electrophoresis 
 
Buffers 
10X TBE: 108g Tris base, 55g boric acid, 9.3g EDTA in 1 litre ddH2O 
5X Loading buffer: 40% sucrose and 0.25% bromophenol blue in 10X TBE 
Agarose gel electrophoresis was used to separate DNA fragments by size following 
restriction enzyme digests and to detect PCR products. Depending on the size of DNA 
fragments to be analysed, between 1% to 2% weight/volume agarose was dissolved in 
100ml of 1X TBE by heating in a microwave oven. After a brief cooling period, 10µl of 
500µg/ml ethidium bromide solution was added and the gel was poured into a mould. 
After setting the gel was placed in an electrophoresis tank filled with 1X TBE buffer. 
Samples were mixed with an appropriate volume of loading buffer immediately prior to 
loading into wells of the gel. The appropriate molecular size ladder was also loaded into 
one well to determine DNA fragment sizes. Samples were electrophoresed at 120V and 
fragments were detected by fluorescence of intercalated ethidium bromide under UV 
illumination.      
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2.1.5 Klenow fill-in 
 
Klenow fill-in was used for the generation of blunt ended DNA where blunt end 
modification was required prior to DNA ligation. This was achieved using DNA PolymeraseI, 
Large (Klenow) Fragment (New England Biolabs UK Ltd, Hitchin, UK). This proteolytic 
product of the E.coli DNA polymerase I enzyme retains 3’ to 5’ exonuclease and 
polymerisation activity and as such is able to fill in 5’ overhangs and remove 3’ overhangs.   
In a standard Klenow fill-in, DNA with sticky ends was incubated with 1U/µg DNA large 
Klenow fragment, 1X NEBuffer 4 (contains 50mM Potassium Acetate, 20mM Tris-acetate, 
10mM Magnesium Acetate, 1mM DTT, pH 7.9 at 25°C), and 33µM dNTP for 15 minutes at 
25°C using a Dyad® thermal cycler (BioRad Laboratories Ltd, Hemel Hempstead, UK). To 
terminate the reaction EDTA was added to a final concentration of 10mM and samples 
were heated at 75°C for 20 minutes.        
2.1.6 Alkaline phosphatase treatment  
 
Alkaline phosphatase enzyme was used to remove 5’ phosphate groups from vector 
backbone DNA in order to prevent self-ligation. The phosphatase enzyme used for this 
work was Calf Intestinal Phosphatase (CIP) (New England Biolabs UK Ltd, Hitchin, UK).        
In addition to DNA, the standard reaction mix for a 50µl phosphatase treatment contained 
5µl 10X NEBuffer 3 (contains 100mM NaCl, 50mM Tris-HCl, 10mM MgCl2, 1mM 
Dithiothreitol,  pH 7.9 at 25°C) and 5U CIP (stored in 10 mM Tris-HCl, 50 mM KCl,1 mM 
MgCl2, 50% Glycerol, 0.1 mM ZnCl2, pH 8.2 at 25°C). Final reaction volumes were made up 
with molecular biology water. Standard reaction conditions entailed a 1 hour incubation at 
37ᵒC using a Dyad® thermal cycler (BioRad Laboratories Ltd, Hemel Hempstead, UK). 
2.1.7 Ligations 
 
Ligations were carried out for the insertion of DNA sequences into CIP treated linear vector 
backbone DNA. All reactions were done in conjunction with a backbone DNA only negative 
control to determine relative background levels of self-ligated vector DNA. All ligations in 
this work were carried out using T4 DNA ligase (New England Biolabs UK Ltd, Hitchin, UK).        
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On Ice, vector backbone DNA was mixed with an approximate 3-fold excess of insert DNA 
(as determined by the appearance of band intensity on a 1% agarose gel). In addition to 
DNA the standard reaction mix for a 20µl ligation contained 2µl 10X T4 DNA ligase buffer 
(containing 50mM Tris-HCl, 10mM MgCl2, 1mM ATP, 10mM DTT, pH 7.5 at 25°C) and 800 U 
of T4 DNA ligase (stored in 10 mM Tris-HCl, 50 mM KCl, 1 mM DTT, 0.1 mM EDTA, 50% 
Glycerol, pH 7.4 at 25°C). Final reaction volumes were made up with molecular biology 
water. All reactions were carried out by overnight incubation at 4°C.  
2.1.8 Bacterial Transformation and expansion of Colonies 
 
Growth medium 
L-Broth: 16 L-Broth capsules (MP Biomedicals, Cambridge, UK) dissolved in 1 litre ddH2O; 
sterilised by heating at 121°C for 20 minutes in a bench top autoclave (Astell, Kent, UK). 
Ampicillin was added to a final concentration of 100µg/ml. 1litre of L-Broth contained 10g 
Tryptone, 5g yeast extract and 0.5g NaCl.   
Bacterial transformations were carried out for the propagation of plasmid DNA. All 
reactions were carried out in conjunction with positive and negative control 
transformations (using pUC19 plasmid DNA and ligation mixture containing backbone DNA 
only respectively). DH5α chemically competent E.coli, pUC19 plasmid DNA and SOC 
outgrowth medium used in this study were supplied by New England Biolabs UK Ltd 
(Hitchin, UK).    
For a standard transformation DH5α competent cells were thawed briefly on ice and 
divided into 25µl aliquots. 5µl of ligation mixture or 1µl pUC19 plasmid was added to one 
individual aliquot of competent cells and incubated on ice for 30 minutes. To allow for DNA 
uptake, all samples and controls were heat shocked at 42°C for 20 seconds and 
immediately placed on ice for a further 5 minutes. 475µl of SOC medium (containing 2% 
Vegetable Peptone, 0.5% Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, and 20 mM Glucose) was then added to each sample followed by a 1 hour 
incubation at 37°C with shaking. As all plasmid constructs contained an ampicillin 
resistance gene, samples were spread onto agar plates containing 100µg/ml ampicillin 
(Melford Laboratories Ltd, Ipswich, UK) under aseptic technique. Plates were incubated at 
37°C overnight.  
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To determine whether ligations had been successful, plates were first checked to ensure 
that higher numbers of colonies were present for each construct in comparison to the 
negative control. The positive control plate was used to verify that transformation had 
occurred. Following these checks colonies were picked using pipette tips and placed in 5ml 
of LB medium. Samples were left in a 37°C shaking incubator overnight. The following day, 
DNA was extracted from 2ml of the cultures using the NucleoSpin® Plasmid kit (Fisher 
Scientific, Loughborough, UK) as per the manufacturer’s instructions. 3 ml of each culture 
was reserved and stored at 4°C.  
To ascertain whether the correct clones had been generated the extracted DNA was used 
in a diagnostic restriction digest whereby the enzymes selected would generate fragments 
of sizes that enabled correct plasmid constructs to be identified. Where positive digests 
were identified the corresponding 3ml of reserved bacterial culture was used to inoculate a 
further litre of LB medium. These cultures were incubated at 37°C overnight with shaking. 
The next day DNA was extracted from the cultures using the Mega Prep kit (Qiagen, 
Crawley, UK) as per the manufacturer’s instructions.  
2.2 Vector production 
2.2.1 Reagents 
 
 Sodium chloride (NaCl) (VWR International Ltd, Lutterworth, UK)               
 Potassium chloride (KCl) (VWR International Ltd, Lutterworth, UK)               
 Dipotassium phosphate (K2HPO4) (VWR International Ltd, Lutterworth, UK)               
 Magnesium chloride (MgCl) (VWR International Ltd, Lutterworth, UK)               
 Tris base (VWR International Ltd, Lutterworth, UK)               
 Phosphate buffered saline (PBS) tablets (OXOID, Basingstoke, UK) 
 Dulbecco’s Modified Eagle Medium (DMEM) (PAA Laboratories Ltd, Yeovil, UK)  
 PBS (PAA Laboratories Ltd, Yeovil, UK) 
 Fetal bovine serum (FBS) (GIBCO, Paisley, UK) 
 10X Trypsin EDTA (PAA Laboratories Ltd, Yeovil, UK)  
 Polyethylenimine (PEI) (Polysciences Inc, Northampton, UK)  
 Deoxycholic acid  (VWR International Ltd, Lutterworth, UK)               
 Benzonase (Sigma-Aldrich Company Ltd, Poole, UK) 
 Glycine (MP Biomedicals, Cambridge, UK)  
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 AVB Sepharose (GE Healthcare UK Ltd, Buckinghamshire, UK)  
 Custom primers (Integrated DNA Technologies, Leuven, Belgium) 
 Molecular biology water (Sigma-Aldrich Company Ltd, Poole, UK) 
 2 X QuantiFast SYBR Green Mastermix (Qiagen, Crawley, UK) 
 Sodium hydroxide (NaOH) (VWR International Ltd, Lutterworth, UK)               
 EDTA (VWR International Ltd, Lutterworth, UK)               
 Glycerol (VWR International Ltd, Lutterworth, UK)               
 Sodium dodecyl sulphate (SDS) (Sigma-Aldrich Company Ltd, Poole, UK) 
 Xylene cyanol (Sigma-Aldrich Company Ltd, Poole, UK)   
 10000X Gel Red (Cambridge Bioscience, Cambridge, UK)  
 Hyper Ladder I (Bioline, London, UK) 
 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) (VWR International 
Ltd, Lutterworth, UK)               
 Methanol (VWR International Ltd, Lutterworth, UK)               
 Acetic acid (VWR International Ltd, Lutterworth, UK)               
 Coomassie Brilliant blue R-250 (VWR International Ltd, Lutterworth, UK) 
 Laemmli buffer (Sigma-Aldrich Company Ltd, Poole, UK) 
 10% Precise Tris-HEPES Gels (Thermo Scientific, Loughborough, UK) 
2.2.2 Triple transfection of HEK293T cells  
 
Buffers 
1X TD buffer: 140mM NaCl, 5mM KCl, 0.7mM K2HPO4, 3.5mM MgCl2, 25mM Tris, pH7.5 in 
1L ddH2O 
PBS: 10 tables/litre ddH2O (OXOID, Basingstoke, UK) 
Triple transfections were carried out for AAV2/8 virus production. By transfecting cells with 
a transgene containing plasmid, a plasmid containing rep and cap genes and an adenoviral 
helper plasmid all genes required for the production and packaging of recombinant vector 
particles were expressed by the cells simultaneously (Nathwani et al, 2001). For each virus 
40× 15cm plates of HEK293T cells were used at approximately 70% confluence on the day 
of transfection. Cells were cultured at 37ᵒC, 5% CO2 in DMEM (PAA Laboratories Ltd, Yeovil, 
UK) with 10% FBS (GIBCO, Paisley, UK) and enzymatically passaged with 1X trypsin EDTA 
(PAA Laboratories Ltd, Yeovil, UK) every 2-3 days.  
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For a standard 40 plate transfection, 6ml of 1mg/ml Polyethyleneimine (PEI) (Polysciences 
Inc, Northampton, UK) was added to 54ml serum free DMEM. In a separate tube 1.8mg of 
helper plasmid (containing essential genes from the adenoviral genome that support 
rescue and replication of AAV genomes), 0.6mg 2/8 plasmid (containing rep and cap 
genes), 0.6mg of transgene containing plasmid, and 40µg of PCL10.1-EF1α-GFP plasmid was 
added to serum free DMEM to a final volume of 62ml. The mixture containing DNA was 
then filtered into the PEI containing mixture through a 0.2µm syringe filter. The solution 
was mixed and incubated at room temperature for 15 minutes. 3ml of transfection solution 
was then added to each 15cm dish of HEK293T cells.  
After 72 hours of incubation, cells were harvested using cell scrapers and transferred to 
250ml conical tubes. A small fraction of each preparation was reserved for flow cytometry 
using a Beckman Coulter CyAn ADP Analyzer (Beckman Coulter UK Ltd, High Wycombe, UK) 
to determine transfection efficiency as a percentage of GFP positive cells. All tubes were 
centrifuged at 1500rpm for 10 minutes. Supernatants were discarded and cell pellets 
resuspended in 25ml 1×TD buffer. Cells were again spun for 10 minutes at 1500rpm and 
supernatants were discarded. Cell pellets were then collectively resuspended in 40ml 1×TD 
buffer. To lyse the cells and release viral particles freeze thaw cycles of 30 minutes at -80ᵒC 
followed by 10 min at 37ᵒC were repeated 5 times.  
Prior to purification cells were incubated at 37ᵒC for 30 minutes with 0.5% deoxycholic acid 
and 50units/ml Benzonase (Sigma-Aldrich Company Ltd, Poole, UK). Lysates were then spun 
at 4000×g for 30 minutes at 18ᵒC, passed through a 0.45µm filter and diluted 1 in 3 in 
filtered PBS.  
2.2.3 Virus purification by affinity chromatography 
 
Buffers 
1M Tris: 121.14g Tris base, pH 8.8 in 1 litre ddH2O 
Glycine buffer: 3.75g Glycine, pH 2.7 in 1 litre ddH2O 
PBS: 10 tables/litre ddH2O, pH 7.5 (OXOID, Basingstoke, UK) 
Affinity chromatography was carried out for the isolation of AAV vector particles from cell 
lysates using an ÄKTA Explorer FPLC system (GE Healthcare UK Ltd, Buckinghamshire, UK) 
and UNICORN 5.20 software. Purification of AAV2/8 was achieved using a 5ml AVB 
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Sepharose (GE Healthcare UK Ltd, Buckinghamshire, UK) packed column (Davidoff et al, 
2004).  
For a standard purification all lines were first washed with 20% ethanol followed by PBS 
(line A11 and A2) and 50mM glycine (line B1). After attaching the sepharose column, the 
affinity medium was equilibrated with filtered PBS pH 7.5 for 10-20 minutes (or until pH 
and absorbance readings were stable) at a flow rate of 2ml/min. The cell lysates obtained 
from 40 plate preparations were then loaded onto the column at 5ml/min through line A2 
(traceable as an increase in absorbance at 260 and 280nm as unbound protein and DNA 
exit the column). Residual unbound protein and DNA was washed off the column in filtered 
PBS allowing for viral particles exclusively to be eluted in 50mM Glycine pH 2.7 (5ml/min). 
The eluate was collected in 1ml fractions into tubes containing 30µl 1M Tris pH 8.8 to 
neutralise the glycine. The virus containing fractions were identified by a peak in 
absorbance at 260 and 280nm. To remove glycine and restore pH, fractions were pooled 
together and dialysed overnight at 4ᵒC in PBS using a 10KDa cut-off dialysis cassette (Slide-
A-Lyzer Thermo Scientific, Loughborough, UK).  
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Figure 2.1: A typical AAV8 purification chromatogram. Red and Blue lines are indicative 
of DNA and protein respectively. The large increase in protein and DNA depicts loading of 
the virus onto the sepharose column. Elution of AAV particles coincides with a drop in pH 
(brown line). Fractions corresponding to the small peak in protein and DNA levels 
contained the purified virus. The amount of virus eluted is measured in milliabsorbance 
units (mAU). 
56 
 
 
2.2.4 Vector titration by Q-PCR 
 
Quantitative-PCR was used to titrate vectors in terms of vector genome (vg) copies per ml 
(Fagone et al, 2011). Using primers designed against the LP1 promoter (5′ primer, 5’-
GGAGAGGAGCAGAGGTTGTC-3’; 3′ primer, 5′- TGGTGGTGCCTGAAGCTGAG-3′), the titre of 
all AAV2/8 viruses was determined from a standard generated from serial dilutions of LP1 
containing plasmid DNA.  
In a standard Q-PCR 10µl of virus samples, negative control samples (Water) and standards 
were added to a 96 well plate in triplicate. Each virus was loaded in three different dilutions 
(1 in 100, 1 in 1000 and 1 in 10000). To each well the following master mix was added: 
12.5µl 2× QuantiFast SYBR Green Mastermix (Qiagen, Crawley, UK), 1µl 5’ primer, 1µl 3’ 
primer (each 2.5µM) and 0.5µl molecular biology water (15µl master mix/well). Plates were 
then sealed, briefly spun by centrifugation and placed in a Realplex thermal cycler 
(Eppendorf, Stevenage, UK). After an initial heating period of 5 min at 95ᵒC the following 
steps were carried out for 40 cycles: 95ᵒC 10 sec and 60ᵒC 30 sec. Copy number of viral 
genomes was calculated by Realplex software (Eppendorf, Stevenage, UK). To calculate 
viral genome copies per ml, copy number recorded per 10µl reaction was multiplied by the 
dilution factor and then by multiplied 100. As all standards used were double stranded 
DNA, values derived for single stranded viruses were multiplied by 2.   
2.2.5 Vector titration by alkaline gel 
 
Buffers 
50X Alkaline electrophoresis buffer: 30g NaOH, 7.31g EDTA, pH 8.0 in 500ml ddH2O 
4X Sample loading buffer: 200µl Glycerol, 80µl 50X alkaline electrophoresis buffer, 60µl 
20% w/v SDS, Xylene cyanol powder (arbitrary amount) in 1ml ddH2O 
1M Tris: 121.14g Tris base, pH 8.0 in 1 litre ddH2O 
0.1M NaCl: 5.84g NaCl in 1 litre ddH2O, heated at 121°C for 20 minutes in a bench top 
autoclave (Astell, Kent, UK). 
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4X Gel red solution: 40µl 10000X Gel red (Cambridge Bioscience, Cambridge, UK) in 100ml 
0.1M NaCl 
To titre viruses more accurately by means of quantifying viral DNA, viruses were run on 
denaturing alkaline gels and band intensity was quantified by comparison against a 
standard (DNA ladder) (Fagone et al, 2011). To make the gels, 0.8g agarose was added to 
98ml ddH2O and heated in a microwave oven to dissolve the agarose. 2ml of 50X alkaline 
electrophoresis buffer was then added and the solution was cooled to below 50ᵒC before 
pouring into a mould. 8.5µl of alkaline sample loading buffer was added to each 25µl 
aliquot of virus to be titred. Samples were mixed well and placed on ice.  Samples were 
then run at 20V on the gel overnight at 4ᵒC with 5µl Hyperladder I (Bioline, London, UK) 
loaded in a separate lane. The next day gels were washed for one hour in 300ml 1M Tris pH 
8.0 with agitation. Gels were then transferred to 100ml of 4x Gelred solution and left for 
two hours in darkness with agitation. After rinsing twice with tap water gels were imaged 
using Genesnap software (Syngene, Cambridge, UK). Images were then used for 
quantification of viral DNA using Gene tools software (Syngene, Cambridge, UK). Output 
raw volume and background values for the intensity of each band were exported into an 
excel file. To calculate viral titre, background was subtracted from raw volume to obtain 
net volume values and a standard curve was generated by plotting ng of DNA in the 
Hyperladder against corresponding net volumes. The equation from the chart was used to 
calculate ng of DNA in each sample and these values were multiplied by 40 to derive DNA 
concentration in ng/ml. Viral titre was then calculated in terms of vector genome copies/ml 
based on the sequence of the viral genome in question.      
For example: 
 An amount of sample containing 6.02×1023 particles is a mole 
 The molecular mass of a substance in grams is equal to its molar mass  
 Therefore, the molecular mass of the theoretical ssDNA sequence TTAAGCGCTTAA 
is 3723.43 Daltons (Da) and the molar mass is 3723.43g 
 Thus 1ng contains: 
 1×10-9 × 6.02×1023 /3723.43 = 1.62×1011 copies 
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2.2.6 Coomassie Stain of Capsid Proteins 
 
Buffers 
10X HEPES running buffer: 121g Tris, 238g HEPES, 10g SDS in 1 litre ddH2O 
Coomassie blue dye: 500ml methanol, 400ml ddH2O, 100ml acetic acid, 2.5g Coomassie 
Brilliant blue R-250 
Destain solution: 250ml methanol, 680ml ddH2O, 70ml acetic acid 
To quantify viral titre by relative band intensity of capsid proteins (VP1, VP2 and VP3), 20µl 
virus samples were heated at 95ᵒC in an equal volume of Laemmli buffer (Sigma-Alrich 
Company Ltd, Poole, UK) for 5 min to denature proteins. Samples, protein ladder and a 
control virus sample of known titre were then run on a pre-made polyacrylamide gel 
(Thermo Scientific, Loughborough, UK) in 1×HEPES running buffer at 150V for 30 min. Gels 
were then stained for 1hr using Coomassie blue dye. After destaining gels were imaged 
using Genesnap software (Syngene, Cambridge, UK). 
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Figure 2.2: Typical QPCR traces and standard. (A) Q-PCR reactions were carried out in 
triplicate to quantify vector genome copies per 10µl of virus sample. Traces for each 
sample are plotted as a curve measuring the increment in product (fluorescence units) over 
time (cycles). Threshold cycle values (Ct) are recorded where product levels enter the 
exponential phase of the Q-PCR reaction (indicated as a red horizontal line). Negative 
control samples correspond to the three blue curves at the far right end of the trace. (B) Q-
PCR standards used to derive viral titre are linear plots of Ct values recorded for serial 
dilutions of a plasmid DNA of known copy number. 
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Figure 2.3: Gel based titration of AAV8. (A) A typical acrylamide gel 
including a protein ladder, a control sample of known concentration (left 
sample 5×1012vg/ml), and a sample under analysis (right sample titred as 
1×1011vg/ml). VP1, VP2 and VP3 bands correspond to upper middle and 
lower bands respectively. (B) A typical alkaline gel with a DNA standard, 
5 µl of a control sample of known concentration (left sample 
1.01×1013vg/ml) and 25µl of two samples under analysis (centre and 
right samples 1.07 and 1.28 ×1012/ml respectively). (C) A typical alkaline 
gel standard plotted as band intensity (volume of bands) against ng of 
DNA in the hyperladder.    
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2.3 Animal studies 
 
All procedures were performed in accordance with institutional guidelines under protocols 
approved by the Institutional Biosafety Committee and the Institutional Animal Care and 
Use Committee at St Jude Children's Research Hospital and the University of Tennessee 
Health Science Center, Memphis. All animal work carried out in the United Kingdom was 
performed under the authority of the UK Home Office Project and Personal Licences 
regulations and was compliant with the guidelines of the University College London ethical 
review committee. 
All mice used in the study were male C57BL/6 aged between 6 and 8 weeks (Purchased 
from Charles River UK Ltd, Margate, UK). AAV2/8 viruses were prepared in X-VIVO 10 
(GIBCO, Paisley, UK) media and administered via tail vein injection at 1×109 to 1×1011 vector 
genomes (vg)/animal with 3-4 mice per group (Nathwani et al, 2001). Mice were bled from 
the tail vein with 1ml insulin syringes at regular intervals and plasma was collected by 
centrifugation (4000×g for 15 min at 4ᵒC) of blood samples in trisodium citrate buffer. 2 to 
4 weeks after the injection date mice were sacrificed and livers were taken for further 
investigations.   
Captive-bred male Macaca mulatta used in this study were aged 4 years and weighed 
between 4 and 5 kg (purchased from Charles River Laboratories, Reno, NV). Peripheral vein 
infusion entailed insertion of an intravenous catheter into the saphenous vein of 
anesthetized animals. The vector was diluted in PBS at 10 ml/kg of the total body weight of 
the macaque and administered through the catheter whilst monitoring the animal's vital 
signs and oxygen saturation (Nathwani et al, 2007). 
2.4 Assessment of human factor IX (hFIX) antigen levels 
2.4.1 Reagents 
 
 DMEM (PAA Laboratories Ltd, Yeovil, UK) 
 FBS (GIBCO, Paisley, UK) 
 Trypsin EDTA (PAA Laboratories Ltd, Yeovil, UK) 
 Fugene HD (Roche Diagnostics Ltd, Burgess Hill, UK) 
 X-VIVO 10 (GIBCO, Paisley, UK) 
 Sodium bicarbonate (NaHCO3) (VWR International Ltd, Lutterworth, UK)               
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 PBS tablets (OXOID, Basingstoke, UK) 
 Bovine serum albumin (BSA) (Sigma-Aldrich Company Ltd, Poole, UK) 
 Tween 20 (Sigma-Aldrich Company Ltd, Poole, UK) 
 36% Hydrochloric acid (HCl) (VWR International Ltd, Lutterworth, UK)               
 1000% recombinant hFIX coagulation reference (Technoclone, Dorking, UK) 
 Rhesus anti-human antisera (prepared at St Jude Children’s research Hospital, 
Memphis, TN) 
 Goat anti human FIX-HRP peroxidise labelled antibody (Affinity Biological Inc, 
Epsom, UK)   
 SIGMA-ALDRICH FASTTM OPD peroxidase substrate (Sigma-Aldrich Company Ltd, 
Poole, UK) 
 PBS (PAA Laboratories Ltd, Yeovil, UK) 
 Recombinant hFIX protein (Sigma-Alrich Company Ltd, Poole, UK) 
 Streptavidin-Coupled dynabeads (Invitrogen Life Technologies, Paisley, UK) 
 Protease inhibitor cocktail (Sigma-Aldrich Company Ltd, Poole, UK) 
 NuPAGE LDS sample buffer (4X) (Invitrogen Life Technologies, Paisley, UK) 
 NuPAGE sample reducing agent (10X) (Invitrogen Life Technologies, Paisley, UK) 
 NuPAGE antioxidant (Invitrogen Life Technologies, Paisley, UK) 
 Molecular biology water (Sigma-Aldrich Company Ltd, Poole, UK) 
 NuPAGE 4-12% Bis-Tris gels (Invitrogen Life Technologies, Paisley, UK) 
 NuPAGE MOPS SDS running buffer (20X) (Invitrogen Life Technologies, Paisley, UK) 
 Bicine (VWR International Ltd, Lutterworth, UK)               
 Bis-Tris (Sigma-Aldrich Company Ltd, Poole, UK) 
 EDTA (VWR International Ltd, Lutterworth, UK)               
 Methanol (VWR International Ltd, Lutterworth, UK)               
 Tris base (VWR International Ltd, Lutterworth, UK)               
 NaCl (VWR International Ltd, Lutterworth, UK)               
 Hybond-C Extra (GE Healthcare UK Ltd, Buckinghamshire, UK) 
 Milk powder (Sigma-Aldrich Company Ltd, Poole, UK) 
 Enhanced chemiluminescence substrate (ECL) (Thermo Scientific, Loughborough, 
UK).   
 Fujifilm Super RX X-ray films (Fisher Scientific, Loughborough, UK) 
 DNeasy® Blood and Tissue kit (Qiagen, Crawley, UK) 
 Custom primers (Integrated DNA Technologies, Leuven, Belgium) 
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 2X QuantiFast SYBR Green Mastermix (Qiagen, Crawley, UK) 
2.4.2 Transfection of HuH7 cells 
 
To test for human factor IX expression from plasmid DNA, transient transfection was 
carried out on HuH7 cells for subsequent hFIX ELISA on supernatants. All HuH7 cells used in 
this study were cultured at 37ᵒC, 5% CO2 in DMEM (PAA Laboratories Ltd, Yeovil, UK) with 
10% FBS (GIBCO, Paisley, UK) and enzymatically passaged with 1X trypsin EDTA (PAA 
Laboratories Ltd, Yeovil, UK) every 2-3 days. The transfection reagent used in this study was 
Fugene HD (Roche Diagnostics Ltd, Burgess Hill, UK). For negative control experiments, cells 
were left untransfected. 
For a standard transfection, the day before transfecting, 5×105 HuH7 cells were plated per 
well in 6 well plates (with 3 wells used for each construct tested). On the day of 
transfection 2µg of the plasmid of interest and 0.2µg of pCl10.1-EF1α-GFP lentiviral vector 
plasmid were added to 100µl of serum free DMEM (PAA Laboratories Ltd, Yeovil, UK). In a 
separate tube 6µl of Fugene HD was added to 100µl DMEM. The two solutions were then 
mixed, incubated at room temperature for 1 hour and added to the cells. After 24 hours 
DMEM was replaced with 1ml X-VIVO 10 (GIBCO, Paisley, UK). After 72 hours of incubation 
at 37ᵒC supernatants were harvested and stored at -80ᵒC for subsequent use in ELISA. 
Transfected cells were used for flow cytometry (using a Beckman Coulter, CyAn ADP flow 
cytometer) in order to determine transfection efficiency in terms of percentage GFP 
positivity. All results from hFIX ELISA were subsequently normalised by the percentage of 
GFP positive cells. 
2.4.3 Transduction of HuH7 cells with AAV2/8 vectors 
 
For in-vitro analysis of hFIX expression levels by ELISA, supernatants were collected from 
AAV2/8 transduced HuH7 cells. HuH7 cells were cultured as described in 2.4.2. For negative 
control cells were left untransduced. As a positive control transduction was carried out 
with AAV2/8-CMV-GFP virus and cells were subsequently used for flow cytometry (using a 
Beckman Coulter, CyAn ADP flow cytometer) to approximate transduction efficiency in 
terms of percentage GFP positivity. 
For a standard HuH7 transduction, the day before transduction, cells were plated at a 
density of 5×104 cells per well in six well plates. The following day media containing serum 
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was replaced with the desired amount of virus (1×105-1×107 vg/cell) in X-VIVO 10 (GIBCO, 
Paisley, UK) to a final volume of 600µl. Plates were incubated at 37ᵒC and gently shaken at 
1 hour intervals for the next 8 hours. X-VIVO 10 was then topped up to 1ml in each well. 48 
hours later supernatants were collected and stored at -80ᵒC for subsequent use in hFIX 
ELISA. Each transduction was performed in triplicate including positive and negative 
controls.  
2.4.4 Human Factor IX enzyme-linked immunosorbent assay (ELISA) 
 
Buffers 
Coating buffer: 0.1M NaHCO3 pH 9.2 (4.201g of NaHCO3 in 500ml ddH2O) 
Washing buffer (PBST): 10 PBS tablets, 500µl Tween20 in 1 litre ddH2O  
Blocking buffer: 6g Bovine serum albumin (BSA) in 100ml washing buffer 
Dilution buffer: 2g BSA in 100ml washing buffer 
Stop solution (3M HCl): 25.86 ml 36% HCl in 100ml ddH2O 
Levels of hFIX in mouse and rhesus plasma or supernatants from transduced cell cultures 
were determined by FIX enzyme-linked immunosorbent assay (ELISA) (Nathwani et al, 
2002). Standards for analysis on cell supernatants and mouse/rhesus plasma were 
prepared by serial dilutions of 1000% recombinant hFIX coagulation reference 
(Technoclone, Dorking, UK) in X-VIVO 10 (GIBCO, Paisley, UK) or naïve plasma respectively.  
HuH7 supernatants and corresponding standards were diluted 1:2 in dilution buffer. Plasma 
samples and corresponding standards were diluted 1:100 in dilution buffer (where 
required, plasma samples were initially diluted in naive murine/rhesus plasma to ensure 
values fell within the range of the standard curve). All Samples and standards were 
prepared on ice and stored long term at -80°C where required. Negative controls consisted 
of X-Vivo 10 only diluted 1:2 for in-vitro analysis or naïve plasma diluted 1:100 for in-vivo 
analysis.  
In a standard factor IX ELISA, 50µl Coating antibody (9µl rhesus anti-human antisera diluted 
in 5ml coating buffer) was added to each well of 96 well microtitre plates and incubated at 
4°C overnight.  The following day all wells were washed 5 times with 200µl washing buffer 
and then blocked in blocking buffer for 1 hour at 37°C. Plates were washed 5 times in 
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washing buffer (200µl/well) and 50µl of diluted standards and samples were then added to 
the wells in duplicate. Plates were incubated with the samples at 37°C for 2 hours. 
Following incubation plates were washed 5 times in washing buffer (200µl/well). Secondary 
antibody was prepared by adding 5µl Goat anti human FIX-HRP peroxidise labelled 
antibody (Affinity Biological Inc, Epsom, UK)  to 10ml of dilution buffer (final concentration 
of 1µg/ml). 100µl of diluted secondary antibody was added to each well. Plates were 
incubated with secondary antibody for 1 hour at 37°C followed by 5 washes with PBST. 
200µl SIGMA-ALDRICH FASTTM OPD peroxidase substrate (Sigma-Aldrich Company Ltd, 
Poole, UK) was then added to each well and colour was allowed to develop for 3 to 4 
minutes. To stop the reaction 50ul/well of 3M HCL was added and colour change was 
assessed spectrophotometrically at 490 nm (Anthos 2001 spectrophotometer). 
  
66 
 
 
  
Figure 2.4: A typical hFIX ELISA standard curve. Absorbance values 
(Y axis) read at 490nm are plotted for samples of known %normal 
hFIX (X axis) prepared by serial dilutions of a coagulation reference. 
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2.4.5 Factor IX immunoprecipitation 
 
Buffers 
PBST: 50µl Tween20 (final concentration 0.01%) in 500ml PBS without calcium or 
magnesium (PAA Laboratories Ltd, Yeovil, UK) 
Human Factor IX immunoprecipitation was carried out on murine plasma samples to purify 
the protein of interest (hFIX) prior to western blotting. For control, Immunoprecipitation 
was carried out on hFIX negative and positive samples (naïve plasma and recombinant hFIX 
standard prepared as serial dilutions of 5mg/µl hFIX concentrate in naïve plasma 
respectively). Streptavidin dynabeads, poly-acrylamide gels, gel loading buffer and reducing 
agent used in this work were all supplied by Invitrogen Life Technologies (Paisley, UK).  
In a standard hFIX immunoprecipitation, 40µl of plasma sample was mixed with 4µl of 
biotinylated rhesus anti-hFIX antibody (350µg/ml) and 0.4µl of protease inhibitor cocktail 
followed by incubation at 37°C for 75 minutes. In a separate tube, magnetic streptavidin 
dynabeads (100µl/sample) were washed in 500µl PBST then placed on a magnet to remove 
the buffer. The washing step was then repeated twice with 200µl PBST. Beads were 
resuspended in 200µl PBST and added to the plasma sample followed by incubation at 
room temperature for 30 minutes on a rotator. Beads were then washed 3 times in 200µl 
PBST. To elute proteins bound to the streptavidin beads 10µl of reducing loading dye (2.5µl 
4× loading buffer, 6.5µl water and 1µl reducing agent) was added to each sample followed 
by incubation at 70°C for 10 minutes. Samples were then placed on a magnet to separate 
the beads and eluted proteins were loaded directly onto 4-12% Bis-Tris poly-acrylamide 
gels for western blotting.     
2.4.6 Western blotting 
 
Buffers 
1X Running buffer: 50ml 20X MOPS buffer (Life Technologies, Paisley, UK) in 1 litre ddH2O 
Transfer buffer: 10ml 20X transfer buffer (81.6g Bicine, 104.6g Bis Tris, 7.5g EDTA in 1 litre 
ddH2O); 40ml Methanol; 200µl anti-oxidant (Invitrogen Life Technologies, Paisley, UK); 
150ml ddH2O  
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Wash buffer (TBST): 50ml 20X TBS (48.4g Tris base, 160g NaCl, approximately 24ml 36% 
HCL/until pH is between 7.4 and 7.8); 2ml Tween 20 in 1 litre ddH2O 
Western blotting was used as a secondary method of determining murine plasma hFIX 
levels in order to verify ELISA results. Standards consisted of serial dilutions of recombinant 
hFIX concentrate (5mg/µl) in naïve C57BL/6 mouse plasma. Negative control samples 
consisted of naïve plasma only. Prior to sample loading on poly-acrylamide gels, all samples 
and standards were subject to immunoprecipitation as described in section 2.4.5. Unless 
otherwise stated all equipment and reagents used in this work were supplied by Invitrogen 
life technologies (Paisley, UK). 
For a standard western blot, pre-cast 4-12% tris glycine poly-acrylamide gels were placed in 
electrophoresis tanks and the reservoir between the gel and the plastic dam was filled with 
1X MOPS running buffer. To maintain proteins in a reduced state, 500µl of antioxidant was 
added to this central reservoir and mixed well using a Pasteur pipette. The remaining 1X 
running buffer was used to fill the outer compartment of the tank. 10µl of samples and 
standards were loaded into wells of the gel and electrophoresed at 125V, 35mA, 5W for 
approximately 2 hours. To transfer proteins, gels were placed on top of three pieces of 
1mm filter paper soaked in transfer buffer. A piece of Hybond-C Extra (GE Healthcare UK 
Ltd, Buckinghamshire, UK) nitrocellulose membrane soaked in transfer buffer was then 
placed on top of the gel followed by another 3 pieces of wet filter paper. To remove air 
bubbles a 5ml plastic pipette was rolled over the top of the gel stack. The stack was then 
placed in a transfer cassette on top of two sponges soaked in transfer buffer. The 
remaining space in the cassette was filled with more soaked sponges before clamping the 
cassette into an electrophoresis tank. Inside the tank, the cassette was filled with transfer 
buffer and the outer chamber was filled with tap water to cool the transfer system. The 
transfer was then run at 25V, 125mA, 15W for 90 minutes. After transfer membranes were 
blocked in 10% milk at 4°C overnight with shaking. Membranes were then washed with 
PBST 4 times over a period of 30 minutes at room temperature. Goat anti human FIX-HRP 
peroxidise labelled antibody (Affinity Biological Inc, Epsom, UK) was diluted 1 in 5000 with 
10% milk (final concentration of 0.4µg/ml) and incubated with the membranes for 2 hours 
at room temperature. Washing of the membranes 4 times with PBST was then repeated 
followed by a 3 minute incubation with enhanced chemiluminescence substrate (ECL) 
prepared in a 1:1 ratio of solution 1 to solution 2 (Thermo Scientific, Loughborough, UK). 
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Protein bands were visualised on Fujifilm Super RX X-ray films (Fisher Scientific, 
Loughborough, UK) using a KONICA MINOLTA SRX-101A film processor.   
2.4.7 Proviral copy number correction 
 
To ensure that differences in plasma hFIX levels achieved with different vectors was not 
due to discrepancy in transduction efficiencies, %hFIX levels were normalised by proviral 
copies per hepatocyte. To determine proviral copy number, genomic DNA was extracted 
from transduced mouse liver samples using the DNeasy® Blood and Tissue kit (Qiagen, 
Crawley, UK) as per the manufacturer’s instructions. Each DNA sample was diluted to a final 
concentration of 7.5ng/µl and subsequently subjected to a quantitative real-time PCR (Q-
PCR) assay. Using primers designed against a 283bp region of the LP1 promoter (5′ primer, 
5’-GGA GAG GAG CAG AGG TTG TC-3’; 3′ primer, 5′- TGG TGG TGC CTG AAG CTG AG -3′), 
copy number was determined from a standard generated by serial dilutions of LP1 
containing plasmid DNA. In a separate reaction, equivalent DNA loading was established 
using primers against murine GAPDH (5’ primer, 5’-TGGAGAGCCCGCTCAGACCC-3’; 3’ 
primer, 5’-GGATTGGGTGTCCCTGCGCC-3’) and a standard of known DNA concentration (ng) 
generated from serial dilutions of mouse genomic DNA. 
In a standard copy number Q-PCR, 5µl of liver DNA samples; negative control samples 
(Water) and standards were added to a 96 well plate in duplicate. To each well the 
following master mix was added: 12.5µl 2× QuantiFast SYBR Green Mastermix (Qiagen, 
Crawley, UK), 1µl 5’ primer, 1µl 3’ primer (each 2.5µM) and 5.5µl molecular biology water 
(20µl master mix/well). Plates were then sealed, briefly spun by centrifugation and placed 
in a Realplex thermal cycler (Eppendorf, Stevenage, UK). After an initial heating period of 5 
minutes at 95ᵒC the following steps were carried out for 40 cycles: 95ᵒC 10 seconds and 
60ᵒC 30 seconds. Copy number of viral genomes and the amount of DNA loaded per well 
was calculated by Realplex software (Eppendorf, Stevenage, UK) using Ct values recorded 
for LP1 and GAPDH standards respectively.   
To calculate copies per cell LP1 copy number results were divided by the amount of DNA 
(ng) in each sample; these figures were then multiplied by 37.5 (the theoretical amount of 
DNA loaded in each well) and divided by 6528.5 (the approximate number of murine cells 
from which 37.5ng of DNA is derived). To normalise plasma hFIX levels by viral genome 
copy number, values of % normal hFIX were divided by copy number/cell observed for the 
corresponding liver DNA sample. 
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2.5 Assessment of S/MAR function 
2.5.1 Reagents 
 
 RNAlater® (Qiagen, Crawley, UK) 
 Qiashredder® (Qiagen, Crawley, UK) 
 RNeasy Plus® kit (Qiagen, Crawley, UK) 
 cDNA synthesis kit (Bioline, London, UK) 
 Molecular biology water (Sigma-Aldrich Company Ltd, Poole, UK) 
 2× QuantiFast SYBR Green Mastermix (Qiagen, Crawley, UK) 
 Custom primers (Integrated DNA Technologies, Leuven, Belgium) 
 Mm_Gapdh_3_SG QuantiTect primer assay (Qiagen, Crawley, UK) 
 EZ-Magna ChIP A-Chromatin Immunoprecipitation Kit (Millipore, Feltham, UK) 
 PBS (PAA Laboratories Ltd, Yeovil, UK) 
 Complete protease inhibitor cocktail (Roche Diagnostics Ltd, Burgess Hill, UK) 
 FBS (GIBCO, Paisley, UK) 
 Formaldehyde (Sigma-Aldrich Company Ltd, Poole, UK) 
 Glycine (MP Biomedicals, Cambridge, UK)  
 ChIP antibodies (Supplied by Millipore, Feltham, UK or Abcam, Cambridge, UK or 
Active Motif, Rixensart, Belgium)  
 Murine β-actin primers (Active Motif, Rixensart, Belgium) 
2.5.2 Determination of hFIX mRNA levels 
 
To determine hFIX RNA levels produced per proviral genome copy, RNAlater® (Qiagen, 
Crawley, UK) stabilised transduced murine liver samples were placed in liquid nitrogen and 
disrupted with a mortar and pestle. Samples were homogenised using Qiashredder® 
(Qiagen, Crawley, UK) columns and RNA was extracted using the RNeasy Plus® kit (Qiagen, 
Crawley, UK) as per the manufacturer’s instructions. RNA was then converted to cDNA by 
using the cDNA synthesis kit (Bioline, London, UK) and cDNA was subsequently used in a Q-
PCR assay. 
In a standard cDNA synthesis reaction approximately 1µg of total RNA was mixed with 1µl 
random hexamers, 10mM dNTP mix and DEPC-treated water (up to 10µl final volume). 
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Reactions were then incubated at 70°C for 5 minutes followed by chilling on ice for 1 
minute. To each reaction 4µl 5×RT buffer, 1µl Ribosafe RNase inhibitor, 0.25µl reverse 
transcriptase (omitted for –RT negative control reactions) and 4.75µl DEPC-treated water 
was added. Samples were incubated for 10 minutes at 25°C followed by 30 minutes at 45°C 
using a Dyad® thermal cycler (BioRad Laboratories Ltd, Hemel Hempstead, UK). The 
reaction was terminated by heating samples to 85°C for 5 minutes followed by cooling on 
ice.      
For a standard Q-PCR, 2µl of cDNA samples; cDNA standards (LP1 containing plasmid DNA) 
and negative controls (-RT and water) were loaded onto a 96well Q-PCR plate in duplicate. 
To each well the following master mix was added: 12.5µl 2× QuantiFast SYBR Green 
Mastermix (Qiagen, Crawley, UK), 1µl 5’ LP1 primer, 1µl 3’ LP1 primer (each 2.5µM see 
2.4.7 for primer sequences) and 8.5µl molecular biology water (23µl master mix/well). Q-
PCR cycling conditions were carried out as previously described in section 2.4.7. LP1 cDNA 
copy number was calculated by Realplex software (Eppendorf, Stevenage, UK) using Ct 
values plotted for the LP1 standard curve.  
To normalise the data by the amount of cDNA loaded for each sample, a separate Q-PCR to 
quantify levels of housekeeping gene cDNA was performed using murine Gapdh primers 
(Qiagen, Crawley, UK).To calculate RNA/copy/cell values of LP1 copies were divided by 
results for cDNA concentration in ng (derived from a murine liver cDNA standard of known 
concentration). Results were then divided by viral genome copy number per cell to give an 
approximation of transcription levels per copy. 
2.5.3 Chromatin immunoprecipitation 
 
Chromatin immunoprecipitation (ChIP) was used to determine protein interations with 
rAAV genomes. Through crosslinking of DNA-protein complexes followed by 
immunoprecipitation with antibodies against a specific protein of interest, ChIP allows for 
the isolation and subsequent quantification (by Q-PCR) of vector genomes in association 
with the chosen precipitated protein. For negative controls immunoprecipitation was 
carried out using either no antibody or rabbit IgG. This work was carried out with the use of 
the EZ-Magna ChIP A-Chromatin Immunoprecipitation Kit (Millipore, Feltham, UK). Unless 
otherwise stated, reagents were sourced from this kit. 
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In a standard ChIP, 200mg of transduced murine liver was cut into small pieces; 
resuspended in 1ml ice cold PBS containing complete protease inhibitor cocktail (Roche 
Diagnostics Ltd, Burgess Hill, UK) and 2% foetal bovine serum (FBS) and pushed through a 
40µm nylon cell strainer (BD Biosciences, Oxford, UK) using the end of a 5ml syringe 
plunger. A further 10ml of PBS solution was added and Cell suspensions were pelleted by 
centrifugation at 3500rpm for 10 minutes at 4°C. Cell pellets were then washed twice in 
10ml PBS solution and resuspended in a further 10ml. To form DNA-protein crosslinks 
270µl of 37% formaldehyde (final concentration of 1%) was added followed by incubation 
at room temperature for 10 minutes. 0.125M Glycine (final concentration) was added to 
quench formaldehyde for 5 minutes at room temperature. Cells were centrifuged as above 
and washed twice in ice cold PBS with protease inhibitor and 2% FBS. With the EZ-Magna 
ChIP A-Chromatin Immunoprecipitation Kit, cell pellets were resuspended in 500µl cell lysis 
buffer containing 2.5µl Protease Inhibitor Cocktail II. All samples were incubated on ice for 
15 minutes whilst vortexing to mix at 5 minute intervals. Samples were then centrifuged at 
800 × g at 4°C for 5 minutes, supernatants were removed and pellets were resuspended in 
500µl nuclear lysis buffer containing 2.5µl Protease Inhibitor Cocktail II. To fragment DNA 
(~size 200 to 500 nucleotides), samples were subjected to sonication. Chromatin sonication 
parameters used were 15 s pulse on and 15 s pulse off for 45 min using a Bioruptor 
sonicator (Diagenode, Liège, Belgium). After sonication, samples were spun at 13000 × g to 
remove debris and supernatants were divided into 50µl aliquots. To each 50µl chromatin 
sample 450µl dilution buffer and 2.25µl Protease Inhibitor Cocktail II was added. From the 
sample delegated as the no antibody negative control, 5µl (1%) of the chromatin solution 
was removed and reserved as ‘input’. To each sample 4µg of specific antibody, 5µg rabbit 
IgG or no antibody was added. 20µl of magnetic protein A beads was added to each sample 
followed by overnight incubation at 4°C with rotation. The following day beads were 
pelleted using a magnet and washed once with 500µl of the following solutions for 5 
minutes at 4°C with rotation: 1) Low Salt Immune Complex Wash Buffer, 2) High Salt 
Immune Complex Wash Buffer, 3) LiCl Immune Complex Wash Buffer, 4) TE Buffer (with 
each wash beads were separated using a magnet). To elute protein-DNA complexes and 
reverse crosslinks, after removing TE buffer, 100µl ChIP elution buffer and 1µl Proteinase K 
was added to each sample. This step was also carried out on the 5µl Input sample reserved 
before immunoprecipitation. Samples were incubated in elution buffer at 62°C with 
shaking for 2 hours followed by incubation at 95°C for 10 minutes. After a brief cooling 
period, beads were separated using a magnet and DNA was purified from each sample 
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using spin columns from the EZ- Magna ChIP A-Chromatin Immunoprecipitation Kit as per 
the manufacturer’s instructions.                     
DNA pull down was quantified by Q-PCR using the following primer pairs designed against 
the AAV genome: 152 (LP1 promoter) 5’ primer, 5’-GGAGTCGTGACCCCTAAAATG-3’; 3’ 
primer, 5’-CTCTGACCTCTGCCCCAGCTC-3’. 366 (LP1 promoter) 5’ primer, 5’-
TTCGGTAAGTGCAGTGGAAG-3’; 3’ primer, 5’-GTTATCGGAGGAGCAAACAG-3’. 1988 (hFIXco 
cDNA) 5’ primer, 5’-GCTTCCTGACTGGCATCATC-3’; 3’ primer, 5’-CAGGTCAGCTTGGTCTTCTC-
3’. For a standard Q-PCR, 2µl of each DNA sample (including negative controls and input) 
was loaded in duplicate onto a 96 well plate. To each well the following master mix was 
added: 7.5µl 2× QuantiFast SYBR Green Mastermix (Qiagen, Crawley, UK), 2µl 5’ primer, 2µl 
3’ primer (each 1.5µM) and 1.5µl molecular biology water (13µl master mix/well). Plates 
were then sealed, briefly spun by centrifugation and placed in a Realplex thermal cycler 
(Eppendorf, Stevenage, UK). After an initial heating period of 5 minutes at 95ᵒC the 
following steps were carried out for 40 cycles: 95ᵒC 10 sec and 60ᵒC 30 sec. Ct values were 
determined by Realplex software (Eppendorf, Stevenage, UK). In a separate reaction, the 
same Q-PCR was performed using primers against β-actin (Active Motif, Rixensart, 
Belgium); this was done to ensure that levels of background DNA pull down were similar 
between samples under comparison.  
To calculate DNA pull down as a percentage of total input chromatin, the average Ct value 
of the input samples were determined and 6.644 cycles was subtracted from this value (the 
number of cycles subtracted to account for the 100-fold dilution of the input chromatin). 
The Ct value observed for each sample (CtS) was then subtracted from the input Ct valve 
(CtI). To calculate the percentage of input this value was used in the following formula:  
100 × 2^(CtI-CtS).  
For example: 
 If the average Ct value of input is 22.4 the adjusted CtI value is 22.4-6.644  
= 15.8 
 If the hypothetical Ct value for viral DNA pull down (CtS) with an anti H3K92me 
antibody is 18.6 then % input is calculated as 100 × 2^(15.8-18.6) 
= 14%  
 The percentage of viral DNA out of the total input chromatin associated with 
H3K92me is therefore 14%. 
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CHAPTER 3 SCAFFOLD/MATRIX ATTACHMENT REGIONS ENHANCE THE 
IN-VIVO POTENCY OF AAV VECTORS 
 
3.1 Introduction 
3.1.1 AAV genomes are maintained as episomal chromatin 
 
As previously described, after entering the cell nucleus, adeno-associated viral vector 
genomes undergo single stranded to double stranded DNA conversion followed by 
intermolecular concatemerisation (Nonnenmacher & Weber, 2012). Vector genomes are 
then predominantly maintained as high molecular weight concatemers in an 
extrachromosomal form. Indeed, the episomal persistence of AAV genomes in-vivo has 
been observed in murine skeletal muscle and in liver with extrachromosomal forms 
representing approximately 99.5% and 90% of vector genomes mediating stable 
transduction in each tissue respectively (Miao et al, 2000a; Nakai et al, 2001; Schnepp et al, 
2003; Schnepp et al, 2005). 
Multiple episomal viral genomes are known to be maintained in chromatin-like structures. 
Examples of such viruses include Epstein-Barr virus, Simian virus 40, polyoma virus and 
Kaposi’s sarcoma-associated herpesvirus (Cremisi et al, 1975; Lu et al, 2003; Shaw et al, 
1979). Members of the parvovirus family have also been observed in association with 
nucleosome structures both in-vitro and in-vivo; this includes minute virus of mice (MVM) 
and AAV (Ben-Asher et al, 1982; Marcus-Sekura & Carter, 1983). Upon digestion of the 
nuclei of AAV infected KB cells (human mouth epidermal carcinoma cells) with micrococcal 
nuclease (an enzyme that hydrolyses chromatin at nucleosome linker regions) a typical 
nucleosomal ladder pattern was revealed on agarose gels; this observation was 
reproducible in both the presence and absence of adenoviral co-infection (Marcus-Sekura 
& Carter, 1983). In a similar study, rAAV genomes were found to persist as chromatin-like, 
supercoiled episomes in the skeletal muscle of non-human primates (NHPs) (Penaud-
Budloo et al, 2008). Thus, given that AAV genomes are known to be associated with 
nucleosomes, it is reasonable to assume that rAAV transgenes may be subject to epigenetic 
silencing through histone modification.            
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3.1.2 Histone deacetylase inhibitors (HDAC inhibitors) enhance AAV mediated 
transgene expression. 
 
Histone deacetylase inhibitors are chemical compounds commonly used to modify the 
acetylation status of histones so that chromatin is arranged in an open euchromatin state 
that allows for gene expression. Examples of FDA (Food and Drug Administration) approved 
HDAC inhibitors include Romidepsin and Vorinostat (Suberoylanilide hydroxamic acid 
(SAHA)) which are used in patients with cutaneous T-cell lymphoma (CTCL); sodium 
phenylbutyrate (used to stimulate foetal haemoglobin expression in sickle cell anaemia 
patients) and Valproic acid (used as an anticonvulsant in the treatment of epilepsy and as a 
mood stabiliser) (Dover et al, 1994; Mann et al, 2007; Phiel et al, 2001; VanderMolen et al, 
2011). In an attempt to understand whether the AAV provirus is subject to repressive 
silencing effects, previous in-vivo studies involving the co-administration of AAV vector and 
HDAC inhibitors have been carried out. 
One such example includes the 2006 study carried out by Okada et al (Okada et al, 2006).  
In this study, U251MG cells were transduced with and AAV2 vector expressing luciferase at 
a dose of 1×104 vg/cell. 3×106 transduced cells were then injected subcutaneously into 
BALB/c mice along with intraperitoneal injection of Romidepsin at 1mg/kg. At 24 hours 
after injection of Romidepsin, a 37.4-fold increase in bioluminescence signal intensity was 
observed in subcutaneous tumours of the cohort that received Romidepsin as compared to 
non Romidepsin treated animals (1.5 ± 0.9 × 106 photons/s/cm2/sr and 4.0 ± 2.4 × 104 
photons/s/cm2/sr respectively). Similarly, after subcutaneously injecting 3×106 U251MG 
cells transduced with AAV-HSV-tk vector into athymic nude mice, a significant reduction in 
tumour growth was observed in mice treated with Romidepsin and Ganciclovir (GCV) as 
compared to animals that received HSV-tk/GCV therapy only. Impressively, in the 
Romidepsin treated cohort 8 out of 10 tumours were completely eliminated at 4 weeks 
post transduction. Crucially, the observation that a HDAC inhibitor is able to enhance AAV 
mediated transgene expression infers that the AAV provirus may be subject to 
transcriptionally repressive histone modifications.  
In support of this notion, we have observed an increase in human factor IX (hFIX) levels 
following co-administration of SAHA with 4×1012vg/kg of AAV vector expressing hFIX in 
non-human primates (unpublished data). However, this data is at odds with that of 
Penaud-Budloo et al whereby no increase in rAAV mediated LEA29Y expression was 
observed following injection of sodium phenylbutyrate into transduced NHPs (Penaud-
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Budloo et al, 2008). Crucially, in the latter mentioned strategy, it is implied that the HDAC 
inhibitor was administered at a time at which transgene expression had plateaued. Yet, in 
our SAHA studies and in the study of Okada et al, the need for early administration (before 
expression reaches steady state) of HDAC inhibitor to observe any increase in transgene 
expression has been noted.         
3.1.3 The use of matrix attachment regions in gene transfer  
 
As previously described, matrix attachment regions are frequently used in the context of 
gene transfer vectors to enhance transgene expression and to prevent epigenetic silencing 
(Gluch et al, 2008). For instance, in 2003, Kurre et al demonstrated the enhancer activity of 
a S/MAR element (taken from the human IFNβ gene) when cloned into an EGFP expressing 
retroviral vector (Kurre et al, 2003). In this study, 1×107 CD34-enriched cells taken from 
baboons (Papio cynocephalus cynocephalus or Papio cynocephalus anubis) were transduced 
with EGFP vector with or without the S/MAR element at an MOI (multiplicity of infection) 
of 0.1 to 0.3. After carrying out myeloablative irradiation on each animal, approximately 
2×107 transduced cells/arm were re-administered to the animal from which they were 
derived (with one arm receiving S/MAR vector transduced cells and the other receiving 
control vector transduced cells). Over a period of 12 months, the mean fluorescence 
intensity (MFI) of EGFP in cells of all haematopoietic lineages was consistently observed to 
be 2- to 9- fold higher in the S/MAR-containing arm as compared to the non S/MAR-
containing arm. Thus it was inferred that S/MARs improve long term proviral expression in 
the context of retroviral vectors.    
Similarly, S/MAR elements have been shown to enhance transgene expression in plasmid 
vectors by preventing promoter silencing due to DNA methylation. For example, in 2008, 
Argyros et al demonstrated the stable expression of luciferase in mouse liver up to 6 
months after hydrodynamic delivery of plasmid vectors containing the α1-antitrypsin 
promoter, a luciferase transgene and the human IFNβ S/MAR (Argyros et al, 2008). In 
comparison, luciferase expression from non-S/MAR containing plasmid vectors was shut off 
one week after vector delivery. By digesting the promoter regions of each vector genome 
with enzymes that are sensitive to cytosine methylation, it was confirmed that this shut off 
of transgene expression was due to DNA methylation in the absence of a S/MAR element. 
Thus S/MARs are able to enhance transgene expression from a variety of gene transfer 
vectors through the prevention of gene silencing. 
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The effect of cloning S/MAR elements into AAV expression cassettes, however, remains 
largely unexplored to date. Given that expression from AAV vectors can be enhanced by 
the use of HDAC inhibitors it seems reasonable to test an epigenetic modifying element in 
the context of AAV. As such, through the inclusion of an S/MAR element in our codon 
optimised human factor IX (hFIXco) AAV expression casette, we sought to investigate 
whether S/MARs are able to enhance Factor IX expression levels in order to permit the use 
of lower vector doses. In our group, we began this analysis with the use of an 809bp S/MAR 
from the human Interferon β gene (IFNβ) as this is the most well documented S/MAR in 
terms of enhancing transgene expression (Kurre et al, 2003; Moreno et al, 2011; Ramezani 
et al, 2003).  
3.1.4 Preliminary results 
 
In our initial studies, a truncated S/MAR (809bp) derived from the 5’ region of the human 
IFNβ gene was cloned immediately 3’ of the hFIXco cDNA in our codon optimised human 
factor IX expression cassette previously described (Nathwani et al, 2006). The S/MAR was 
cloned in both forward and reverse orientation (Figure 3.1, ssAAV-LP1-hFIXco-IFN-F and 
ssAAV-LP1-hFIXco-IFN-R respectively) and used in the context of single stranded AAV 
vectors pseudotyped with serotype 8 capsid protein.     
Each vector was administered to 6-8 week old male C57Bl/6 mice (N=6) via the tail vein at a 
dose of 4x1012 vector genomes (vg)/kg. Plasma hFIX levels were determined at various time 
points over a period of 8 weeks post vector administration. The kinetics of hFIX expression 
was consistent with our previous findings, with detectable hFIX levels observed by 2 weeks 
and steady state levels observed by 4 weeks (Figure 3.2) (Nathwani et al, 2001). Steady 
state hFIX levels were highest in the cohort transduced with ssAAV-LP1-hFIXco-IFN-R at 
188±18% of normal. This was an approximate 10-fold increase in transgene expression 
levels as compared to cohorts of mice transduced with control vector containing no S/MAR 
(ssAAV-LP1-hFIXco-Control, 17±1.2% of normal) and ssAAV-LP1-hFIXco-IFN-F (20±4% of 
normal). Proviral copy numbers in liver were consistent in each cohort at approximately 0.3 
copies/hepatocyte (Figure 3.3). As such, differences in transgene expression were not due 
to variation in transduction efficiency. 
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Figure 3.1: Construction of single stranded AAV-hFIXco containing IFNß 
S/MAR: Schematic of vectors. Each vector is represented schematically as it is 
packaged inside the virion. Common features include the hybrid liver specific 
promoter (LP1), SV40 intron, codon-optimised human FIX cDNA (hFIXco) and a 
truncated SV40 late polyA (tSV40pA) flanked by AAV inverted terminal repeats 
(ITRs represented as hairpin loops).  
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Figure 3.2 FIX expression in C57BL/6 mice. Transgene expression profiles 
after tail- vein administration of 4×1012vg/kg (n=6) of ssAAV-hFIXco-IFN-F/R 
and ssAAV-hFIXco-Control vectors into 6 to 8 week old male C57BL/6 mice. 
All results are shown as an average together with the standard error of the 
mean (±SEM). 
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3.1.5 Chapter aim 
 
The overriding goal of this study was to improve the potency of AAV vectors. This may be 
possible with the Interferon β S/MAR but its relatively large size compromises the 
packaging of an optimal expression cassette given the fact that the maximum packaging 
capacity of single stranded AAV is only 4.7kb. So can we enhance the potency of AAV with 
alternative S/MAR elements? S/MARs selected for a head to head comparison in our 
AAV2/8-LP1-hFIXco expression casette included regions from the apolipoprotein B (apoB) 
and hypoxanthine-guanine phosphoribosyltransferase (HPRT) genes. The apoB S/MAR is 
well documented to have an insulatory role against positional chromatin effects (Namciu et 
al, 1998). In contrast, the HPRT S/MAR has primarily been documented to have a role in 
autonomous replication (Sykes et al, 1988). Additionally, a region of the Kaposi sarcoma 
herpes virus (KSHV) genome known to promote autonomous replication was utilised as a 
non-S/MAR control element (Stedman et al, 2008).  
Through this analysis, at a dose of 4×1012vg/kg, AAV8 vectors containing HPRT and ApoB 
S/MAR elements were found to enhance hFIX expression levels in mice by 28-fold as 
compared to control vectors containing no S/MAR or KSHV elements. This advantage in 
transgene expression was maintained when using the HPRT vector at a dose two orders of 
magnitude lower (4×1010vg/kg). The HPRT vector also mediated 4-fold higher levels of hFIX 
expression in NHPs as compared to animals receiving the control vector containing no 
S/MAR. These results collectively suggest the ability to enhance AAV mediated transgene 
expression with S/MAR elements; this may permit the use of lower vector doses. 
3.2 Materials and methods 
3.2.1 AAV-hFIX vector production and purification 
 
The ssAAV vector encoding hFIX has previously been described (Nathwani et al, 2001). 
Elements of this expression cassette include a hybrid liver-specific promoter (LP1) that 
consists of core domains from the human apolipoprotein hepatic control region and the 
human alpha-1-antitrypsin promoter followed by a codon optimized hFIX cDNA. For the 
subsequent insertion of S/MAR elements, 10µg of this vector plasmid was digested for 3 
hours at 37°C in a standard 100µl reaction using BbsI and HpaI restriction enzymes and 10% 
NEBuffer 4 (standard conditions described in 2.1.3). An oligonucleotide (flanked by BbsI 
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and HpaI restriction sites) encoding a multiple cloning site (MCS) followed by a truncated 
SV40 polyadenylation (tSV40pA) sequence was then inserted into the hFIX vector backbone 
using a standard 20µl ligation reaction as described in section 2.1.7 (AAV-LP1-hFIX-Control). 
HPRT, ApoB and KSHV DNA elements were synthesised and sequenced by Genescript 
(Piscataway, USA) and were packaged in pUC57 plasmids flanked by NotI sites. To insert 
these elements into the AAV-LP1-hFIX-Control plasmid, 10µg of pUC57 and AAV-LP1-hFIX-
Control plasmid (containing a NotI site in the MCS) was digested at 37°C for 3 hours using 
the NotI restriction enzyme and 10% NEBuffer 3 in standard 100µl reactions. Following gel 
purification (see sections 2.1.3 and 2.1.4) the S/MAR fragments were cloned into the NotI 
digested multiple cloning site (3’ of hFIXco CDNA) using a standard 20µl ligation reaction. 
The IFNß S/MAR was taken from the retroviral vector plasmid named MP4253.SFGmSR-
preMSV.eGFP (a gift from Dr Martin Pule, UCL Cancer Institute, UK) and ligated as a blunt 
fragment into the EcoRV site of the MCS in LP1-hFIXco-Control plasmid. Subsequent 
transformations were carried out as per standard protocol (section 2.1.8). Colonies were 
expanded and screened as described in 2.1.8 and enzymes used for standard 10µl 
screening digests (carried out at 37°C for 1 hour) included: SacI and NdeI (IFNβ S/MAR 
plasmids), DdeI and NotI (ApoB S/MAR plasmids), HindIII (HPRT S/MAR plasmids) and PstI 
(KSHV control plasmids). All plasmids were also screened for the presence of intact ITRs 
using standard 10µl AhdI and BglI restriction digests (digested for 1 hour at 37°C).          
 All vectors were made by the adenovirus-free transient transfection method described in 
section 2.2.2, using a chimeric AAV2 Rep-8Cap packaging plasmid (pAAV8-2) and an 
adenoviral helper plasmid. Vectors were purified as detailed in 2.2.3. All vector titres were 
determined by standard quantitative real-time PCR (Q-PCR) and coomassie gel methods 
(sections 2.2.4 and 2.2.6 respectively).  
3.2.2 Animal studies 
All procedures were performed in accordance with institutional guidelines as previously 
described (section 2.3). Tail-vein administration of rAAV vector particles was performed in 
6 to 8 week old immunocompetent male C57BL/6 mice as single bolus injections (maximum 
volume of 200µl) using 1ml syringes. Prior to injection or bleeding, mice were briefly 
warmed at 39°C to dilate the tail vein. Mice were injected with 4×1012vg/kg and killed 4 to 8 
weeks after vector administration. For the low dose analysis HPRT and control vectors were 
injected at a dose of 4×1010vg/kg and mice were killed 4 weeks after administration. Blood 
samples were taken from the tail vein at one week intervals over the course of the 
82 
 
experiment. To separate plasma, blood samples were spun at 4000× g in tri-sodium citrate 
buffer for 15 minutes at 4°C. In all cases livers were harvested for subsequent molecular 
analysis. Vectors were infused into rhesus macaques at a dose of 4×1012vg/kg via the 
peripheral vein as described in section 2.3. Blood samples were taken from NHPs at 
variable time points over the course of 37 weeks after vector administration. Liver samples 
were harvested from NHPs at 37 weeks for molecular analysis.   
3.2.3 HuH7 cell culture and transduction 
HuH7 cells were cultured as described in section 2.4.2. Transduction of HuH7 was carried 
out as per standard protocol (section 2.4.3) using 1×105vg of each vector per cell. 
3.2.4 Determination of FIX levels 
Human FIX antigen levels in cell supernatants, rhesus plasma and murine plasma samples 
were determined by enzyme-linked immunosorbent assay (ELISA) as previously described 
(section 2.4.4). Briefly, microtiter plates were coated with 50 μL of polyclonal rhesus 
antihuman serum and incubated overnight at 4°C followed by immunocapture of the hFIX 
antigen in standards, test samples and negative controls. Standards were prepared as 
dilutions of hFIX coagulation reference in naïve murine/rhesus plasma or serum free DMEM 
and all samples and standards were diluted 1:100 or 1:2 in PBST containing 2% BSA (plasma 
and cell supernatant samples respectively). After a 2 hour incubation at 37°C, plates were 
washed and incubated for 1 hour with 100 μL/well goat anti-hFIX horseradish peroxidase 
(HRP)–conjugated polyclonal secondary antibody at a final concentration of 1 μg/mL. Plates 
were developed with o-phenylenediamine dihydrochloride peroxidase substrate and colour 
change was assessed spectrophotometrically at 490 nm. Statistical difference between 
experimental groups was determined by 1-way analysis of variance (ANOVA) using 
GraphPad Prizm version 4.0 software (GraphPad, San Diego, CA). 
Western blotting to determine hFIX protein levels was carried out as previously described 
in section 2.4.6 with prior antigen immunoprecipitation carried out to minimize non-
specific background (section 2.4.5). 
3.2.5 Molecular studies 
 
Proviral copy number was determined by standard protocol as described in section 2.4.7. 
Briefly, genomic DNA extracted from ssAAV8-LP1-hFIXco transduced murine/rhesus liver 
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was subjected to a quantitative real-time PCR (Q-PCR) assay using primers designed to 
amplify a 283bp region of the LP1 promoter (see 2.4.7 for sequences). The Q-PCR reaction 
was performed in a total volume of 25 μL containing 2× QuantiFast SYBR Green Mastermix 
and 37.5ng genomic DNA. Primers against murine GAPDH were used to establish 
equivalent DNA loading. Proviral copy number was calculated as previously described    
To determine transgene expression levels, hFIX mRNA levels were detected by standard 
protocol as described in section 2.5.2. Briefly, approximately 1 μg total murine liver RNA 
from each sample was subjected to reverse transcription. 5μL cDNA was then used in a Q-
PCR reaction as described previously with primers designed to amplify a 127bp region of 
the hFIXco cDNA (see 2.5.2 for sequences). GAPDH primers were used to establish 
equivalent cDNA loading.  
          
3.3 Results 
3.3.1 In-vitro transduction analysis 
 
To determine the ability of alternative S/MARs to enhance AAV mediated transgene 
expression, the 587bp S/MAR from the first intron of the human Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) gene (Sykes et al, 1988) and the 486bp S/MAR from the 
3’ region of the Apolipoprotein B (ApoB) gene (Namciu et al, 1998) were cloned into the 
ssAAV-LP1-hFIXco vector plasmid immediately 3’ of the hFIXco cDNA in forward and 
reverse orientation (ssAAV8-LP1-hFIXco-HPRT-F, ssAAV8-LP1-hFIXco-HPRT-R, ssAAV8-LP1-
hFIXco-ApoB-F and ssAAV8-LP1-hFIXco-ApoB-R respectively). To account for any possible 
artefacts of expression enhancement, a 520bp non-SMAR control element (with some 
S/MAR like properties) derived from the the Kaposi sarcoma herpes virus (KSHV) genome 
(Stedman et al, 2008) was also cloned dowstream of the hFIXco cDNA in forward and 
reverse orientation (ssAAV8-LP1-hFIXco-KSHV-F and ssAAV8-LP1-hFIXco-KSHV-R 
respectively) (Figure 3.3).     
Each vector used in this study was pseudotyped with serotype 8 capsid protein and initially 
tested in-vitro by transducing 50000 HuH7 cells at a dose of 1×105vg/cell (Figure 3.4). At 
72hrs after transduction hFIX levels in cell supernatants taken form ssAAV-LP1-hFIXco-
HPRT-F, ssAAV-LP1-hFIXco-HPRT-R and ssAAV-LP1-hFIXco-ApoB-R transduced cells were 
comparable at 2.494±0.37%, 2.361±0.61% and 2.739±0.30% of normal respectively.   This 
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was a respective 2-fold, 4-fold and 23-fold increase in transgene expression as compared to 
ssAAV-LP1-hFIXco-IFN-R (1.161±0.12%) (Not significant), ssAAV-LP1-hFIXco-Control 
(0.614±0.09%) (P=<0.05, One-way ANOVA) and ssAAV-LP1-hFIXco-ApoB-F (0.1065±0.95%) 
transduced cells (P=<0.05, One-way ANOVA). hFIX levels in supernatants taken from ssAAV-
LP1-hFIXco-KSHV-F/R and untransduced cells were not detectable.  
3.3.2 Incorporation of HPRT and ApoB S/MARs in AAV expression cassettes 
enhances transgene expression in-vivo 
 
As in-vitro hFIX levels were particularly low (because AAV8 is inefficient at transducing cells 
in culture for reasons that are unknown) (Martino et al, 2013), it was necessary to verify 
these trends in-vivo. Each AAV8 vector was administered as a single bolus injection into the 
tail vein of 6-8 week old immunocompetent male C57/BL76 mice at dose of 4×1012vg/kg 
(N=3). Plasma hFIX levels were detected by ELISA over a time period of 4 weeks after vector 
administration. Similar to in-vitro observations, highest hFIX levels were observed in 
cohorts of mice transduced with ssAAV8-LP1-hFIXco-HPRT-F and ssAAV8-LP1-hFIXco-ApoB-
R (1401±87% and 1540±149% of normal respectively) (Figure 3.5). This was an approximate 
3.5 and 4-fold increase in hFIX levels as compared to ssAAV8-LP1-hFIXco-IFN-R (398±79%) 
and ssAAV8-LP1-hFIXco-HPRT-R (403±75%) cohorts respectively and an approximate 28-
fold increase as compared to ssAAV8-LP1-hFIXco-Control transduced mice (52±3%) 
(P=<0.0001, One-way ANOVA).    
Cohorts that received ssAAV8-LP1-hFIXco-ApoB-F, ssAAV8-LP1-hFIXco-KSHV-F and ssAAV8-
LP1-hFIXco-KSHV-R vector showed similar hFIX expression levels as compared to those 
observed in the ssAAV8-LP1-hFIXco-Control transduced animals at 47±7%, 22±6% and 
62±6% respectively.   
After correcting transgene expression levels by proviral copies/cell, ssAAV8-LP1-hFIXco-
HPRT-F was observed to be the most potent vector with hFIX levels in these transduced 
animals 4-fold higher than those observed in the ssAAV8-LP1-hFIXco-ApoB-R cohort 
(P=<0.0001, one way ANOVA) (Figure 3.6). Thus, the increase in transgene expression levels 
in the HPRT cohorts was not due to improved transduction efficiency as copy numbers 
were lowest in ssAAV8-LP1-hFIXco-HPRT-F and ssAAV8-LP1-hFIXco-HPRT-R transduced 
animals at 4.7±1.3 and 2.9±0.7 copies/cell respectively. The high levels of plasma hFIX 
observed in the HPRT-F cohort were confirmed by western blotting (Figure 3.6).  
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Figure 3.3: Construction of single stranded AAV-hFIXco vectors 
containing S/MAR elements. Vectors are represented 
schematically as they are packaged inside the virion. Common 
features of all vectors are described in figure 3.1. All S/MAR 
elements were cloned into the multiple cloning site of the 
control vector plasmid (3’ of the codon optimised hFIX cDNA). 
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Figure 3.4: Transgene expression in HuH7 cells. FIX levels in 
supernatants at 72 hours after transduction of HuH7 cells with 
1×105vg/cell (n=3) are represented graphically as averages ±SEM.  
Negative = supernatants from untransduced cells.  
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Figure 3.5: Transgene expression in C57BL/6 mice. % FIX levels at 4 weeks 
post tail-vein administration of 4×1012vg/kg (n=4) of all vectors depicted are 
represented graphically as averages ±SEM.  
 
88 
 
 
 
 
  
Figure 3.6: Proviral copy number correction. A) Proviral Copies/cell in liver. 
Proviral copy number was determined by a Q-PCR assay on liver samples collected 4 
weeks after transduction and depicted as mean proviral copies/cell ±SEM. B) 
Correction of %FIX levels. Results are presented as mean %FIX levels ± SEM 
corrected for proviral copy number to account for any variation in transduction 
efficiency. C) FIX western blot. FIX antigen levels in murine plasma 4 weeks post tail-
vein administration of 4×1012vg/kg of ssAAV-hFIXco-Control  and ssAAV-hFIXco-
HPRT-F are represented by western blot. Lanes labelled with percentage values 
refer to serial dilutions of recombinant FIX protein (% of normal). Naïve refers to a 
plasma sample from an untransduced animal. The strongest protein band 
representing plasma hFIX from a ssAAV8-LP1-hFIXco-HPRT-F transduced animal is 
highlighted with an arrow.      
 
C 
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3.3.3 hFIX mRNA analysis 
 
As the LP1 promoter restricts transgene expression to hepatocytes (Nathwani et al, 2006), 
at 4 weeks after gene transfer, we assessed hFIX mRNA levels in murine liver samples taken 
from a selected number of cohorts (Figure 3.7). After normalizing hFIX mRNA levels by 
housekeeping gene transcript levels (GAPDH) and proviral copy number, mRNA levels/copy 
were greatest in ssAAV8-LP1-hFIXco-HPRT-F animals at 433±132 relative units (RU). This 
was an approximate 2-fold increase as compared to ssAAV8-LP1-hFIXco-HPRT-R 
(264±57RU) and ssAAV8-LP1-hFIXco-IFN-R (176±81RU) cohorts but a greater than 20-fold 
increase in transcript levels as compared to ssAAV8-LP1-hFIXco-Control transduced mice 
(18±6RU) (P=0.0451, one way ANOVA). This trend in mRNA levels is consistent with plasma 
antigen levels observed in respective cohorts. As such, it is inferred that increased hFIX 
protein levels observed following transduction with S/MAR containing vectors was, at least 
in part, due to elevated transcription levels or improved mRNA stability.      
3.3.4 HPRT S/MAR element enhances transgene expression at lower vector doses 
 
The ssAAV8-LP1-hFIXco-HPRT-F vector maintained its increased potency in terms of in-vivo 
transgene expression (when compared to ssAAV8-LP1-hFIXco-Control) following 
administration of a lower dose (4×1010vg/kg) (Figure 3.8). At 4 weeks after vector 
administration, hFIX levels in the ssAAV8-LP1-hFIXco-HPRT-F cohort were approximately 
85-fold higher than that observed in the ssAAV8-LP1-hFIXco-Control cohort (508±83% and 
6±1% of normal respectively) (P=0.0038, T test). 
Proviral copy numbers in the liver of all animals were comparable at approximately 0.005-
0.008 copies/hepatocyte (Figure 3.9). Therefore, the increase in hFIX levels observed 
following transduction with the ssAAV8-LP1-hFIXco-HPRT-F vector was not due to variation 
in transduction efficiency. As such this vector may allow for rAAV doses to be minimised 
without compromising therapeutic effect. 
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Figure 3.7: FIX mRNA levels in liver. mRNA levels were determined by a 
Q-PCR assay on cDNA derived from total liver RNA collected 4 weeks 
after tail-vein administration of 4×1012vg/kg  of ssAAV-hFIXco-IFN-R, 
ssAAV-hFIXco-HPRTF/R and ssAAV-hFIXco-Control into C57BL/6 mice. 
Results are presented as mean mRNA levels corrected for levels of 
GAPDH cDNA present in each sample ±SEM and then corrected for 
proviral copy number to account for variation in transduction efficiency.       
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Figure 3.8: FIX expression in male C57BL/6 mice: low dose analysis. 
Transgene expression profiles over a period of 4 weeks after tail- vein 
administration of 4×1010vg/kg  (n=3) of  ssAAV-hFIXco-Control and 
ssAAV-hFIXco-HPRT-F vectors into  6 to 8 week old immunocompetent 
male C57BL/6 mice. Results are presented as averages ±SEM. Mean FIX 
values at the final time point are significantly different (P=0.0038, T 
test). 
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Figure 3.9: Proviral copy number correction. Proviral copy number 
was determined by a Q-PCR assay on C57BL/6 murine liver samples 
collected 4 weeks after transduction with ssAAV-LP1-hFIXco-Control 
and ssAAV-LP1-hFIXco-HPRT-F vectors at a dose of 4×1010vg/kg. 
Results are depicted as mean proviral copies/cell ±SEM. 
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3.3.5 Higher transgene expression with ssAAV8-LP1-hFIXco-HPRT-F and ssAAV8-
LP1-hFIXco-IFN-R in nonhuman primates  
 
All work with rhesus macaques was done in collaboration with Andrew Davidoff (St. Jude 
Children’s research hospital Memphis, TN). 4×1012vg/kg of ssAAV8-LP1-hFIXco-Control, 
ssAAV8-LP1-hFIXco-IFN-R or ssAAV8-LP1-hFIXco-HPRT-F vector was administered to the 
peripheral vein of male adolescent rhesus macaques as previously described (Nathwani et 
al, 2007). Vector administration was well tolerated with no perturbation of vital signs or 
liver transaminases (alanine aminotransferase < 45U/L) over a period of 37 weeks after 
transduction.  
Plasma hFIX was detectable within 72hours of vector administration, reaching peak levels 
of 53.9±10% at 5 days in the ssAAV8-LP1-hFIXco-HPRT-F transduced monkey (Figure 3.10). 
In contrast the animals transduced with ssAAV8-LP1-hFIXco-IFN-R and ssAAV8-LP1-hFIXco-
Control had respective peak hFIX levels of 7% and 5% (Figure 4). Similarly, steady state hFIX 
levels were 4-fold and 3-fold higher in the monkey transduced with ssAAV8-LP1-hFIXco-
HPRT-F (17±4% of normal) when compared to the animals that received ssAAV8-LP1-
hFIXco-Control (4±2% of normal) and ssAAV8-LP1-hFIXco-IFN-R (6±0.1%) respectively. The 
mean transgene copy number in the liver by Q-PCR was 32±9, 12±5 and 13±7 proviral 
copies/cells respectively for the monkeys transduced with ssAAV8-LP1-hFIXco-Control, 
ssAAV8-LP1-hFIXco-IFN-R and ssAAV8-LP1-hFIXco-HPRT-F. Thus, single stranded AAV 
vectors containing HPRT and IFN-S/MAR mediated higher FIX expression/copy of proviral 
DNA when compared to control vector in NHPs (10-fold and 4-fold increase respectively).  
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Figure 3.10: Higher potency of S/MAR containing vector in nonhuman 
primates. A) Transgene expression profiles. FIX levels in rhesus plasma were 
determined over a period of 37 weeks after peripheral vein administration of 
4×1012vg/kg of ssAAV-LP1-hFIXco-HPRT-F, ssAAV-LP1-hFIXco-IFN-R and ssAAV-
LP1-hFIXco-Control vectors. Results are depicted as averages of repeat ELISA 
results ±SEM (n=1). B) Proviral copy number correction. To account for 
variation in transduction efficiency, proviral copy number was determined by 
a Q-PCR assay on liver samples collected 37 weeks after transduction. Results 
are depicted as % normal FIX levels corrected for proviral copies per cell.  
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3.4 Discussion 
 
The need for high vector doses to achieve a therapeutic effect has been observed in 
multiple rAAV gene therapy clinical studies including trials for lipoprotein lipase deficiency, 
Leber’s congenital amaurosis, α1-antitrypsin deficiency and haemophilia B (Bainbridge et 
al, 2008; Flotte et al, 2004; Flotte et al, 2011; Nathwani et al, 2011; Stroes et al, 2008). In 
many cases the administration of higher doses appears to coincide with an increased risk of 
toxicity mediated by T cell responses against capsid antigens (Manno et al, 2006; Mingozzi 
et al, 2009; Nathwani et al, 2011). To address this matter, this study has systematically 
evaluated the expression enhancement effect of multiple S/MAR elements in the context 
of our AAV8-LP1-hFIXco system with the overall aim of improving vector potency in order 
to minimise dose requirements.  
Tail vein administration of 4×1012 vg/kg resulted in a 10 to 28-fold increase in plasma hFIX 
levels in mice transduced with vector containing S/MAR elements as compared to levels 
achieved with control vectors containing no S/MAR or S/MAR-like KSHV elements. These 
results are fully consistent with previous studies that document the enhancer effect of 
S/MARs in other gene transfer systems including retroviral constructs and plasmid DNA 
(Argyros et al, 2008; Kurre et al, 2003).  
Although these results were found to be statistically significant, it is important to mention 
that sample size/power calculations should, in future, be used to determine and justify 
animal numbers used per group. To calculate the sample size (number of animals) required 
to compare means of 2 normally distributed groups of equal size, the following formula can 
be used: 
n= (σ1
2
 + σ2
2) (Z1-α/2 + Z 1-β)
2/Δ2 
In this formula n =sample size, σ is the expected standard deviation of the mean, Z1-α/2 is 
constant and dependent on chosen significance level, Z 1-β is constant and dependent on 
the chosen probability/power and Δ2 is the difference between the two expected means 
(Kadam & Bhalerao, 2010). 
In the context of this study, these calculations would be based on the increase in gene 
expression that one might anticipate based on previous S/MAR related literature. For 
instance, from previous work, a 2 fold increase in gene expression would be a conservative 
estimate of expression enhancement when using the IFNβ S/MAR vector (Kurre et al, 
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2003). As such, if based on our preliminary studies we assume FIX expression levels of 17% 
in the control group, we can assume FIX levels of 34% in the group receiving the S/MAR 
containing vector. As deviation from the mean can be moderately variable in these 
experiments, a reasonable expected standard deviation of 10% can be implemented. Using 
the above formula and a significance level (α) of 5% (meaning we accept a 5% possibility of 
results occurring through chance) and a power (1-β) of 80% (meaning we accept a 20% 
chance of generating false negative results) the following can be calculated for this 
example: 
n=(102 + 102) (1.96+0.84)2/(34-17)2=5.426 
= 6 animals per group  
(Where Z1-α/2 is constant at 1.96 when using a significance level of 5% and Z 1-β is constant at 
0.84 when using a power of 80%.) 
In this example, the requirement for 6 animals per group is calculated which was the initial 
number of mice used in this study per group (see page 77). In future experiments it will also 
be important to determine the reproducibility of these results by testing S/MAR containing 
vectors in further groups of animals and with new preparations of AAV vectors. This will 
allow us to conclusively establish that these observations were not influenced by 
experimental artefacts such as contamination of vector stocks, degradation of vector or 
injection/human error.  
Following correction for proviral copy number in liver, highest hFIX levels (approximately 
150-fold greater than control) were observed with ssAAV8-LP1-hFIXco-HPRT-F vector 
containing a S/MAR element from the HPRT gene in forward orientation. Interestingly, the 
orientation of the S/MAR sequences in AAV vectors appears to be important for all three 
elements used in this study: a feature that has also been observed in the context of 
retroviral and lentiviral vectors (Auten et al, 1999; Dang et al, 2000; Kurre et al, 2003; 
Ramezani et al, 2003). As the structure of S/MARs in relation to the transgene appears to 
be the primary determinant of S/MAR activity (as opposed to DNA base composition) the 
reason why we and others have observed an orientation dependent effect in the context of 
gene transfer vectors may be purely related to structure.  
The 809bp human IFNβ S/MAR has previously been shown to prevent repressive epigenetic 
modifications in the context of episomally maintained plasmid vectors and retroviral 
vectors (Argyros et al, 2011; Argyros et al, 2008; Dang et al, 2000; Moreno et al, 2011; 
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Ramezani et al, 2003). Similarly, the ApoB S/MAR has been shown to have a role in 
insulating associated transgenes from silencing effects (Namciu et al, 1998). However, 
results from ssAAV8-LP1-hFIXco-HPRT-F transduced animals were somewhat unanticipated 
as, in contrast, the HPRT S/MAR is primarily documented to support autonomous 
replication (Sykes et al, 1988). As such, one might expect an observation of sustained 
expression through episome retention as opposed to expression enhancement. 
The expression enhancement effect observed with ssAAV8-LP1-hFIXco-HPRTF was 
reproducible in rhesus macaques with 4-fold increased levels of hFIX observed in animals 
transduced with 4×1012vg/kg of ssAAV8-LP1-hFIXco-HPRTF as compared to control. 
However, plasma FIX levels observed in the macaque transduced with ssAAV-LP1-hFIXco-
Control were lower than that reported previously for ssAAV-FIX vectors containing the 
HCR-hAAT regulatory element (peaking at 5% and 14% of normal physiological hFIX levels 
respectively): suggesting our synthetic small LP1 promoter may not be as strong (Davidoff 
et al, 2005). As such it will be important to test S/MAR elements in AAV vectors with 
alternative promoters. Nonetheless, consistent with data in mice, the addition of HPRT 
S/MAR to the LP1-hFIXco expression cassette appears to improve hFIX expression in NHPs. 
However, larger numbers of monkeys are needed to establish this observation conclusively 
as this result is currently limited by the use of one animal per group. As such, it is possible 
that heterogeneity between animals may have influenced these results. For instance, if 
animals treated with S/MAR containing vectors had lower serum anti-AAV8 antibody titres, 
it is possible that hFIX expression may be observed as increased due to reduced immune 
neutralisation of the vector as opposed to the incorporation of S/MAR elements. To rule 
out this possibility, it will be important to reproduce these results in larger numbers of 
animals to enable the subsequent generation of statistical conclusions. 
 In common with episomal plasmids and onco-retroviral vector systems, through a Q-PCR 
assay, we have found S/MARs to mediate expression augmentation in mice and nonhuman 
primates through increased levels of transcription or improved RNA stability. At the high 
dose of 4×1012 vg/kg, after correcting for proviral copy numbers, 10-fold and 24-fold higher 
levels of liver hFIX mRNA were observed in ssAAV8-LP1-hFIXco-IFN-R  and ssAAV8-LP1-
hFIXco-HPRT-F cohorts compared to ssAAV8-LP1-hFIXco-Control animals respectively. This 
was fully consistent with results obtained for plasma hFIX antigen levels.   
AAV mediated gene transfer can be enhanced with the use of several agents. In addition to 
HDAC inhibitors this includes androgens (5 alpha dihydrotestosterone) and proteasome 
98 
 
inhibitors (e.g. carbobenzyl-L-leucyl-L-leucyl-L-leucinal and bortezomib) (Jennings et al, 
2005; Monahan et al, 2010). However, the need to administer these drugs before or at the 
same time as gene transfer adds complexity to the scheduling of vector administration. 
Furthermore, these drugs give rise to significant side effects that could negatively impact 
the toxicity profile of the rAAV vector in use. Thus, through the incorporation of S/MAR 
elements in our LP1- hFIXco expression cassette we have come up with a novel, inbuilt 
solution to overcome some of the limitations of rAAV gene transfer. As such, this data 
represents a necessary step towards improving the potency and safety of rAAV vectors for 
broader clinical use. 
However, as this analysis has only involved the use of S/MAR elements in the context of our 
LP1-hFIXco AAV expression cassette, we cannot rule out the possibility that S/MARs may 
not have the same effect when incorporated into alternative AAV transcription units. As 
such it will be important to test S/MARs in conjunction with different transgenes. 
Nevertheless, this study has clearly demonstrated the beneficial used of matrix attachment 
regions in the context of a vector that has been shown to work effectively in humans. Thus 
we have improved the potency of a vector that is applicable to a clinical setting.    
To summarise, we have critically evaluated three S/MAR elements in the context of single 
stranded AAV vectors encoding human FIX in cell lines, mice and rhesus macaques. In all 
cases S/MAR elements were found to enhance transgene expression. The basic mechanism 
behind the up regulation of hFIX when using S/MARs was evaluated by analysing hFIX 
mRNA levels following gene transfer; our results are indicative of enhanced transcription 
levels or improved mRNA stability with S/MARs. Taken as a whole, S/MARs may help to 
achieve the overall goal of improved AAV vector potency. 
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CHAPTER 4 MATRIX ATTACHMENT REGION DELETION ANALYSIS 
 
4.1 Introduction 
4.1.1 Recombinant AAV packaging capacity 
 
The packaging capacity of recombinant adeno-associated virus is widely accepted to be 
limited to the size of wild type genomes (approximately 4.7kb). The use of rAAV in gene 
transfer is therefore largely restricted to the treatment of disorders whereby the coding 
sequence of the therapeutic gene is equivalent to or shorter than 4.7Kb (Grieger & 
Samulski, 2005). Consequently, research into rAAV-mediated gene therapy for many 
disorders (including some forms of Leber congenital amaurosis, cystic fibrosis, Haemophilia 
A and Duchenne muscular dystrophy) has been somewhat impeded; as a result multiple 
groups have further investigated the upper limits of AAV packaging. In the context of single 
stranded rAAV vectors pseudotyped with serotype 5 capsid protein, one group has 
previously demonstrated the ability to package expression cassettes containing murine 
Abca4, human MYO7A, and human CEP290 genes for the potential treatment of common 
sensorineural blinding diseases known as recessive Sargardt disease (rSTG), Usher 
syndrome (USH) and Leber congenital amaurosis (LCA) respectively (respective final 
cassette sizes of 8.9, 8.1 and 8.9kb)(Allikmets, 1997; Allocca et al, 2008; den Hollander et al, 
2006; Keats & Corey, 1999). However, in a similar study, this observation was not 
reproduced and by southern blot analysis of vector DNA run on alkaline agarose gels, AAV 
vectors pseudotyped with serotype 2, 5 and 8 capsids were deemed unable to tolerate the 
packaging of genomes exceeding 5.2kb (demonstrated by the presence of heterogeneous; 
fragmentary genome populations) (Wu et al, 2010).   
It has previously been shown that the limitation of packaging capacity can be overcome by 
splitting expression cassettes between two separate vectors (Duan et al, 2000; Nakai et al, 
2000; Senapathy & Carter, 1984; Sun et al, 2000; Yan et al, 2000). After co-transduction, 
the two separate halves of the vector genome become reconstituted through ITR mediated 
intermolecular concatamerization: thus providing a complete platform for transgene 
expression. Two examples of dual vector strategies include the use of trans-splicing or 
homologous recombination between single stranded AAV genomes (described in figure 
4.1). However, in a study carried out by Duan et al using the β-galactosidase gene as a 
template, the efficiency of both dual vector strategies was observed to be significantly 
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lower in comparison to the administration of a single vector only. In this study, trans-
splicing and homologous recombination vectors provided respective β-galactosidase 
activity of 4.28% and 0.37% of that observed following transduction with a single vector 
only 7 weeks after injection of 5×1010vg into the anterior tibialis muscle of C57BL/6 mice 
(Duan et al, 2001). As such, for efficient transgene expression to be achieved, rAAV gene 
transfer is limited to the capacity of a single vector.  
The issue of packaging capacity becomes even more pertinent in the context of self-
complementary vectors. As previously mentioned, self-complementary vectors are 
designed to overcome the rate limiting step of single stranded to double stranded 
conversion of rAAV genomes. To achieve this effect, both plus and minus strands must be 
packaged within the same virion (Figure 4.2); as such, the packaging capacity of self-
complementary vectors is reduced by approximately 50% (2.3kb)(McCarty et al, 2003; 
McCarty et al, 2001).   
As a result of this limitation, the first aim of this chapter was to reduce the space occupied 
by S/MAR elements within our LP1-hFIXco expression cassette. This was achieved by 
carrying out a deletion analysis on the IFNβ and HPRT S/MAR sequences in order to 
determine the minimal sequences required for factor IX expression enhancement.    
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Figure 4.1: Split AAV Vector Strategies. Split vector strategies are represented 
schematically. A) Trans splicing vectors. Each vector contains either the splice donor or 
splice acceptor site of a common intron. Following concatemerisation the two halves of the 
vector are reconstituted by cellular splicing machinery. B) Overlapping vectors. 
Overlapping vectors contain a large region of identical sequence (xxxxxxx). This enables 
homologous recombination and subsequent reconstitution of the expression cassette.   
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Figure 4.2: Schematic of a self-complementary AAV vector. A self-complementary AAV 
vector is represented schematically as it would be packaged inside a virion. Sense and 
antisense DNA strands are contained in the same vector (each having a maximum size of 
approximately 2.3Kb). The vector folds at the mutated central ITR (∆trs) for the joining of 
complementary DNA strands.  
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4.1.2 Identifying regulatory sequences in S/MARs 
 
The second aim of the S/MAR deletion analysis was to identify sequence motifs that may 
contribute to the enhancer activity of S/MARs. Through studies such as protein binding 
microarray (PBM) and chromatin immunoprecipitation followed by deep sequencing (ChIP-
Seq) it has become possible to identify key regulatory sequences involved in transcription 
factor (TF) binding (Barski & Zhao, 2009; Berger & Bulyk, 2009). With this information, it is 
possible to generate computational models of transcription factor binding affinity 
(representations of biological sequence motifs) referred to as position weight matrix 
(PWM) models (Stormo, 2000). Databases containing information on PWMs can therefore 
be used for the in-silico elicitation of motif sequences from a user provided input sequence 
(Bailey et al, 2006). As each motif is linked to a particular group of transcription factors, the 
user is able to assign potential biological roles to the motifs elicited (Buske et al, 2010). 
Using the gene ontology for motifs (GOMO) algorithm, descriptive terms of possible 
biological function (gene ontology (GO) terms) are provided; as such there is potential to 
identify regions of an input sequence that are involved in processes such as gene 
expression, chromatin assembly or mRNA processing (to name but a few GO terms) 
(Ashburner et al, 2000; Buske et al, 2010). Thus, through such analysis, we aimed to 
identify potential motifs that contribute to the enhancer effect of potent S/MAR fragments.   
As primary DNA sequence is a lesser determinant of S/MAR activity, in our deletion 
analysis, truncated S/MARs were either generated arbitrarily or by identifying the strongest 
regions of base unpairing through computational analysis (SIDD profiles). S/MAR fragments 
were cloned into the 3’ region of our AAV-LP1-hFIXco expression cassette to systematically 
assess their impact on transgene expression in cell lines and in animal models. In this study 
we identified two S/MAR fragments capable of enhancing hFIX transgene expression in 
HuH7 cells and C57BL/6 mice (IFNβ S/MAR fragment 2 and HPRT S/MAR fragment 2b). 
HPRT fragment 2b also demonstrated potent enhancer activity in the context of a self-
complementary vector both in-vitro and in-vivo.  
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4.2 Materials and methods 
4.2.1 AAV-hFIX vector production and purification 
The ssAAV vector encoding hFIX is described in section 3.2.1. Fragments of the IFNβ S/MAR 
were generated using the standard HotStar Taq PCR method described in section 2.1.2 with 
pAV-LP1-hFIXco-IFN-R plasmid DNA used as a template. HPRT S/MAR fragments were 
generated using the standard Phusion High-Fidelity DNA Polymerase PCR method described 
in section 2.1.2 with pAV-LP1-hFIXco-HPRT-F plasmid used as template DNA. All 5’ primers 
used to generate IFNβ and HPRT S/MAR fragments contained the KpnI restriction site 
(GGTACC) and all 3’ primers contained the NotI restriction site (GCGGCCGC) for subsequent 
digestion of PCR products and ligation into the multiple cloning site of KpnI-NotI digested 
pAV-LP1-hFIXco-MCS-TSV40pA plasmid DNA. The following primer pairs were used for PCR 
amplification of S/MAR fragments: 
IFNβ FR1 5’: 5’-ATCGGGTACCCAACTTGTCAA-3’ 
IFNβ FR1 3’: 5’-ATCGGCGGCCGCTTATTTTTT-3’ 
IFNβ FR2 5’: 5’-ATCGGGTACCATTTTACAATG-3’ 
IFNβ FR2 3’: 5’-ATCGGCGGCCGCTTTTTAATT-3’ 
IFNβ FR3 5’: 5’-ACTGGGTACCCAAAGTCCTAA-3’ 
IFNβ FR3 3’: 5’-ATCGGCGGCCGCACTGTTCTC-3’ 
 
HPRT FR1 5’: 5’-CGCGGGTACCCAAGTTATAT-3’ 
HPRT FR1 3’: 5’-AATTGCGGCCGCGATAATTTG-3’ 
HPRT FR2 5’: 5’-CGCGGGTACCCCAAGGAGAT-3’ 
HPRT FR2 3’: 5’-ATATGCGGCCGCTGACAGAGC-3’ 
HPRT FR2a 5’: 5’-CGCGGGTACCAGGTGTTTTT-3’ 
HPRT FR2a 3’: 5’-ATATGCGGCCGCCAAACTTCT-3’ 
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HPRT FR2b 5’: 5’-GCGCGGGTACCGGAAATATTA-3’ 
HPRT FR2b 3’: 5’-ATATGCGGCCGCTGACAGAGC-3’ 
Annealing temperatures used to generate IFNβ FR1, IFNβ FR2, IFNβ FR3, HPRT FR1, HPRT 
FR2, HPRT FR2a and HPRT FR2b were 56.8, 53.9, 61.8, 57.3, 64.7, 61.3 and 60.3°C 
respectively. Following the PCR reactions S/MAR fragments were electrophoresed on 1% 
agarose gels and purified by gel extraction methods as detailed in sections 2.1.3 and 2.1.4. 
NotI and KpnI Restriction digests were carried out for 3 hours at 37°C on total extracted 
S/MAR fragment DNA in 50µl reactions containing 10% NEBuffer 2 and 1% BSA (standard 
conditions described in 2.1.3). To prepare the vector backbone 10µg of pAV-LP1-hFIXco-
MCS-TSV40pA plasmid DNA was NotI and KpnI digested 3 hours at 37°C in a 100µl reaction 
with the same conditions as described above. Vector backbone DNA was purified by gel 
extraction and ligated with S/MAR fragment DNA as detailed in 2.1.7. Subsequent 
transformation was carried out as per standard protocol (section 2.1.8). Colonies were 
expanded and screened as described in 2.1.8 and enzymes used for standard 10µl 
screening digests (carried out at 37°C for 1 hour) were SspI (IFNβ fragments 1 and 3) NdeI 
(IFNβ fragment 2) and PstI together with NotI (HPRT fragments 1-2b). Competent E.coli 
containing correct plasmid constructs were expanded as described in section 2.1.8. 
To generate self-complementary vector plasmids, a DNA fragment containing the MCS and 
TSV40pA was first generated using the standard Phusion High-Fidelity DNA Polymerase PCR 
method described in section 2.1.2 with pAV-LP1-hFIXco-MCS-TSV40pA plasmid DNA as a 
template. The 5’ primer was designed with the addition of a BbsI restriction site (GAAGAC) 
for subsequent BbsI digestion of the PCR product and ligation of the sticky-blunt fragment 
into vector backbone DNA (Sc-LP1-hFIXco-SV40pA) with a 5’ BbsI digested end and 3’ blunt 
end. Primer sequences used for this PCR were 5’: 5’-ATGAGAAGACCAAGCTGACCTG-3’ and 
3’: 5’-TGTAGTTAATGATTACAAATAAAGC-3’. The annealing temperature used was 50.9°C. To 
generate the vector backbone 10µg of Sc-LP1-hFIXco-SV40pA plasmid DNA was digested 
with SpeI-HF (high fidelity) for 3 hours at 37°C with 10% NEBuffer 4 in a standard 100µl 
reaction. Total backbone DNA was then gel extracted and blunt ends were generated as 
described in 2.1.5. Total backbone DNA was then digested with BbsI for 2 hours at 37°C 
with 10% NEBuffer 2 in a standard 50µl reaction. The MCS-TSV40pA PCR product was gel 
purified and digested with BbsI for 2hrs as described above. Ligation, transformation and 
plasmid propagation were carried out as previously described. Screening digests for the 
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detection of correct Sc-LP1-hFIXco-MCS-TSV40pA construct were carried out as standard 1 
hour 10µl reactions using EcoRI and NotI restriction enzymes (double digest). 
To insert HPRT fragment 2b into the multiple cloning site of Sc-LP1-hFIXco-MCS-TSV40pA, 
standard Phusion High-Fidelity DNA Polymerase PCR was carried out to amplify fragment 
2b using the pAV-LP1-hFIXco-FR2b-tSV40pA plasmid as a template. Primers were designed 
with KpnI restriction sites for subsequent cloning of fragment 2b into KpnI digested Sc-LP1-
hFIXco-MCS-TSV40pA DNA. Primer sequences used for this PCR were 5’: 5’-
GGCGTGGTACCGGAAATATTA-3’ and 3’: 5’-TGAGGTACCGCTGACAGAGCA-3’. The annealing 
temperature used was 60.3°C. Total fragment 2b and 10µg Sc-LP1-hFIXco-MCS-TSV40pA 
DNA was digested with KpnI for 3hours at 37°C with 10% NEBuffer 1 and 1% BSA in 
standard 50µl and 100µl reactions respectively. Vector backbone DNA was then alkaline 
phosphatase treated as described in 2.1.6. Subsequent cloning steps were carried out as 
previously described with SspI and PstI double digests used for 10µl screening reactions. 
All plasmids generated were sequenced to ensure the presence of correct DNA inserts 
(data not included). All plasmids were also screened for the presence of intact ITRs using 
standard 10µl AhdI and BglI restriction digests (digested for 1 hour at 37°C).          
All vectors were made by the adenovirus-free transient transfection method described in 
section 2.2.2, using a chimeric AAV2 Rep-8Cap packaging plasmid (pAAV8-2) and an 
adenoviral helper plasmid. Vectors were purified as detailed in 2.2.3. All vector titres were 
determined by standard quantitative real-time PCR (Q-PCR) and coomassie gel methods 
(sections 2.2.4 and 2.2.6 respectively). HPRT short fragment vectors were additionally titred 
by alkaline agarose gel electrophoresis as described in section 2.2.5.   
4.2.2 Animal studies 
All procedures were performed in accordance with institutional guidelines as previously 
described. Tail-vein administration of rAAV vector particles was performed in 6 to 8 week 
old immunocompetent male C57BL/6 mice as single bolus injections (maximum volume of 
200µl) using 1ml syringes. Prior to injection or bleeding, mice were briefly warmed at 39°C 
to dilate the tail vein. For the IFNβ S/MAR vectors, mice were injected with 4×1012vg/kg 
and killed 4 weeks after vector administration. HPRT vectors were injected at a dose of 
4×1010vg/kg and mice were killed 2 weeks after administration. Blood samples were taken 
from the tail vein at one week intervals over the course of the experiment. To separate 
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plasma, blood samples were spun at 4000× g in tri-sodium citrate buffer for 15 minutes at 
4°C. In all cases livers were harvested for subsequent molecular analysis.  
4.2.3 HuH7 cell culture and transduction 
HuH7 cells were cultured as described in section 2.4.2. Transduction of HuH7 was carried 
out as per standard protocol (section 2.4.3) using 1×107vg of each vector. 
4.2.4 Determination of FIX levels 
Human FIX antigen levels in cell supernatants and murine plasma samples were determined 
by enzyme-linked immunosorbent assay (ELISA) as previously described (section 2.4.4 and 
3.2.4).  
Western blotting to determine hFIX protein levels was carried out as previously described 
in section 2.4.6 with prior antigen immunoprecipitation carried out to minimize non-
specific background (section 2.4.5). 
4.2.5 Molecular studies 
Proviral copy number was determined by standard Q-PCR protocol as described in section 
2.4.7 and 3.2.5.  
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4.3 Results 
4.3.1 Deletion analysis of IFN-ß S/MAR identifies a smaller region with potent 
enhancer activity 
 
As S/MARs do not contain obvious consensus sequences, in order to identify the smallest 
region required for enhancement of hFIX expression in the context of rAAV vectors, the 
809bp IFN-ß S/MAR was arbitrarily divided into three fragments of approximately 300bp. 
Each fragment was then cloned into the ssAAV-LP1-hFIXco vector plasmid downstream of 
the hFIXco cDNA in reverse orientation (Figure 4.3). ssAAV8-LP1-hFIXco-FR1, ssAAV8-LP1-
hFIXco-FR2 and ssAAV8-LP1-hFIXco-FR3 vectors contained the proximal 290bp, central 
297bp or distal 375bp of the IFNβ S/MAR respectively. Each ssAAV expression cassette 
containing a truncated IFN-ß S/MAR fragment was pseudotyped with serotype 8 capsid 
protein and initially tested by in-vitro transduction of HuH7 cells at a dose of 1×107vg/cell. 
For comparison a group of cells was transduced with the same dose of ssAAV8-LP1-hFIXco-
IFN-R containing the full 809bp IFN-ß S/MAR.   
By this analysis, the highest levels of hFIX were observed in cells transduced with ssAAV-
LP1-hFIXco-FR2 vector at 0.575 ± 0.03% of normal (Figure 4.4). This was significantly higher 
than hFIX levels observed with all other vectors tested (P=<0.0001, one way ANOVA) with 
an approximate increase of 2-fold as compared to ssAAV-LP1-hFIXco-IFN R (0.312 ± 0.045%) 
and ssAAV-LP1-hFIXco-FR1 (0.245 ± 0.030%) transduced cells and a respective 4-fold and 5-
fold increase as compared to ssAAV-LP1-hFIXco-Control (0.160 ± 0.014%) and ssAAV-LP1-
hFIXco-FR3 (0.114 ± 0.005%) transduced cells.       
As hFIX expression levels observed in-vitro were particularly low, it was necessary to verify 
trends in transgene expression in-vivo. As such, each vector was administered as a single 
bolus injection into the tail vein of 6-8 week old male C57BL/6 mice (n=4) at a dose of 
4x1012vg/kg. Transduction efficiency was assessed at 4 weeks after gene transfer by 
assessing plasma hFIX levels and transgene copy number in the liver. At 4 weeks post 
injection mice transduced with ssAAV8-LP1-hFIXco-IFN-R expressed hFIX at 398 ± 79% of 
normal levels (Figure 4.5). Human FIX expression in the cohorts transduced with ssAAV8-
LP1-hFIXco-FR1 or ssAAV8-LP1-hFIXco-FR3 was comparable at 467 ± 19% and 406 ± 42% of 
normal respectively. In contrast, transduction with ssAAV8-LP1-hFIXco-FR2 resulted in an 
significant threefold increase in hFIX expression to 1202 ± 205% of normal (P=<0.0001, one 
way ANOVA). Observed trends in transgene expression were verified by western blot to 
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detect hFIX protein in murine plasma samples taken at 4 weeks post vector administration 
(Figure 4.5). Collectively, these results suggest the possible presence of repressive motifs in 
fragments 1 and 3. 
To confirm that these observations were not due to increased transduction efficiency with 
S/MAR containing vectors, all results were normalised by genome copies per hepatocyte as 
determined by a Q-PCR assay on transduced liver DNA samples. Although average values of 
copies per cell varied between individual cohorts (7.7±0.9 to 27.6±1.9), overall trends of 
transgene expression levels remained unchanged after correcting hFIX levels (Figure 4.6). 
Indeed by this analysis the ssAAV-LP1-hFIXco-FR2 vector maintained the approximate 3-
fold advantage over ssAAV-LP1-hFIXco-IFN-R with normalised hFIX levels of 86.9±12RU 
(relative units) and 33.6±3.4RU respectively.   
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Figure 4.3: Construction of single stranded AAV-hFIXco vectors containing truncated 
IFNß S/MAR fragments. Vectors are represented schematically as they are packaged 
inside the virion. Common features of all vectors are described in figure 3.1. IFNβ S/MAR 
fragments were generated by a standard PCR method and cloned immediately 
downstream of the hFIXco cDNA in reverse orientation. ssAAV-LP1-hFIXco-IFN-R and 
vector genomes containing IFNß S/MAR fragments are approximately 3.3Kb and 2.8Kb in 
size respectively. 
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Figure 4.4: Transgene expression in HuH7 cells. FIX levels in 
supernatants at 72 hours after transduction of HuH7 cells with 
1×107vg/cell (n=3) are represented graphically as averages ±SEM.  
Negative = untransduced cell supernatants. Control, IFN-R, FR1, FR2 and 
FR3 refers to ssAAV-LP1-hFIXco-control, ssAAV-LP1-hFIXco-IFN-R, ssAAV-
LP1-hFIXco-FR1, ssAAV-LP1-hFIXco-FR2 and ssAAV-LP1-hFIXco-FR3 
vectors respectively. 
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Figure 4.5: Transgene expression in C57BL/6 mice. Top) % FIX levels at 4 weeks post tail-
vein administration of 4×1012vg/kg (n=4) of all vectors depicted are represented 
graphically as averages ±SEM. Bottom) FIX antigen levels in murine plasma 4 weeks after 
administration of 4×1012vg/kg of all vectors depicted are represented by western blot. 
250% and 62.5% refers to the amount of recombinant hFIX protein (% of normal) loaded 
into each respective well. Naïve refers to a plasma sample from an untransduced animal. 
The strongest protein band (representing plasma hFIX from a ssAAV8-LP1-hFIXco-FR2 
transduced animal) is highlighted with an arrow.   
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Figure 4.6: Proviral copy number correction. A) Proviral Copies/cell in liver. 
Proviral copy number was determined by a Q-PCR assay on murine liver samples 
collected 4 weeks after transduction and depicted as mean proviral copies/cell 
±SEM. B) Correction of %FIX levels. Results are presented as mean %FIX levels ± 
SEM corrected for proviral copy number to take account variation in transduction.       
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4.3.2 Deletion analysis of HPRT S/MAR identifies a smaller region containing core 
enhancer activity 
 
In a separate study the HPRT S/MAR was divided into four fragments. S/MAR fragments in 
this analysis were chosen using the in-silico SIDD profiling technique that serves to map 
regions of DNA helix unwinding (an S/MAR property) within a given sequence (Benham et 
al, 1997). By this method two regions requiring low theoretical energy levels to undergo 
DNA strand separation were identified in the HPRT S/MAR sequence (analysed in the 
context of the full ssAAV expression cassette). Fragment 1 of the HPRT S/MAR corresponds 
to the proximal 150bp region of helix destabilization whilst fragment 2 corresponds to a 
central 250bp region. Fragment 2 was then further subdivided into fragments of 90bp and 
130bp (fragments 2a and 2b respectively) (Figure 4.7).  
Each ssAAV expression cassette containing a truncated HPRT S/MAR fragment was 
pseudotyped with serotype 8 capsid protein and assessed in-vitro by transducing HuH7 
cells at a dose of 1×107vg/cell.  For comparison a group of cells was transduced with the 
ssAAV8-LP1-hFIXco-HPRT F vector containing the full 587bp HPRT S/MAR at the same dose. 
Highest levels of hFIX expression were observed in ssAAV-LP1-hFIXco-HPRT-F and ssAAV-
LP1-hFIXco-FR2b transduced cells at 4.313 ± 0.009% and 4.079 ± 0.830% respectively 
(Figure 4.8). This was a respective 3-fold, 7-fold and 12-fold increase as compared to 
ssAAV-LP1-hFIXco-FR2 (1.463 ± 0.330%), ssAAV-LP1-hFIXco-FR2a (0.586 ± 0.045) and 
ssAAV-LP1-hFIXco-FR1 (0.344 ± 0.081%) transduced cells (P=<0.05, one way ANOVA). 
To verify trends of transgene expression in-vivo all vectors were administered as a single 
bolus injection into the tail vein of 6-8 week old male C57Bl/6 mice (n=3) at a dose of 
4x1010vg/kg (determined by alkaline gel titration). hFIX levels were assessed 2 weeks after 
vector administration and variations in transduction efficiency were determined by proviral 
copy number analysis in the liver. Highest hFIX expression levels were observed in the 
ssAAV8-LP1-hFIXco-HPRT-F transduced cohort at 46±9% of normal (Figure 4.9). This was an 
approximate 11.5 and 15-fold increase in transgene expression as compared to ssAAV8- 
ssAAV8-LP1-hFIXco-FR1 (4±1%) and ssAAV8-LP1-hFIXco-FR2a (3±2%) trasduced animals 
respectively. However, hFIX levels observed in the LP1-hFIXco-FR2 and ssAAV8-LP1-hFIXco- 
FR2b cohorts were not found to be significantly different to those observed in ssAAV8-LP1-
hFIXco-HPRT-F transduced mice (P=>0.05, one way ANOVA) with hFIX levels in these 
cohorts reaching  24±5% and 35±7% of normal respectively.  
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Changes in transgene expression were not accounted for by discrepancy in transduction 
efficiency as average proviral copy number in the liver of mice transduced with each of the 
5 different vectors was comparable at approximately 0.5±0.1 to 2.6±2.3 copies/hepatocyte 
(Figure 4.10A). Mean %hFIX/copy levels were not found to be significantly different 
between ssAAV8-LP1-hFIXco-FR2, ssAAV8-LP1-hFIXco-FR2b and ssAAV8-LP1-hFIXco-HPRT-F 
(P=>0.05, one way ANOVA) at 52.4±26.6RU, 68.5±7.7RU and 97.1±29.5RU respectively 
(Figure 4.10B). In agreement with in-vitro data, these results collectively suggest that the 
130bp HPRT fragment 2b present in ssAAV8-LP1-hFIXco-FR2, ssAAV8-LP1-hFIXco-FR2b and 
ssAAV8-LP1-hFIXco-HPRT-F vectors may contain the core elements required for enhancing 
the AAV transgene expression in-vivo. 
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Figure 4.7: Construction of single stranded AAV-hFIXco vectors containing truncated HPRT 
S/MAR fragments. Vectors are represented schematically as they are packaged inside the 
virion. HPRT S/MAR fragments were generated by a standard PCR method and cloned 
immediately downstream of the hFIXco cDNA in forward orientation (FR1, FR2, FR2a and 
FR2b). 
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Figure 4.8: Transgene expression in HuH7 cells. FIX levels in supernatants at 72 hours 
after transduction of HuH7 cells with 1×107vg/cell (n=3) are represented graphically 
as averages ±SEM.  Negative = untransduced cell supernatants. Control, HPRT-F, FR1, 
FR2 FR2a and FR2b refers to ssAAV-LP1-hFIXco-control, ssAAV-LP1-hFIXco-HPRT-F, 
ssAAV-LP1-hFIXco-FR1, ssAAV-LP1-hFIXco-FR2, ssAAV-LP1-hFIXco-FR2a and ssAAV-
LP1-hFIXco-FR2b transduced cells respectively. 
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Figure 4.9: Transgene expression in C57BL/6 mice. % FIX levels at 2 weeks after 
tail-vein administration of 4×1010vg/kg (n=3) of all vectors depicted are 
represented graphically as averages ±SEM.  
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Figure 4.10: Proviral copy number correction. A) Proviral Copies/cell in liver. 
Proviral copy number was determined by a Q-PCR assay on murine liver samples 
collected 2 weeks after transduction with 4×1010vg/kg of each vector depicted. 
Results are presented as mean proviral copies/cell ±SEM. B) Correction of %hFIX 
levels. Results are presented as mean %FIX levels ± SEM corrected for proviral 
copy number to account for variation in transduction.       
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4.3.3 HPRT Fragment 2b enhances transgene expression in self-complementary 
vectors 
 
Due to its reduced size, we were able to assess the HPRT fragment 2b S/MAR in the context 
of a self-complementary vector with the S/MAR sequence again cloned immediately 3’ of 
the hFIXco transgene. Each scAAV cassette (containing no S/MAR or fragment 2b) was 
pseudotyped with serotype 8 capsid protein and used to transduce HuH7 cells at a dose of 
1×107vg/cell. As detailed in figure 4.11, 20-fold higher hFIX antigen levels were observed in 
sc-LP1-hFIXco-FR2b transduced cells (1.283±0.269%) as compared to sc-LP1-hFIXco-Control 
transduced cells (0.064±0.026%) (P=0.0093, student T-test). 
For in-vivo analysis both vectors were administered as a single bolus injection into the tail 
vain of 6 to 8 week old male C57BL/6 mice at a dose of 4×1010vg/kg (n=3). hFIX levels were 
assessed over a period of 4 weeks after gene transfer followed by proviral copy number 
analysis in the liver.  
At 4 weeks hFIX levels in the scAAV8-LP1-hFIXco-HPRT-FR2b transduced cohort were 
approximately 105±6% (Figure 4.12). This was a 35-fold increase (P=0.0038, student T-test) 
in transgene expression as compared to scAAV8-LP1-hFIXco-Control transduced animals 
(3±1%). Differences in transgene expression levels were not accounted for by variance in 
proviral copy number as copies in the liver of transduced animals were comparable at 
approximately 2.1-3.1 copies/hepatocyte (Figure 4.13). These data suggest that S/MAR 
elements are also effective in a self-complementary format.   
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 Figure 4.11: Transgene expression in HuH7 cells. FIX levels in supernatants at 
72 hours after transduction of HuH7 cells with 1×107vg/cell (n=3) are 
represented graphically as averages ±SEM.   
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Figure 4.12: HFIX levels in C57BL/6 mice. % FIX levels at 4 weeks after tail-
vein administration of 4×1010vg/kg (n=3) of scAAV-LP1-hFIXco-control and 
scAAV-LP1-hFIXco-FR2b are represented graphically as averages ±SEM.  
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Figure 4.13: Proviral copy number correction. A) Proviral Copies/cell in liver. 
Proviral copy number was determined by a Q-PCR assay on murine liver 
samples collected 4 weeks after transduction with 4×1010vg/kg of each vector 
depicted. Results are presented as mean proviral copies/cell ±SEM. B) 
Correction of %FIX levels. Results are presented as mean %FIX levels ± SEM 
corrected for proviral copy number to take account of variation in transduction.       
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4.4 Discussion 
 
The relatively small packaging capacity of rAAV vectors imposes a degree of limitation on 
rAAV mediated gene therapy (Grieger & Samulski, 2005). Indeed, AAV research for the 
treatment of multiple disorders has been somewhat constrained by vector packaging 
capacity. Consequently, the ability to improve gene expression from AAV cassettes whilst 
minimising increases in cassette size is of great interest. As such, in order to minimise the 
space occupied by S/MARs within AAV expression cassettes and to discover minimal 
sequences required to enhance transgene expression, we carried out a deletion analysis on 
IFNβ and HPRT S/MARs. 
Through this analysis we identified one region of each S/MAR that was able to mediate 
potent enhancer activity. In the case of the IFNβ S/MAR, transduction with a fragment 2 
containing vector demonstrated a 2-fold increase in hFIX antigen levels as compared to 
ssAAV-LP1-hFIXco-IFN-R vector in-vitro. As this assay was limited by poor in-vitro 
transduction with serotype 8 vectors, this trend was verified by in-vivo analysis. Following 
tail vein administration of 4×1012vg/kg of each IFNβ S/MAR vector to C57BL/6 mice, a 3-fold 
increase in transgene expression was maintained in the ssAAV-LP1-hFIXco-FR2 cohort as 
compared to ssAAV-LP1-hFIXco-IFN-R transduced animals. In the HPRT S/MAR analysis, 
respective hFIX levels were comparable both in-vitro (4.313 ± 0.009% and 4.079 ± 0.830%) 
and in-vivo (46 ± 9 % and 35 ± 7%) following transduction with ssAAV-LP1-hFIXco-HPRT-F 
and ssAAV-LP1-hFIXco-FR2b vectors. In the context of a self-complementary vector, the 
HPRT fragment 2b was also found to enhance hFIX levels by 35-fold as compared to control 
vector in mice. These observations suggest that truncated S/MAR elements are able to 
mediate enhanced transgene expression; as such, S/MAR elements have potential use in 
conjunction with larger transgenes or in the context of self-complementary expression 
cassettes. However, it is again worth mentioning that these experiments should, in future, 
be repeated with further groups of animals and fresh batches of vector in order to ensure 
that these observations are reproducible and not the result of experimental artefacts. 
Animal numbers must also be justified through the use of sample size calculations as 
described in section 3.4.  
In an attempt to identify key regulatory motifs in our truncated S/MARs, the IFNβ fragment 
2 sequence was entered into a motif elicitation programme (MEME). Discovered motifs 
were then entered into the Gene Ontolgy for Motifs (GOMO) algorithm in order to deduce 
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potential biological roles of the sequences (Boden & Bailey, 2008; Buske et al, 2010). By 
this analysis, the only gene ontology (GO) term unique to fragment 2 was ‘nucleosome 
assembly’ which was associated with the sequence AAAAGM (where M is the IUPAC 
degenerate base symbol for C or A) that is present twice in the fragment 2 sequence. As 
such we speculate that IFNβ S/MAR fragment 2 may contain a nucleation site for helix 
unwinding otherwise known as the core unwinding element (CUE). In previously published 
literature all S/MARs are documented to have multiple base unwinding regions (BURs) with 
one region typically containing a CUE (Bode et al, 2000). Indeed the loose CUE consensus 
sequence (AAATATATT) that is found in a few but not all S/MARs is present in our fragment 
2 sequence. However, through motif elicitation we were unable to identify sequences to 
suggest the presence of repressive motifs in IFNβ S/MAR fragments 1 and 3. As such, it is 
possible that one of these fragments may demonstrate structural as opposed to sequence 
based hindrance on transgene expression.     
The only unique nucleotide motif found in HPRT fragment 2b was TYRTTT (where 
Y=pyrimidine and R=purine). This motif occurs twice in the 2b sequence and was associated 
with the GO term ‘gene expression’. As such, this motif may represent a core enhancer 
sequence, although this matter requires further validation. Future investigation into this 
matter could include a mutational analysis on motif sequences to observe potential 
inhibitory effects on transgene expression. Alternatively, the potency of fragment 2b may 
be purely structural due to the large quantity of poly-pyrimidine and poly-purine tracts 
present in the sequence. As suggested in previous literature reports, these sequences may 
enable the formation of non-B DNA structures: which in turn catalyze transcription 
(Boulikas, 1993).    
One limitation of this study was the inability to test multiple variants of truncated S/MAR 
elements. For instance, it is possible that through high-throughput elicitation of every 
possible sequence permutation available, we may have identified a more potent S/MAR 
fragment. However, due to the burden on vector production and subsequent analysis that 
this would cause, such an approach falls beyond the scope of this project.  
To summarise, through deletion analysis, we have successfully identified two truncated 
S/MAR regions that enhance transgene expression levels both in-vitro and in-vivo. Overall, 
this makes the use of S/MAR elements more applicable to AAV research by minimizing the 
amount of space occupied by S/MAR sequences within a given expression cassette. The 
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exact explanation for the potency of these sequences remains to be defined and may be 
due to specific sequence motifs or secondary structure. 
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CHAPTER 5 THE FUNCTION OF MATRIX ATTACHMENT REGIONS IN AAV 
EXPRESSION CASSETTES 
5.1 Introduction 
5.1.1 The role of S/MARs in preventing transcriptional gene silencing 
 
As previously described, the theory of repeat induced gene silencing (RIGS) suggests that 
transgenes arranged in multicopy concatemeric arrays are subject to silencing through an 
‘aberrant’ RNA based mechanism  (Garrick et al, 1998; Selker, 1999). These silencing events 
can take the form of post transcriptional mRNA degradation or transcriptional gene 
silencing (TGS) by histone modification (Moazed, 2009). In the context of our LP1-hFIXco 
expression cassette, S/MAR elements are observed to enhance levels of hFIX mRNA. As 
such, it is plausible that RIGS is active following rAAV mediated gene transfer and that, in 
the absence of a S/MAR, exogenous mRNAs are degraded and/or transcription is halted by 
repressive chromatin configurations. This would infer that S/MARs function to maintain an 
open euchromatin state and to stabilise exogenous transcripts in the context of rAAV.  
In proviral DNA extracted from the liver of rhesus macaques transduced with ssAAV-LP1-
hFIXco-Control, no CpG methylation of the LP1 promoter was observed by bisulphate 
sequencing at up to one year (full duration of the study) after gene transfer (Figure 5.1). 
Thus, differences in FIX expression between the control vector (ssAAV-LP1-hFIXco-Control) 
and S/MAR containing vectors (ssAAV-LP1-hFIXco-IFN-R and ssAAV-LP1-hFIXco-HPRT-F) 
were not due to methylation of the LP1 promoter. Any TGS events occurring in conjunction 
with rAAV gene transfer must therefore result from repressive histone modification.  
Therefore, to determine whether S/MARs prevent transcriptional gene silencing, the first 
aim of this study was to compare histone modification profiles of ssAAV-LP1-hFIXco-
Control, ssAAV-LP1-hFIXco-IFN-R and ssAAV-LP1-hFIXco-HPRT-F proviral genomes. This was 
assessed by chromatin immunoprecipitation (ChIP) using antibodies against histone 
proteins H3K9me2 (histone 3 dimethylated on lysine 9), H3K4me2 (histone 3 dimethylated 
on lysine 4) and H3Ac (acetylated histone 3).      
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Figure 5.1: Cytosine methylation profiles of the AAV LP1 promoter revealed by bisulphite 
sequencing. Bisulphite sequencing was carried out on DNA extracted from rhesus liver 
samples 1 week, 2 months and 1 year after peripheral vein administration of scAAV8-LP1-
hFIXco vector at a dose of 2×1012vg/kg. The vector genome is represented schematically 
(top). Boxes represent CpG regions of the LP1 promoter (bottom). Unfilled boxes depict 
non-methylated CpG regions.             
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5.1.2 Polycomb group (PcG) complexes are recruited during RNAi based silencing  
  
In order to investigate whether S/MARs reduce the binding of proteins involved in RIGS, 
ChIP experiments using an antibody against a Polycomb group (PcG) protein were carried 
out on chromatin extracted from ssAAV-LP1-hFIXco-Control and ssAAV-LP1-hFIXco-IFN-R 
transduced mouse livers.   
Polycomb group (PcG) proteins were first discovered in Drosophila Melanogaster and are 
well known for their ability to maintain genes in a silenced state (Okulski et al, 2011). The 
most commonly known example of PcG function involves the silencing of homeotic (Hox) 
genes in the early embryo when Hox expression is no longer required for axis formation 
and gastrulation (Czermin et al, 2002). In the fruit fly, the recruitment of PcG complexes is 
also observed in conjunction with repeat induced gene silencing (Pal-Bhadra et al, 1997). 
For example, the introduction of two to six copies of the Alcohol dehydrogenase (Adh) 
gene in flies resulted in the progressive decrease in Adh expression as opposed to the 
enhanced expression effects anticipated after increasing gene dosage (Pal-Bhadra et al, 
2002). This effect was analogous to the events of cosuppression/RIGS as transcriptional 
silencing of the Adh gene occurred simultaneously with the production of RNAi. Through 
immunostaining of the chromosomes of transduced flies, sites of Adh gene insertion were 
found in association with PcG proteins; thus it is inferred that polycomb proteins are 
involved in the maintenance of TGS that is brought about by repeat induced gene silencing 
(Pal-Bhadra et al, 1997). This study provided the context for our aim to compare levels of 
polycomb protein associated with control and S/MAR containing AAV genomes.  
In the fly, the Enhancer of Zeste (E(Z)) protein is continually required to maintain gene 
silencing even after embryogenesis (Czermin et al, 2002). Therefore, enhancer of Zeste 
homolog 2 (EZH2) was our chosen mammalian PcG protein target. This homolog forms the 
catalytic subunit of Polycomb repressive complex 2 (PRC2) and is known for its 
methyltransferase activity which results in the repressive histone mark of lysine 27 
trimethylation on histone 3 (H3K27me3) (Cavalli, 2012). EZH2 is also known for its ability to 
transfer methyl groups to lysine 9 on histone 3; therefore levels of this marker (H3K9me2) 
were also assessed in this study.  
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5.1.3 S/MAR binding proteins are involved in chromatin remodelling 
 
By using S/MAR affinity columns, multiple S/MAR binding proteins have been isolated from 
cell extracts via chromatography techniques (Kohwi-Shigematsu et al, 1998). Examples of 
such proteins include Scaffold attachment factor A (SAF-A), high mobility group (HMG) 
proteins, special AT-rich sequence binding 1 (SATB1) protein and nucleolin. All of these 
proteins can be broadly categorised as components of chromatin remodelling complexes. 
For instance SATB1 acts as a ‘docking site’ for the recruitment of chromatin remodelling 
proteins that serve to regulate gene expression through the modification of histones or 
through the mobilization of nucleosomes (Yasui et al, 2002). Similarly SAF-A and HMG 
proteins also play a fundamental role in nucleosome dynamics and are known to interact 
with the SWItch Sucrose NonFermentable (SWI/SNF) complex which redistributes 
nucleosomes along DNA sequences (Bianchi & Agresti, 2005; Vizlin-Hodzic et al, 2011). 
HMG proteins are also involved in the recruitment of transcription factors and DNA 
bending activities which facilitate transcription (Bianchi & Agresti, 2005). Nucleolin is a 
further example of a known histone chaperone that possesses a HMG-like domain and 
binds to S/MAR affinity columns with high stringency.  The nucleolin protein is able to 
destabilise histone octamers and consequently activates the dissociation of histone 2A-
histone 2B (H2A-H2B) dimers by SWI/SNF. Furthermore, nucleolin has been shown to 
facilitate the elongation of RNA Polymerase II through nucleosomes during transcription 
(Angelov et al, 2006; Dickinson & Kohwi-Shigematsu, 1995).         
As known S/MAR binding proteins are heavily involved in nucleosome assembly and 
histone eviction during transcription, the final aim of this study was to determine whether 
proteins involved in nucleosome dynamics are associated with S/MAR containing AAV 
expression cassettes. To assess this matter, ChIP experiments using an antibody against 
nucleolin were carried out on chromatin extracted from ssAAV-LP1-hFIXco-Control and 
ssAAV-LP1-hFIXco-IFN-R transduced murine livers.  
In this study we consistently observed a 2 to 4-fold enrichment of the repressive H3K9me2 
marker in association with ssAAV-LP1-hFIXco-Control genomes as compared to ssAAV-LP1-
hFIXco-IFN-R and ssAAV-LP1-hFIXco-HPRT-F. This was accompanied by a decrease in 
association of active H3K4me2 and H3Ac markers on ssAAV-LP1-hFIXco-Control DNA. In 
comparison to control genomes a significant increase in the binding of nucleolin and a 2.4-
fold decrease of EZH2 binding was observed in association with ssAAV-LP1-hFIXco-IFN-R 
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genomes, although these observations require further validation.   Collectively, these data 
suggest that S/MARs prevent transcriptional gene silencing of rAAV expression cassettes 
through the recruitment of proteins that maintain DNA in an open euchromatin state.  
5.2 Materials and methods 
5.2.1 Chromatin immunoprecipitation 
 
Chromatin immunoprecipitation (ChIP) was carried out on murine liver samples as 
described in section 2.5.3. Briefly 200mg of transduced or naïve liver was pushed through a 
nylon cell strainer in 2ml of PBS solution containing 2% foetal bovine serum (FBS) and 
protease inhibitor cocktail. Cells were then centrifuged at 3500rpm for 10 minutes and cell 
pellets were washed twice in 10ml of the aforementioned PBS solution. Formaldehyde was 
added to final concentration of 1% followed by incubation at room temperature for 10 
minutes to form DNA-protein crosslinks. To quench formaldehyde, glycine was added to a 
final concentration of 0.125M and solutions were incubated for 5 minutes at room 
temperature. Cells were then pelleted and washed twice in ice cold PBS solution as above.  
To shear DNA, a Bioruptor sonicator was used with the sonication parameters set to 15 
seconds pulse on and 15 seconds pulse off for 45 minutes. Chromatin immunoprecipitation 
was carried out using the EZ-Magna ChIP A-Chromatin Immunoprecipitation Kit (Millipore, 
Feltham, UK) as per the manufacturer’s instructions. All immunoprecipitations were carried 
out at 4°C overnight with either 4µg of specific antibody or with no antibody as control. Pull 
down of LP1 promoter DNA was quantified by Q-PCR using primers described in section 
2.5.3. 
5.3 Results 
5.3.1 S/MARs confer higher transgene expression through epigenetic modification 
of the ssAAV-LP1-hFIXco genome 
 
To evaluate the in-vivo chromatin status of ssAAV-LP1-hFIXco-Control vector genomes in 
comparison to ssAAV-LP1-hFIXco-IFN-R or ssAAV-LP1-hFIXco-HPRT-F genomes, we carried 
out ChIP experiments on chromatin extracted from murine liver collected 4-8 weeks after 
tail vein administration of 4x1012vg/kg of ssAAV-LP1-hFIXco-Control, ssAAV-LP1-hFIXco-IFN-
R or ssAAV-LP1-hFIXco-HPRT-F. 
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In comparison to ssAAV-LP1-hFIXco-IFN-R transduced animals, vector genomes from the 
ssAAV-LP1-hFIXco-Control cohort consistently showed 2 to 4-fold enrichment of repressive 
heterochromatin markers (dimethylation of lysine 9 on histone 3 [H3K9me2] (not 
significant) and heterochromatic adaptor proteins [HP1α]) (P=0.0003 to 0.0012, T test) in 
the LP1 promoter region (Figure 5.2). Both H3K9me2 and HP1α marks correlate with 
inactive gene promoters (Lienert et al, 2011). An increase in association of histone 3 with 
dimethylation on lysine 4 (H3K42me) as well as acetylation of histone 3 lysine residues 
(H3Ac) was also observed within the distal region of the LP1 promoter of ssAAV-LP1-
hFIXco-IFN-R genomes when compared to the promoter of ssAAV-LP1-hFIXco-Control (not 
significant, P=0.396 and 0.367 respectively, student T tests). As previously described, both 
H3K4me2 and H3Ac represent markers of transcriptionally active genes (Yan & Boyd, 2006).  
When compared to the ssAAV-LP1-hFIXco-HPRT-F cohort, ssAAV-LP1-hFIXco-Control 
genomes again showed a significant 2 to 3-fold enrichment of the H3K9me2 
heterchromatin marker (Figure 5.3) (P=0.002 to 0.023, student T tests). Additionally, a 
significant 2 to 4-fold enrichment of H3K4me2 and 2 to 6-fold enrichment of H3Ac was 
observed in association with LP1 promoter regions of ssAAV-LP1-hFIXco-HPRT-F genomes 
(P=0.034 to 0.013 and 0.003 to 0.001 respectively, student T tests).  
Collectively, these results suggest that the higher levels of hFIX expression observed in 
ssAAV-LP1-hFIXco-IFN-R and ssAAV-LP1-hFIXco-HPRT-F cohorts was due to the 
maintenance of S/MAR containing expression cassettes in a chromatin configuration that is 
permissive to transcription. 
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Figure 5.2: Epigenetic modification of ssAAV-LP1-hFIXco proviral DNA. ChIP was 
carried out on chromatin extracted from liver samples collected 6 weeks after tail-
vein administration of 4X1012vg/kg of ssAAV-LP1-hFIXco-IFN-R and ssAAV-LP1-hFIXco-
Control vectors into 4 to 6 week old male C57BL/6 mice. All results are presented as a 
percentage of total input chromatin (calculated as an average from 2 Ct values) ±SEM. 
Data are from one animal and representative of results that were reproduced in a 
minimum of three animals. (A) ChIP analysis on proximal LP1 chromatin.  The vector 
genome region amplified by Q-PCR corresponds to the proximal region of the 
promoter (position152). (B) ChIP analysis on distal LP1 chromatin. The vector 
genome region amplified by Q-PCR was the distal region of the promoter 
(position366).  Antibodies used for ChIP included anti H3K9me2, anti HP1α, anti 
H3K4me2 and anti H3Ac.  
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Figure 5.3: ChIP analysis on ssAAV-LP1-hFIXco-Control and ssAAV-LP1-hFIXco-HPRT-F 
chromatin. ChIP was carried out on chromatin extracted from liver samples collected 4 
weeks after tail-vein administration of 4X1012vg/kg of ssAAV-LP1-hFIXco-HPRT-F and 
ssAAV-LP1-hFIXco-Control vectors into 4 to 6 week old male C57BL/6 mice. All results 
are presented as a percentage of total input chromatin (calculated as an average from 2 
Ct values) ±SEM. Data are from one animal and representative of results that were 
reproduced in three animals. A, B and C refers to ChIP analysis on proximal promoter 
(152), distal promoter (366) and transgene (1988) chromatin regions respectively. 
Antibodies used for ChIP included anti H3K9me2, anti H3K4me2 and anti H3Ac.     
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5.3.2 Preliminary mechanistic data  
 
To assess potential mechanisms behind the maintenance of S/MAR containing genomes in 
a transcriptionally active state, we carried out further ChIP studies on ssAAV-LP1-hFIXco-
Control and ssAAV-LP1-hFIXco-IFN-R genomes extracted from murine livers taken 4 weeks 
after tail vein administration of 4x1012vg/kg of ssAAV-LP1-hFIXco-Control and ssAAV-LP1-
hFIXco-IFN-R vectors. Antibodies used for this analysis included anti nucleolin (a known 
S/MAR binding protein and histone chaperone) and anti EZH2 (a PcG protein involved in 
the methylation of histone 3).  
In comparison to ssAAV-LP1-hFIXco-Control genomes, preliminary results show a significant 
69-fold and 94-fold increase in nucleolin association with promoter and hFIX transgene 
regions of ssAAV-LP1-hFIXco-IFN-R genomes respectively (P=0.003 and 0.005 respectively, T 
tests) (Figure 5.4). Additionally, an approximate 2.4-fold enrichment of EZH2 was observed 
in association with the promoter of ssAAV-LP1-hFIXco-IFN-R genomes as compared to the 
promoter of ssAAV-LP1-hFIXco-Control genomes although this was not found to be 
significant (P=0.241) (Figure 5.5).    
Taken as a whole these results suggest that, in the context of our LP1-hFIXco rAAV vector, 
S/MARs enhance transgene expression through the recruitment of known S/MAR binding 
proteins involved in the movement of histones. Furthermore, S/MARs may also have a role 
in preventing the binding of PcG group proteins that are involved in the formation of 
heterochromatin by methylation of histone 3 at lysine residues 9 and 27.      
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Figure 5.4 Preliminary nucleolin ChIP analyses. ChIP was carried out on chromatin 
extracted from the liver of 4-6 week old male C57BL/6mice transduced with 
4×1012vg/kg of ssAAV-LP1-hFIXco-control or ssAAV-LP1-hFIXco-IFN-R. All results are 
presented as a fold enrichment of % input against % input values from no antibody 
experiments (calculated as an average from 2 Ct values divided by average %Input 
values from experiments using no antibody ±SEM). Data are from one animal only. 
A and B correspond to experiments using Q-PCR primers against proximal 
promoter (366) and transgene regions (1988) respectively.  
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Figure 5.5: Preliminary EZH2 ChIP analyses. ChIP was carried out on chromatin 
extracted from the liver of 4-6 week old male C57BL/6mice transduced with 
4×1012vg/kg of ssAAV-LP1-hFIXco-control or ssAAV-LP1-hFIXco-IFN-R. Results 
are calculated as an average from 2 Ct values divided by average %Input values 
from experiments using no antibody ±SEM. Data are from one animal only. Q-
PCR was carried out using primers against vector genome region 366 (distal 
LP1 promoter). 
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5.4 Discussion 
 
Repeat induced gene silencing is a phenomenon known to occur simultaneously with gene 
transfer as a host defence mechanism against viral infection (Moazed, 2009). These gene 
silencing events halt transcription of exogenous sequences through the recruitment of 
proteins that enable the formation of repressive chromatin configurations. In this study we 
assessed whether rAAV genomes are subject to such silencing events and whether this is 
prevented through the incorporation of S/MAR elements into rAAV expression cassettes.  
Consistent with the work of other groups, we did not detect any methylation of our LP1 
promoter sequence by bisulphate sequencing (Leger et al, 2011). This infers that any 
silencing events occurring after gene transfer must be due to histone modifications. As 
such, we analysed the association of histones H3K9me2, H3K4me2 and H3Ac with control 
and S/MAR containing genomes by ChIP. Through this analysis we consistently found the 
IFNβ and HPRT S/MAR elements to decrease the association of repressive histone 
modifications (H3K9me2) and increase the association of euchromatin marks (H3K4me2 
and H3Ac) with our AAV expression cassettes (Lienert et al, 2011; Yan & Boyd, 2006).  We 
also observed a significant decrease in association of the repressive HP1α mark with ssAAV-
LP1-hFIXco-IFN-R genomes (Wreggett et al, 1994). Collectively, these results suggest that 
silencing events may indeed occur following rAAV gene transfer. These observations are in 
agreement with previous gene transfer studies, involving the use of HDAC inhibitors to 
enhance gene expression, which suggest that AAV genomes are subject to epigenetic 
silencing (Okada et al, 2006). Thus, the increase in mRNA levels observed with S/MAR 
vectors may be mediated through the prevention of such silencing events. In future 
experiments to determine S/MAR function, it may be interesting to see whether the co-
administration of a S/MAR vector with a HDAC inhibitor results in a synergistic or additive 
effect on gene expression.   
To understand how S/MARs mediate the prevention of gene silencing, we carried out ChIP 
experiments against the nucleolin protein. Nucleolin is a S/MAR binding protein involved in 
the movement of histones and facilitating transcription (Angelov et al, 2006; Dickinson & 
Kohwi-Shigematsu, 1995). Although this work requires repetition, in this study we observed 
a significant increase in the association of nucleolin with ssAAV-LP1-hFIXco-IFN-R genomes 
as compared to ssAAV-LP1-hFIXco-Control. As such, it is inferred that S/MARs mediate their 
enhancer properties through the recruitment of proteins involved in nucleosome assembly 
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and histone eviction. This is consistent with data from previous chromatography studies 
designed to detect S/MAR binding proteins (Kohwi-Shigematsu et al, 1998). However, in 
addition to chromatin remodelling function, S/MARs have other biological properties that 
could potentially influence AAV transgene expression. For instance, S/MARs have the ability 
to bring the AAV proviral DNA into close proximity to key nuclear regulatory elements 
within the nucleus by forming “anchor points” with nuclear matrix (Bode et al, 2000). This 
may, in turn, enhance promoter activity by bringing promoter sequences into close 
proximity with key transcription factors required for the initiation of gene expression. 
Therefore, there would be value in investigating whether there is an increased binding of 
proteins that attach DNA to the nuclear matrix (such as SATB1) in S/MAR containing AAV 
genomes (Dickinson et al, 1997). Furthermore, it is also possible that the increased levels of 
mRNA observed when using S/MAR elements may be due to improved RNA stability as 
opposed to increased transcription levels through the prevention of silencing. To assess this 
matter, the integrity of mRNA samples could be determined more scrupulously by carrying 
out a quantitative PCR analysis using primers designed against 5’ and 3’ ends of the 
transcript (Fajardy et al, 2009). This would allow us to determine whether hFIX mRNA is 
more readily degraded in the absence of S/MAR elements.        
As described above, polycomb proteins have previously been detected at silenced genes in 
association with RIGS events (Pal-Bhadra et al, 1997). To determine whether AAV silencing 
is analogous to RIGS, we carried out ChIP experiments against the EZH2 polycomb protein. 
By this analysis we observed a 2.4-fold enrichment of EZH2 at the promoter regions of 
ssAAV-LP1-hFIXco-Control genomes compared to ssAAV-LP1-hFIXco-IFN-R. However, this 
observation was not statistically significant and will therefore need further validation 
through repeat experiments. In future work it would also be valuable to assess levels of 
alternative polycomb proteins in association with control and S/MAR containing vector 
genomes. From this experiment we can say that S/MAR elements may prevent the binding 
of polycomb proteins that is mediated by RIGS. However, to conclusively establish whether 
repeat induced genome silencing occurs after AAV gene transfer, it will be important to 
detect RNAi complementary to transgene sequences through strategies such as northern 
blotting.     
In summary, detailed epigenetic analysis showed that the AAV-LP1-hFIXco provirus does 
not undergo DNA methylation in the liver of macaques following systemic administration. 
However, LP1 promoter sequences within the proviral genome become associated with 
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histones containing repressive marks. The inclusion of S/MARs appears to decrease the 
level of proviral DNA heterchromatinization and facilitate the maintenance of AAV 
concatemers in an open chromatin, and therefore transcriptionally active configuration. 
This may be achieved through the recruitment of proteins that reassemble nucleosomes 
and/or through preventing the binding of repressive chromatin remodelling complexes 
such as polycomb group proteins. Although the exact mechanism through which S/MARs 
exert their chromatin remodelling function remains to be elucidated, these data are fully 
consistent with previous reports of S/MAR function, of nucleosome association with AAV 
genomes, and of repeat induced gene silencing following viral infection (Garrick et al, 1998; 
Gluch et al, 2008; Penaud-Budloo et al, 2008). Therefore, S/MARs may help to achieve the 
overall goal of improved AAV vector potency by preventing silencing of the provirus. 
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CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS 
 
The need for large numbers of vector particles to achieve a therapeutic effect has been 
observed in multiple clinical trials for rAAV mediated gene transfer. In the absence of 
immune suppression, such a large vector load appears to provoke T cell responses against 
capsid antigens resulting, in some cases, in the abrogation of transgene expression and the 
potential risk of toxicity due to immune mediated clearance of transduced cells (Manno et 
al, 2006; Nathwani et al, 2011). To address this matter, this study aimed to enhance the 
potency of rAAV vectors allowing lower doses, shown to be safe in humans, to be utilised. 
The transduction of target cells by AAV can be influenced by multiple factors including 
inefficient cell surface binding, endosomal degradation, conversion of single stranded 
genomes to transcriptionally active double stranded forms and recipient gender (Davidoff 
et al, 2003; Fisher et al, 1996; Mackus et al, 2003; Yan et al, 2002). These insights into the 
biology of AAV transduction have enabled the generation of various enhanced vectors 
ranging from constructs with mutated capsid proteins to vectors with altered DNA 
configurations or expression cassettes (Loiler et al, 2003; McCarty et al, 2003; Miao et al, 
2000b; Nathwani et al, 2009; Pang et al, 2011; Petrs-Silva et al, 2009; Rabinowitz et al, 
2004; Wu et al, 2008). However, the possibility to prevent epigenetic silencing of rAAV 
genomes remains relatively unexplored. As vector genomes of the parvovirus family, 
including MVM and AAV, have been shown to adopt a chromatin-like configuration in-vitro 
and in-vivo, it is rational to anticipate epigenetic silencing of the rAAV provirus (Ben-Asher 
et al, 1982; Marcus-Sekura & Carter, 1983; Penaud-Budloo et al, 2008). Furthermore, 
studies that demonstrate enhanced AAV mediated transgene expression in mice, following 
administration of HDAC inhibitors, suggest that AAV genomes may be subject to repressive 
histone modifications (Okada et al, 2006). As such, we aimed to enhance the potency of 
our ss-AAV8-LP1-hFIXco-TSV40pA vector through the incorporation of S/MAR elements into 
the AAV8-LP1-hFIXco expression cassette previously used in the clinic.  
Following tail vein administration of 4×1012 vg/kg to 6 to 8 week old male C57BL/6 mice, 
S/MAR containing vectors were found to mediate a 10 to 28-fold increase in plasma hFIX 
levels as compared to vectors containing no S/MAR or control KSHV elements. These data 
are fully supported by previous reports of S/MAR function in other gene transfer vectors 
(Argyros et al, 2008; Auten et al, 1999; Dang et al, 2000; Moreno et al, 2011; Ramezani et 
al, 2003). After correcting for proviral copy numbers in the mouse liver, the ssAAV-LP1-
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hFIXco-HPRT-F vector was found to mediate the highest levels of transgene expression. As 
such, this vector was selected for a low dose analysis (4×1010vg/kg) in mice. At 4 weeks 
after transduction with the lower vector dose, the ssAAV-LP1-hFIXco-HPRT-F cohort 
expressed hFIX at levels approximately 85-fold higher than those observed in ssAAV-LP1-
hFIXco-control transduced animals. Thus, it is inferred that S/MARs are indeed able to 
enhance the potency of AAV and consequently allow for the use of lower vector doses. 
Although enhanced transgene expression was the desired effect of incorporating S/MAR 
elements into our expression cassette, it is important to mention that overexpression of 
hFIX could potentially have adverse effects. For instance, in mice, elevated circulatory 
levels of hFIX have been shown to cause thrombosis, myocardial fibrosis and reduced 
survival age (Ameri et al, 2003). As such, it is possible that after a longer follow up period 
we may have observed these effects in animals injected with S/MAR containing vectors. 
Furthermore, over-production of transgenic proteins may potentially result in the 
activation of cellular stress responses, cell growth arrest and cytotoxicity (Narayanan et al, 
2011).  As a result, the appropriate dose of these vectors must be considered carefully for 
future applications. In future studies it may also be possible to assess cell toxicity in-vitro 
after transduction with S/MAR containing vectors at a range of doses followed by 
enumeration of dead and live cells.  
Studies in nonhuman primates provided the opportunity to validate our observations in an 
animal model that is more relevant to translational research. After peripheral vein injection 
of 4×1012vg/kg, steady state hFIX levels corrected for proviral copy number were 
approximately 4-fold and 10-fold higher in ssAAV-LP1-hFIXco-IFN-R and ssAAV-LP1-hFIXco-
HPRT-F transduced animals respectively as compared to the macaque receiving ssAAV-LP1-
hFIXco-control. This is a crucial observation as the potential for a reduction of vector doses 
by an order of magnitude would have an important impact on the safety of AAV gene 
transfer to the human population. In future studies it will be important to assess the 
biological activity of the hFIX protein produced from S/MAR containing vectors. However, 
in our unpublished data using lentiviral constructs we have not found the HPRT S/MAR to 
interfere with the activity of human coagulation factor VIII by chromogenic assay. We are 
therefore confident that hFIX activity will not be affected in the context of rAAV. Although 
the need to repeat this analysis in a greater number of animals and with new batches of 
vector is acknowledged, as a proof of principle study these results have strong implications 
for the use of S/MAR elements in AAV vectors. 
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However, as previously mentioned, we cannot conclusively say that S/MARs enhance the 
potency of all AAV vectors. Thus, in future experiments it would be valuable to test S/MARs 
in the context of different expression cassettes. Furthermore, as the effect of S/MARs 
depends heavily on DNA structural influences, it may also be interesting to test S/MAR 
elements at alternative positions within the AAV genome (Schubeler et al, 1996). 
Nonetheless, the strength of this study lies with the fact that we have assessed S/MARs in 
an expression cassette that has been used clinically. As such, this study will be of interest to 
those working on translational strategies for the treatment of haemophilia B.  
Through hFIX mRNA quantification and ChIP analysis, our data suggests that S/MARs 
improve AAV transgene expression by maintaining AAV concatamers in an open chromatin 
configuration that is permissive to transcription. This was inferred by the decrease in 
repressive histone modifications (H3K9me2 and HP1α) and increase in active histone 
modifications (H3K4me2 and H3Ac) associated with S/MAR containing proviral chromatin 
compared to control vector chromatin extracted from transduced murine liver. 
Furthermore, we observed a respective 69 and 94-fold enrichment of the histone 
chaperone protein nucleolin at the distal promoter and transgene regions of the ssAAV-
LP1-hFIXco-IFN-R genome in comparison to the same regions of the ssAAV-LP1-hFIXco-
control genome. Therefore, we speculate that AAV proviral DNA may be subject to repeat 
induced gene silencing events that are prevented in the presence of a S/MAR through the 
recruitment of chromatin remodelling complexes.  
In the fruit fly Polycomb proteins are known to be involved in the maintenance of 
transcriptional gene silencing brought about by RIGS (Pal-Bhadra et al, 1997; Pal-Bhadra et 
al, 2002). In our ChIP studies using an antibody against EZH2 (PcG protein) we observed a 
2.4-fold enrichment of EZH2 binding in association with control vector genomes as 
compared to ssAAV-LP1-hFIXco-IFN-R. This analysis supports the notion that AAV silencing 
may be analogous to RIGS and that S/MARs may prevent such silencing events. However, 
as this was a preliminary study only, this observation will require repetition. In follow up 
studies it may also be valuable to carry out ChIP experiments against alternative PcG 
proteins or histone modifications that PcG proteins give rise to, such as methylation of 
lysine 27 on histone 3 (H3K27me) (Cheutin & Cavalli, 2012). Alternatively, for high through-
put elicitation of proteins bound to control and S/MAR containing genomes, it may be 
possible to carry out analyses such as Global ExoNuclease-based Enrichment of Chromatin-
Associated Proteins for Proteomics (GENECAPP) (explained in figure 6.1) (Smith et al, 2011; 
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Wu et al, 2011). However, to conclusively establish that AAV proviral genomes are subject 
to RIGS, future studies could include northern blotting on RNA extracted from transduced 
livers to detect siRNA that is complementary to exogenous DNA sequences. As murine 
models exist for the conditional knockout of the Dicer gene (a ribonuclease involved in 
siRNA production) it may also be possible to analyse whether AAV mediated transgene 
expression is enhanced in the absence of RNAi in-vivo (Figure 6.2) (Martins et al, 2008).  
As previously discussed in section 5.4, it will also be of interest to assess other potential 
mechanisms of S/MAR activity. For example, the attachment of vector DNA to the nuclear 
matrix may enable enhanced expression levels through putting promoter regions into close 
proximity with key nuclear factors required for transcription. As such, the enhanced 
transgene expression that we have observed may be due to increased promoter activity as 
opposed to prevention of gene silencing. As the nuclear matrix is also a location for 
proteins involved in RNA transport and processing, it is also possible that the mechanism 
behind our observations may be due to RNA stability and not increased levels of gene 
expression. As previously discussed, this matter could be assess through further chromatin 
immunoprecipitation experiments using antibodies against matrix attachment factors or 
matrix associated proteins. 
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Figure 6.1: Schematic of the GENECAPP protocol. In the GENECAPP process, chromatin is 
prepared from mouse liver cells by crosslinking proteins to DNA using formaldehyde. 
Chromatin is then sheared by sonication and enzymes such as E.coli Exonuclease III are 
used to generate regions of single stranded DNA. Single stranded regions are then able to 
bind to complementary biotinylated oligos that are held on a streptavidin coated solid 
support.  Proteins are eluted using high salt or urea buffers or through the use of 
competitive biotin. Eluted proteins can then be used for protein identification by mass 
spectrometry. Adapted from: (Wu et al, 2011). 
1) Push control and S/MAR 
transduced livers through a 
cell strainer. Wash cells. 
2) Crosslink proteins to DNA with 1% 
Formaldehyde. Quench with 250mM 
Tris pH 8 
3) Sonicate to shear DNA 
4) Exonuclease digest to obtain single 
stranded DNA regions 
5) Bind chromatin to complementary 
biotinylated oligos held on a 
streptavidin coated solid support 
 
6) Elute and use for mass spectrometry 
to identify proteins 
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Figure 6.2: Schematic of conditional Dicer knockouts. Mice expressing 
Cre recombinase (flanked by estrogen-receptor ligand-binding 
domains) under the control of a liver specific promoter are crossed 
with mice carrying loxP sites either side of exon 21 of the Dicer (RNAse 
III) gene. In the offspring of these animals injection of Tamoxifen 
stimulates the activity of Cre and Dicer is knocked out in the liver 
through recombination of loxP sites. rAAV vectors can then be injected 
to assess transgene expression in the absence of RNAi. Adapted from: 
(Martins et al, 2008).    
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Through deletion analysis we have identified a 297bp region of the IFNβ S/MAR with 
potent enhancer activity (fragment 2). At the equivalent dose (4×1012vg/kg) we observed 
an approximate 3-fold increase in murine plasma hFIX levels when using the ssAVV8-LP1-
hFIXco-FR2 vector as compared to ssAVV8-LP1-hFIXco-IFN-R, ssAVV8-LP1-hFIXco-FR1 and 
ssAVV8-LP1-hFIXco-FR3 vectors. To identify key regulatory motifs in our truncated S/MAR, 
the fragment 2 sequence was entered into a motif elicitation programme (MEME) (Bailey et 
al, 2006). Discovered motifs were then entered into the Gene Ontolgy for Motifs (GOMO) 
algorithm in order to deduce potential biological roles (Buske et al, 2010). By this analysis 
relevant gene ontology (GO) terms elicited for motifs in fragment 2 included: positive 
regulation of transcription from RNA polymerase II promoter, mRNA processing, positive 
regulation of gene-specific transcription, and nucleosome assembly. These GO terms are 
consistent with our findings from ChIP and RNA analyses. However, through the same in-
silico approach we were unable to discover any motifs in fragments 1 and 3 which would 
allow us to label these sequences as categorically repressive. The only GO term that was 
unique to fragment 2 was nucleosome assembly. As such we speculate that the fragment 2 
sequence may contain a nucleation site for helix unwinding otherwise known as the core 
unwinding element (CUE) (Bode et al, 2000). In support of this notion, the loose CUE 
consensus sequence (AAATATATT) that is found in some but not all S/MARs is present in 
our fragment 2 sequence.  
In the HPRT S/MAR deletion analysis we identified a 130bp region (Fragment 2b) that was 
able to enhance hFIX expression to levels comparable to those achieved with the ssAAV8-
LP1-hFIXco-HPRT-F vector following administration of 4×1010vg/kg to the tail vein of 
C57BL/6 mice (35±7% and 46±9% respectively).  At the same dose, this S/MAR fragment 
also mediated a 35-fold increase in transgene expression as compared to control 
transduced mice in the context of self-complementary vectors. Through in-silico motif 
analysis key GO terms associated with motifs of HPRT fragment 2b included: chromatin 
assembly, mRNA processing, gene expression and regulation of production of small RNA 
involved in gene silencing by RNA. Again, this is fully consistent with our RNA and 
chromatin immunoprecipitation results and supports the idea that S/MARs may prevent 
RNA based gene silencing. As previously described, to identify whether these motifs are in 
fact critical for S/MAR function, future work could include a mutational analysis of motif 
sequences. If the enhancer effect of the S/MAR fragment is ablated after site directed 
mutagenesis of the motif, it would infer that the sequence is required for S/MAR activity. 
Alternatively, to determine the importance of primary DNA sequence, random scrambled 
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sequences of the S/MAR fragment could be generated using the EMBOSS Shuffleseq 
programme.      
Taken as a whole our deletion analyses suggest that truncated S/MAR elements are able to 
mediate enhanced levels of transgene expression when incorporated into AAV expression 
cassettes. Therefore, our short S/MAR fragments may prove to be useful in self-
complementary vectors as well as in single stranded vectors where the vector genome is 
close to the packaging capacity of AAV. The exact sequence composition of S/MAR 
fragments that is necessary for this effect remains to be conclusively determined. 
Therefore, in addition to mutation of motifs previously elicited in-silico, methods for 
discovering protein binding motifs (such as protein binding microarray described in figure 
6.3) may be valuable to identify sequences that are required to enhance the potency of 
AAV vectors (Berger & Bulyk, 2009). However, it should be noted that the enhancer effect 
of S/MARs could be mediated through DNA structure alone as opposed to primary 
sequence (Boulikas, 1993). Finally, from this study, we are unable to say whether we have 
discovered the optimum S/MAR fragment. Generating a greater number of fragments to 
assess every possible sequence permutation would be required to optimise these 
elements. This can be achieved through protocols such as incremental truncation 
(described in figure 6.4) that utilise enzymes such as exonuclease III to progressively 
shorten a DNA sequence over a given time course (Ostermeier et al, 1999). However, due 
to the time required to embark on this endeavour and the heavy burden in terms of vector 
production and subsequent experimentation, this approach was not employed in the 
current study.  
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Figure 6.3: Schematic of protein binding microarrays (PBMs). To 
carry out a PBM, array plates are coated with double stranded DNA 
regions of interest. Candidate binding proteins are labelled with an 
epitope and added to the array to bind to DNA with the required 
recognition sequence. A flurophore labelled antibody against the 
protein is then used to detect DNA-protein binding through 
fluorescence imaging. Adapted from: (Bulyk, 2007).   
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Figure 6.4: Generation of incremental truncation libraries. To generate multiple 
truncations of a DNA sequence, plasmid DNA containing the sequence of interest is 
linearised by restriction digest and then subject to digestion with Exonuclease enzymes 
that remove nucleotides in a unidirectional manner. Several aliquots are removed over the 
digestion period to obtain truncated sequences of variable lengths. DNA overhangs are 
removed enzymatically for subsequent ligation of vector DNA. Plasmids with truncated 
sequences can then be used in virus production. 
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To conclude, we have critically evaluated S/MAR elements in the context of single stranded 
rAAV vectors encoding human FIX in murine models and rhesus macaques. In all cases 
S/MAR elements were found to enhance transgene expression. The basic mechanism 
behind the up regulation of hFIX when using S/MARs was evaluated by analysing hFIX 
mRNA levels following gene transfer. Our results are indicative of enhanced transcription 
levels or improved mRNA stability with S/MARs. Chromatin immunoprecipitation results 
suggest that S/MARs mediate this effect through the prevention of repressive histone 
modifications. However, the exact mechanism through which expression augmentation 
occurs remains to be defined. Through deletion analysis we were able to identify short 
regions of the IFNβ and HPRT S/MAR that enhance transgene expression in single stranded 
and self-complementary vectors. This reduced the space occupied by S/MARs in our AAV 
vector and also allowed us to identify sequence motifs that may have a role in S/MAR 
function. Taken as a whole, S/MARs have demonstrated a significant enhancer effect in the 
context of rAAV vectors. As such, S/MARs may help to achieve the overall goal of improved 
vector potency leading to reduced vector doses. This will have an important impact on the 
safety of rAAV gene transfer in humans. 
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